










The handle http://hdl.handle.net/1887/26502 holds various files of this Leiden University 
dissertation. 
 
Author: Willems, Lianne Irene 
Title: Direct and two-step activity-based profiling of proteases and glycosidases 
Issue Date: 2014-06-24 
 
 
Direct and two-step activity-based profiling of 





ter verkrijging van 
de graad van Doctor aan de Universiteit Leiden, 
op gezag van Rector Magnificus prof. mr. dr. C. J. J. M. Stolker, 
volgens het besluit van het College voor Promoties 
te verdedigen op dinsdag 24 juni 2014 








Lianne Irene Willems 








Promotoren  Prof. dr. H. S. Overkleeft 
   Prof. dr. G. A. van der Marel 
 
Overige leden Prof. dr. J. M. F. G. Aerts  
   Prof. dr. J. Brouwer 
   Prof. dr. D. J. Vocadlo 
   Dr. M. Verdoes  




















Table of contents 
 















































List of publications 163 
Curriculum vitae 166 
6 
 
























































African green monkey kidney 







































double doublet  
double double doublet 
double double triplet 
density functional theory 
N,N-diisopropylethylamine 
4-(N,N-dimethylamino)pyridine 














murine lymphoid cell line 
molar equivalents 
ethyl 
fetal bovine serum 
























































high resolution mass spectrometry 
horseradish peroxidase 
heteronuclear single quantum 
coherence 
Hertz 














messenger ribonucleic acid 
mass spectrometry 
N-acetylgalactosamine 
National Center for Biotechnology 
Information 
N-methyl-2-pyrrolidone 
nuclear magnetic resonance 
2-oxoglutarate 









































partial complementary single 
strand DNA 
petroleum ether 
parts per million 
polyvinylidene difluoride 
quartet 
mouse leukaemic monocyte 






sodium dodecyl sulfate 
succinimidyl 
triplet 
tetrabutyl ammonium fluoride 
tert-butyldimethylsilyl 
Tris-buffered saline 






triple double doublet 



















Chemical biology is defined as the field of research in which chemical tools and 
approaches are applied to understand and control biological processes. The chemical 
techniques that are developed for this objective involve contributions from many areas of 
chemistry, in particular from organic chemistry. Principles and knowledge inherent to 
organic chemistry, such as reactivity and selectivity, are applied to manipulate specific 
biomolecules in biological samples (cell extracts, living cells, and sometimes even animal 
models) in order to gain insight into the mechanisms underlying the biological processes in 
which these molecules participate or to identify potential new therapeutic strategies. 
Chemical biology research spans a wide range of applications including the use of small 
molecule chemical probes to inhibit, modify or enrich a particular protein of interest, the 
targeting of cell surface receptors with synthetic molecules, and the use of synthetic 
oligonucleotides or other small molecules to control gene expression. Further applications 
involve the synthesis of modified glycosides and lipids and their incorporation into 
glycoconjugates and post-translationally modified proteins by the cell’s metabolic 
machinery, the introduction of unnatural amino acids into recombinant proteins, and the 
design of synthetic and enzymatic methods to manipulate and study post-translational 
modifications. The work described in this thesis involves the development of chemical tools 
and methods for activity-based protein profiling (ABPP), an area of chemical biology 
research that aims to obtain information on the activity of a protein or protein family within 




1.1 Activity-based protein profiling 
ABPP has emerged as a powerful strategy to study the activity of enzymes in complex 
proteomes.1-6 Enzyme expression levels do frequently not correlate directly to their activity, 
as the activity of many enzymes is regulated by post-translational modifications, protein-
protein interactions and/or the action of endogenous small molecule inhibitors. The 
importance of monitoring enzymatic activity can be illustrated by the class of cysteine 
proteases. These enzymes are synthesized as inactive precursors that need to be 
proteolytically cleaved in order to become catalytically active.7,8 Therefore, methods to 
quantify mRNA or protein levels would provide only limited information on the amount of 
active cysteine proteases, a parameter of great physiological relevance for these enzymes. 
To enable the profiling of enzymatic activity, ABPP approaches make use of chemical probes 
termed activity-based probes (ABPs) that are directed to the active site of an enzyme or 
enzyme family. These probes are designed to be recognized by a specific target protein and 
react in a mechanism-based manner with an active site residue, thereby labeling only the 
catalytically active form of the enzyme. The binding of the probe to the enzyme should be 
covalent and irreversible in order to facilitate the analysis of labeled proteins by for instance 
SDS-PAGE or mass spectrometry. A large number of ABPs that target many different enzyme 
classes has been developed over the past decades, enabling the selective labeling of 
enzymatic activity in complex biological samples such as cell lysates, cell cultures and 
sometimes even living organisms.1-3 Besides the monitoring of a specific enzymatic activity, 
ABPP strategies are also used to identify and characterize (unknown) protein functions, to 
study up- and down-regulation of enzymatic activity in various disease states, to discover 
and evaluate putative new enzyme inhibitors and to identify the protein targets of 
covalently binding natural products.1-6  
In general, ABPs contain three essential structural elements as depicted schematically in 
Figure 1.1A. These elements are a reactive group, also named the ‘warhead’, a recognition 
element and a detectable agent. The warhead mediates irreversible binding of the probe to 
the enzyme of interest by reacting in a mechanism-based manner with the catalytically 
active amino acid residue of the enzyme. It is often an electrophilic moiety that is 
susceptible to attack by the active site nucleophile. The warhead needs to be sufficiently 
reactive to allow reaction with the intended active site residues while it should not react 
with off-target amino acid residues or any other functionalities present in the sample. Most 
ABPs also contain a recognition element that confers selectivity towards a specific protein of 
interest and that, by binding in the active site, brings the warhead of the probe and the 




structure of the recognition element and the reactivity of the warhead can be tuned to 
provide selective targeting of a specific enzyme or multiple members of an enzyme class. 
The third common feature of all ABPs is a means to visualize, isolate, identify and/or 
quantify the labeled proteins by for example SDS-PAGE, microscopy or mass spectrometry 
analysis. This functionality can either be a reporter group that enables the direct 
visualization and/or isolation of target enzymes (Figure 1.1B) or a reactive moiety that can 
be used to introduce the tag in a later stage (Figure 1.1C). Based on the nature of this third 
element ABPs are classified as either direct or two-step ABPs, respectively. Commonly used 
reporter entities for ABPP studies include fluorescent tags that enable visualization of the 
labeled proteins on gel and by fluorescence microscopy, affinity tags such as biotin for 
enrichment of labeled proteins and subsequent mass spectrometry analysis or detection by 
Western blotting, or a combination of these. Quenched fluorophores that only become 
fluorescent after binding of the ABP to a target enzyme can strongly reduce background 
labeling and thereby provide significant advantages for (in vivo) imaging applications.9 The 
three main elements of ABPs may be separated by additional linkers that can be used to 
minimize steric hindrance or modulate solubility and membrane-permeability of the probe.   
  
 
Figure 1.1. Schematic representations of one- and two-step ABPP strategies. A) General composition of a direct ABP 
(left) and a two-step ABP (right). B,C) Labeling of enzymatic activity by a direct ABP (B) or a two-step ABP (C). SDS-




Moreover, chemically-cleavable linkers may be included to facilitate the selective release of 
target proteins after affinity purification10-15 and targeting elements can be added for 
targeted delivery of the probe to a specific cell type or cellular compartment.16,17  
The enzymes that are most readily targeted by ABPs are those that form a covalent 
intermediate with their substrate at some point in the catalytic mechanism. The formation 
of such an intermediate can be exploited for the design of a probe that reacts in a manner 
similar to the substrate and thereby forms a covalent and irreversible bond with the active 
site of the enzyme. An example is the labeling of cysteine proteases using the biotinylated 
peptide epoxysuccinate DCG-04 (1) (Figure 1.2), which was shown to react specifically with a 
number of cysteine proteases of the cathepsin family in cell extracts.18 The epoxide moiety 
of the ABP, which functions as the warhead, is attacked by the catalytically active cysteine 
residue in the active site, resulting in opening of the epoxide ring and the formation of a 
stable covalent bond between the enzyme and the probe (Figure 1.3A).19 In cases where no 
covalent enzyme-substrate intermediate is formed, activity-based profiling can be achieved 
by applying suicide substrates that act via an indirect binding mechanism. For example, 
fluorogenic ABP 2 (Figure 1.2) was developed to report on the activity of β-galactosidases by 
reacting as shown in Figure 1.3B.20 This probe contains a latent quinone methide precursor 
which is released upon hydrolysis by a target enzyme. The highly reactive species that is 
formed can subsequently react with a nearby nucleophilic amino acid residue, yielding an 
immobilized fluorescent label. Although suicide substrates bind in a mechanism-based 
manner, the reactive species that is released may react with a nucleophile distant from the 
active site or even another component in the sample, so that this type of ABP does not 
specifically label the protein of interest. In this thesis the focus is on the first class of ABPs 
which directly modify a catalytically active amino acid residue. It should be kept in mind that 
the use of these probes results in the subsequent inhibition of catalytic activity and may 
thereby potentially disturb the system at hand, especially when applied to living organisms. 
  





Figure 1.3. Examples of two mechanisms by which ABPs can bind to their target enzymes. A) Direct alkylation of the 
catalytically active amino acid residue: labeling of cysteine proteases by ABP 1. B) Targeting with suicide substrates: 
labeling of inverting β-galactosidases by fluorogenic ABP 2. ‘Nuc’: nucleophile. 
 
1.2 Two-step activity-based probes 
In contrast to direct ABPs such as DCG-04 (1, Figure 1.2), two-step ABPs do not contain a 
reporter group but are instead functionalized with a small reactive moiety, or ‘ligation 
handle’, that can be used to introduce a tag via a selective ligation reaction after binding of 
the probe to a target enzyme (Figure 1.1C). Two-step labeling experiments are particularly 
useful when the covalent attachment of a fluorescent group or an affinity tag to an ABP 
interferes with binding to the intended enzyme(s), selectivity and/or cell-permeability of the 
probe. An inherent consequence of the introduction of a tag is that it reduces the 
resemblance a probe may possess to an enzyme substrate. Furthermore, the presence of a 
relatively bulky reporter group is not always tolerated in the active site of an enzyme and 
the tag might also render the ABP less cell-permeable or reduce its bioavailability. Two-step 
ABPP strategies may solve these issues by allowing the temporal separation of an ABP and a 
reporter group. A further advantage as compared to direct ABPP is the option to use 
different reporter groups depending on the experimental settings and the desired method 




that are targeted by a two-step ABP, the ligation handle of the probe needs to react 
selectively and efficiently with a reactive group to which the tag is attached. At the same 
time interference with any other (biological) functionalities should be avoided. Therefore 
reactions are used which are commonly referred to as bioorthogonal ligation reactions.21 A 
frequently used example of a bioorthogonal ligation reaction is the copper(I)-catalyzed [2+3] 
cycloaddition of an azide with an alkyne, a reaction generally referred to as ‘click’ reaction 
(Figure 1.4A).22,23 Both of the reactive moieties are small and can be incorporated into an 
ABP without significantly affecting the properties of the probe. The power of this strategy 
was first illustrated by the labeling of enzymatic activity in cell extracts with azide-
functionalized sulfonate 3 followed by reaction with rhodamine-alkyne 4 and copper(I) as 
the catalyst (Figure 1.4C).24 A second example of a bioorthogonal ligation reaction is the 
Staudinger-Bertozzi ligation, in which an azide is again used as a ligation handle. In this case 
two-step labeling is achieved via selective reaction with a phosphine reagent (Figure 1.4B).25 
This strategy has been applied to profile the activity of the proteasome β-subunits by 
treating cultured cells with azide-modified proteasome inhibitor 5 (Figure 1.4C) and labeling 
the target proteins after cell lysis with biotin-phosphine 6.26 A further description of the 




Figure 1.4. A) Copper(I)-catalyzed azide-alkyne [2+3] cycloaddition. B) Staudinger-Bertozzi ligation. C) Structures of 




1.3 Probe design and selected examples 
As a starting point for the design of novel ABPs, the structure of a natural substrate of 
the enzyme of interest can be used, which is then equipped with a tag and modified in such 
a way that reaction with the enzyme results in covalent and irreversible binding. Knowledge 
of the catalytic mechanism and/or reactivity towards particular electrophiles is essential. In 
many cases known mechanism-based inhibitors, in turn frequently based on natural 
substrates, are used as a scaffold to which a reporter entity is attached for analysis of the 
target proteins. In this respect, nature often provides a source of inspiration. For example, 
the structure of the potent biotin-tagged proteasome ABP 7 was derived from the naturally 
occurring irreversible proteasome inhibitor epoxomicin by extension of the N-terminus of 
the peptide epoxyketone with a biotinylated linker (Figure 1.5).27,28 The proteasome 
contains three catalytically active β-subunits that have different substrate preferences but 
each employ an N-terminal threonine residue as the active site nucleophile, a distinctive 
feature that is only found in a few other proteases. This particular aspect of the 
proteasome’s catalytic mechanism is exploited by the inhibitor to achieve selective targeting 
of this enzyme. The binding mechanism involves reaction of both the hydroxyl group and the 
primary amine of a catalytic threonine residue with the ketone and the epoxide of the 
inhibitor warhead, respectively, to form a stable morpholine ring (Figure 1.6A).29 
 
 
Figure 1.5. Structures of biotinylated epoxomicin-derived proteasome probe 7, azide-tagged (8) and fluorescently 
labeled (9) cyclophellitol derivatives that target retaining β-glucosidases and fluorescently labeled aziridine-based 





Figure 1.6. Binding mechanisms of various classes of ABPs. Inhibition of the proteasome by epoxomicin derivatives 
(A), retaining β-glucosidases by cyclophellitol analogues (B) and deubiquitinating enzymes by ubiquitin-vinyl sulfone 
(C). Ub75: Ubiquitin lacking its C-terminal glycine residue. 
Another example of ABP development guided by a mechanism-based inhibitor is based 
on the retaining β-glucosidase inhibitor cyclophellitol, which is itself a remarkable example 
of rational design coinciding with the isolation of the natural product.30-32 This mechanism-
based inhibitor has served as a basis for the synthesis of direct and two-step ABPs (8 and 9, 
Figure 1.5) that selectively label the human enzyme glucocerebrosidase in cell extracts and 
cultured cells.33 Interestingly, the introduction of the hydrophobic fluorescent tag in probe 9 
proved to strongly enhance its affinity as compared to the parent compound cyclophellitol. 
Irreversible binding of these probes is thought to occur by attack of the nucleophilic 
glutamic acid residue in the active site of retaining β-glucosidases on the epoxide moiety of 
the ABPs (Figure 1.6B).34 A second glutamic acid residue, which is essential for substrate 
hydrolysis by acting as a general acid/base, was shown to be also requisite for binding of the 
epoxide probes.33 In a later study, an aziridine-based ABP (10) was revealed to inhibit 
retaining β-glucosidases with enhanced potency and enabled in vivo profiling of enzymatic 
activity.35 However, labeling also occurred in the absence of the general acid/base residue in 
the active site, presumably due to the high reactivity of the aziridine moiety. As a result the 
probe is capable of labeling enzymes that lack catalytic activity on their natural substrate 
and therefore it may be considered not to be a ‘true’ ABP.  
The biotinylated peptide epoxysuccinate DCG-04 (1, Figure 1.2) represents a further 
example of an ABP that is derived from a natural product, the irreversible cysteine protease 




epoxysuccinate warhead, was modified by elaboration of the peptide portion to allow 
incorporation of an affinity tag.18  
Besides inhibitor-inspired probe design, the structure of a substrate and its binding 
mechanism to the protein of interest can also serve directly as a basis for novel ABPs. This 
strategy was illustrated by the synthesis of ABPs based on the small (76 amino acids) protein 
ubiquitin to target deubiquitinating enzymes, a class of cysteine proteases that recognize a 
range of substrates modified with one or more ubiquitin units which are linked via their C-
terminus to a lysine residue of another ubiquitin or to the protein substrate. The 
substitution of the C-terminal glycine residue of recombinant ubiquitin with a vinyl sulfone 
warhead and subsequent radioiodination led to an ABP that labels a number of 
deubiquitinating enzymes in cell extracts (Figure 1.6C).37 In later studies, other thiol-reactive 
electrophiles were attached to epitope-tagged ubiquitin to modify the reactivity of the 
probes towards specific deubiquitinating and ubiquitin-conjugating enzymes.38,39 These 
probes also exemplify the uncommon use of protein-derived ABPs rather than small 
molecule chemical probes, with a major drawback being that their large size excludes in situ 
and in vivo applications. 
The fine balance between reactivity and selectivity of an ABP is essential to achieve 
specific labeling of a desired protein or set of proteins. The rational design of a warhead, in 
particular its reactivity, can be an important factor to modify the range of enzymes that is 
targeted by an ABP. This aspect of ABP design is clearly illustrated by the development of 
probes 11-13 (Figure 1.7), which all contain an α-halogenated methylketone as the 
warhead.40-42 Iodide is a good leaving group and the iodomethylketone is an excellent 
electrophile for SN2 reactions with soft nucleophiles such as thiolates, while being stable 
towards nucleophilic attack by hard nucleophiles such as water. As a result, iodoacetamide 
has a high intrinsic reactivity towards cysteine residues, so that tagged derivatives such as 
biotinylated probe 1140 and two-step probe 1241 are capable of labeling virtually all cysteine 
residues within a biological sample. Consequently these reagents are not applicable as ABPs 
but they are generally used for the global profiling of protein expression by mass 
spectrometry analysis. The incorporation of a ‘light’ (hydrogen) or ‘heavy’ (deuterium) 
isotope-labeled linker into the ABP (11) or, in case of probe 12, into the ligation reagent 
enables the relative quantification and parallel identification of individual proteins from two 
complex biological samples. In addition to these global labeling experiments, probe 12 was 
used to demonstrate how selectivity can be realized without lowering the reactivity of the 
probe.41 Highly reactive cysteine residues, which likely include catalytic residues and for 





Figure 1.7. Structures of biotinylated (11) and alkyne-functionalized (12) iodoacetamide reagents and fluorescently 
labeled ABPs that target caspases (13) and deubiquitinating enzymes (14). 
with low reactivity by using varying concentrations of the iodoacetamide reagent. While the 
cysteine residues with low reactivity are labeled in a concentration-dependent manner, 
labeling of the most reactive cysteine residues is equally efficient when a substoichiometric 
amount or an excess of the reagent is used. This strategy enables the annotation of highly 
reactive cysteines regardless of their natural abundance and can be used to identify new 
residues with putative catalytic activity.  
In contrast to the iodoacetamide reagents, fluoromethylketone inhibitors and their 
derivatives, such as the fluorescein-functionalized ABP 13 (Figure 1.7),42 have a very low 
intrinsic reactivity towards cysteine residues because the fluoride is a very poor leaving 
group and the carbon-fluorine bond is much more stable than the carbon-iodine bond. In 
this case, selective activity-based labeling of a specific class of cysteine proteases, the 
caspases, was achieved by incorporation of a peptide into the ABP that specifically binds 
these enzymes and thereby brings the warhead in close proximity to the active site cysteine 
residue so that a reaction takes place.  
Another example of the use of a warhead which is essentially a very poor electrophile is 
the terminal alkyne in ABP 14, which was shown to label deubiquitinating enzymes in an 
activity-based manner.43 While the alkyne moiety is generally considered to be unreactive 
towards nucleophiles and therefore frequently used for bioorthogonal ligation reactions, 
attachment to a specific and tightly binding substrate of deubiquitinating enzymes was 
demonstrated to induce attack of the catalytically active cysteine residue on the alkyne 
warhead. The same strategy was also applied to label caspase activity.43 Small molecule 
cysteine protease inhibitors that were derivatized with an alkyne warhead showed no 




contrast, the functionalization of larger peptide fragments of a natural caspase-1 substrate 
with an alkyne warhead yielded selective caspase-1 ABPs. 
1.4 Aim and outline of this thesis 
Most of the ABPs that have been developed to date target hydrolytic enzymes, in 
particular proteases and esterases, that employ an amino acid residue (serine, threonine, 
cysteine) as the active site nucleophile. Novel ABPP strategies are increasingly more directed 
towards the development of ABPs that target other enzyme families, often with different 
catalytic mechanisms or low expression levels. At the same time the targeting of enzyme 
activities with tight substrate specificity and the interest in in vivo applications of ABPP 
necessitates the use of ABPs that are modified with a small ligation handle instead of a 
reporter group. Relatively few bioorthogonal ligation methods, however, have been applied 
to the two-step profiling of enzymatic activity. The first part of this thesis therefore aims to 
develop new bioorthogonal ligation methods for use in ABPP. In addition, the complexity of 
biological processes and the involvement of many proteins and other biomolecules in 
cellular processes and disease development often requires the study of multiple targets 
simultaneously, and therefore attention is also focused on tandem labeling strategies in 
which multiple ligation reactions are performed concurrently in a single experiment.  
Chapter 2 gives an overview of the various bioorthogonal ligation methods that have 
been described in literature, with an emphasis on the application of bioorthogonal 
chemistry in ABPP. Frequently used ligation reactions include copper(I)-catalyzed as well as 
strain-promoted [2+3] cycloadditions of an azide with an alkyne, Staudinger-Bertozzi ligation 
of an azide with a phosphine, Diels-Alder reactions between electron-rich dienes and an 
electron-deficient dienophiles and inverse-electron-demand Diels-Alder reactions of 
tetrazine with strained alkenes (Figure 1.8).21  
While many examples exist of the use of azides and alkynes as ligation handles in two-
step ABPs (Figures 1.8A and 1.8B, respectively),1,44 Diels-Alder [4+2] cycloadditions have not 
yet been applied to ABPP. The selectivity of these reactions together with the generally 
small size of the reagents renders Diels-Alder ligations promising new strategies for two-step 
ABPP. Chapter 3 describes the development of a Diels-Alder based approach (Figure 1.8C) 
for the labeling of endogenous enzymatic activity. Four different diene-conjugated 
proteasome ABPs are applied to the labeling of proteasome activity in cell extracts by 
reaction with a fluorescently labeled maleimide as a dienophile. The application of the Diels-
Alder ligation to the labeling of another class of enzymes, cysteine proteases of the 





Figure 1.8. Reagents for commonly used bioorthogonal ligation reactions. 
presented in which the Diels-Alder ligation is used together with the Staudinger-Bertozzi 
ligation for the labeling of multiple enzymatic activities in the same sample. 
The inherent reactivity of maleimide towards cysteine residues poses severe limitations 
on its use in bioorthogonal labeling experiments. In order to improve the selectivity of the 
ligation reaction, an alternative two-step ABPP strategy that is based on the inverse-
electron-demand Diels-Alder reaction of tetrazine with norbornene (Figure 1.8D) is 
investigated in Chapter 4. Labeling of proteasome activity is accomplished by using a 
norbornene-functionalized proteasome ABP and a fluorescently labeled or biotin-tagged 
tetrazine reagent. This approach enables the selective labeling of active proteasome β-
subunits in vitro and in situ. Moreover, a triple ligation strategy involving tetrazine ligation, 
Staudinger-Bertozzi ligation and copper(I)-catalyzed click reaction is developed for the 
simultaneous labeling of three different proteolytic activities in a single experiment. 
An enzyme class that has remained somewhat resistant to ABPP is that of the 
glycosidases, though at least a number of glycosidases employ a mechanism involving a 
covalent enzyme-substrate intermediate and are thus possible candidates for ABP 
development. The first ABPs for this class of enzymes were based on 2-deoxy-2-
fluoroglycosides, substrate mimics in which the hydroxyl group next to the anomeric center 
has been substituted with a fluorine.45 A drawback of these inhibitors, though well suited for 
structural studies on transition states, is that they bind in a reversible manner. Nonetheless 
it was shown that the covalent intermediate formed between a number of these ABPs and 




proteins on gel.45,46 In a later study another type of glycosidase ABPs was developed based 
on the irreversible retaining β-glucosidase inhibitor cyclophellitol (see Figure 1.5).33,35 In a 
comparative study the cyclophellitol derivatives proved to be superior to 2-deoxy-2-
fluoroglucosides in terms of potency and labeling efficiency on two retaining β-
glucosidases.46 The second part of this thesis describes the development of differently 
configured isomers of the cyclophellitol-based ABPs for the labeling of two mechanistically 
related glycosidases, retaining α- and β-galactosidases, for which at present no covalent and 
irreversible probes have been reported in literature. 
Chapter 5 details the synthesis of galactopyranose-configured probes that contain an 
electrophilic aziridine or epoxide moiety in either an α- or a β-configuration47 with the aim 
to achieve activity-based profiling of retaining α- and β-galactosidases, respectively (Figure 
1.9). Both direct ABPs functionalized with a fluorescent Bodipy tag or a biotin tag are 
synthesized as well as probes that are derivatized with an azide for two-step labeling 
experiments. The biological evaluation of these probes is presented in the following two 
chapters. In Chapter 6 the inhibitory potency of the α-configured epoxide- and aziridine-
based probes (15 and 16, Figure 1.9) is evaluated on the recombinant human enzyme α-
galactosidase A. The most potent compounds, the aziridines ABPs, are then used to visualize 
the active enzyme on gel. In addition, it is demonstrated that the fluorescently labeled 
aziridine ABP enables the labeling of endogenous retaining α-galactosidase activity in cell 
extracts. Chapter 7 describes the evaluation of the β-configured epoxide-based probes (17, 
Figure 1.9) for their ability to inhibit and label the recombinant enzyme 
galactocerebrosidase, a human retaining β-galactosidase. Furthermore, it is revealed that 
the small structural difference between the β-galactopyranose probe scaffold developed in 
this thesis and the previously reported β-glucopyranose-configured isomers (e.g. ABPs 8 and 
9, Figure 1.5), namely only the stereochemistry of a single hydroxy substituent, has resulted 
in a dramatic change in selectivity. Consequently, the two differently configured ABPs allow 
the selective labeling of retaining β-galactosidases and retaining β-glucosidases, 
respectively, without any observed cross-reactivity. 
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A bioorthogonal ligation is defined as a process in which two reactants that are added to 
a biological sample react with each other in a chemoselective manner. This implies that the 
reagents are non-toxic and inert to any other functionality present and that the chemistry 
does not interfere with the biological system at hand. Ideally, the reactants that participate 
in a bioorthogonal ligation reaction should react fast in aqueous environments, in a 1:1 ratio 
and in a quantitative yield with respect to each other. Furthermore, easy access to the 
required reagents and stability under physiological conditions are requisite for the 
successful use of bioorthogonal chemistry in a wide range of applications and in different 
fields of research. The biological samples in which bioorthogonal reactions are intended to 
take place increase in complexity ranging from a cell extract (tissue lysate), to a cell or tissue 
culture to an animal model, with each of these posing additional demands that may 
complicate the accomplishment of a selective chemical transformation. The actual 
complexity of a biological sample is also dependent on the type of experiment. Whereas 
labeling of a biomolecule in cell extracts has to occur in the presence of (nearly) all possible 
biomolecules, in a cell-surface labeling experiment only those molecules present at the 
outer cell membrane may interfere with the reaction. In contrast to many biological 
processes, in which the problem of selectivity is solved by catalysts that recognize 




selective manner, bioorthogonal chemistry aims to develop reagent pairs that react without 
the assistance of a (biological) catalyst. The chemical reactants thus need to have a high 
intrinsic reactivity towards each other whereas at the same time they need to be inert 
towards any other biological functionality. Considering the required level of selectivity 
combined with the fact that a quantitative process of two isolated reactants in a 
stoichiometric ratio is not easily achieved, it is not surprising that to date a truly 
bioorthogonal reagent pair has not yet been developed. Nonetheless, significant progress is 
being made and gradually more ligation reactions have emerged that fulfill most of the 
criteria of bioorthogonality.  
2.2 Bioorthogonal chemistry: scope and limitations 
The concept of bioorthogonal chemistry was first introduced by the labeling of cell 
surface N-glycoproteins using a ketone-functionalized analogue of N-acetylmannosamine.2 It 
was demonstrated that N-levulinoyl-mannosamine is a valid substrate of the sialic acid 
biosynthesis machinery of mammalian cells. When added to a cell culture it is converted into 
levulinoyl sialic acid and subsequently incorporated into N-glycoprotein chains to eventually 
end up on the cell surface. The ketone moiety of the levulinoyl groups can then be reacted 
with a tagged hydrazide in a bioorthogonal fashion (Figure 2.1A), as neither of the two 
reactants is present in naturally occurring cell surface biomolecules. In a subsequent study 
the same objective was achieved with much higher efficiency by making use of another 
ligation reaction, referred to as the Staudinger ligation or Staudinger-Bertozzi ligation 
(Figure 2.1B, top panel).3 Metabolic incorporation of an azide-functionalized mannosamine 
derivative followed by reaction with a biotinylated phosphine enabled the selective labeling 
of cell surface N-glycoproteins that contained the azide-modified sialic acids. Azides and 
phosphines are both unreactive towards biological functionalities but react readily with each 
other in an aqueous environment. The phosphine reagents used for this ligation strategy are 
designed such that the aza-ylide intermediate is captured by intramolecular reaction with a 
methyl ester to form a stable amide bond between the two reagents. Whereas ketones are 
present in a number of endogenous molecules, azides have not yet been detected in 
eukaryotes, which together with their small size and general inertness towards biological 
functionalities renders them ideal reagents for bioorthogonal chemistry. Another 
bioorthogonal ligation dating from the same period as the Staudinger-Bertozzi ligation is the 
copper(I)-catalyzed Huisgen [2+3] cycloaddition of an azide with a terminal alkyne, a reactive 
group that is also non-perturbing to biological systems. This cycloaddition, termed ‘click’ 





Figure 2.1. Schematic representations of commonly used bioorthogonal ligation reactions. A) Ketone-hydrazide 
condensation. B,C) Reactions using an azide as one of the reagents: copper(I)-catalyzed Huisgen [3+2] azide-alkyne 
cycloaddition, strain-promoted azide-alkyne cycloaddition and Staudinger-Bertozzi ligation of an azide with a 
phosphine. D) Light-induced reaction of tetrazole with an alkene. E) Diels-Alder [4+2] cycloaddition of a conjugated 
diene with a dienophile. F) Inverse-electron-demand Diels-Alder reaction of tetrazine with a strained alkene. 
and, in particular, chemical biology.4-8 As a bioorthogonal ligation strategy the click reaction 
requires the installation of either an azide or an alkyne in a biomolecule and subsequent 
reaction with the complementary reactant to which a reporter entity is attached (Figures 
2.1B, middle panel and 2.1C). Click chemistry was first used as a bioorthogonal ligation 
method for the labeling of enzymatic activity in cell extracts using an azide-functionalized 
ABP and a fluorescently labeled alkyne.8 The fact that this reaction is catalyzed by copper(I), 
which is toxic to cells and living organisms, precludes its use for in situ and in vivo labeling. 
Although this aspect makes the click reaction not strictly bioorthogonal, it is still one of the 
most widely used ligation reactions in chemical biology research due to the small size of the 
reagents and the selectivity and speed of the reaction, which proceeds considerably faster 
than the Staudinger-Bertozzi ligation.9 In order to solve the issue of toxicity, a ‘strain-
promoted’ click reaction has been developed that makes use of ring strain to drive the 
reaction and thereby eliminates the need for a copper catalyst.10 A wide and rapidly growing 
number of substituted cyclooctynes has been reported to enable the labeling of 
biomolecules on the cell-surface and in living animals via strain-promoted cycloaddition with 
azides (Figure 2.1B, bottom panel).10-21 In addition to the azide-alkyne cycloaddition several 




reactions, for example the reaction of cyclooctynes with other dipoles such as nitrones22 and 
the light-induced cycloaddition of tetrazole and an alkene (Figure 2.1D), termed ‘photoclick’ 
chemistry, which occurs via the in situ formation of a nitrile imine.23,24 
Of the various bioorthogonal reactions alternative to click chemistry and Staudinger-
Bertozzi ligation, those based on Diels-Alder [4+2] cycloadditions are probably the most 
promising since they are generally very selective and efficient under mild, aqueous 
conditions. ‘Standard’ Diels-Alder chemistry involves the reaction of a conjugated electron-
donating diene with an electron-deficient dienophile such as maleimide (Figure 2.1E). An 
inherent disadvantage of these Diels-Alder reactions is the propensity of the dienophile to 
undergo 1,4-conjugate addition, which necessitates the masking of free thiols in the 
biological sample at hand in order to prevent cross-reactivity and thereby essentially 
precludes in situ and in vivo applications.25 This problem can be overcome by the use of 
inverse-electron-demand Diels-Alder cycloadditions in which tetrazine, an electron-deficient 
diene, is reacted with a strained alkene such as norbornene (Figure 2.1F). These reagents 
generally show no reactivity towards cysteine residues. The potential of the tetrazine 
ligation strategy was first demonstrated by the live cell imaging of cancer cells that were 
treated with norbornene-modified antibodies and subsequently labeled through reaction 
with a fluorescently labeled tetrazine.26 In the following years, the selectivity and 
exceptionally fast kinetics of the tetrazine ligation have led to a rapidly growing number of in 
situ and in vivo applications.27-33 The set of available reagents has been expanded with 
different dienophiles, most notably cyclopropene27,28 and trans-cyclooctene,29-35 as well as 
various substituted tetrazines that exhibit altered reactivity and/or stability.36 A related 
ligation strategy that is based on the reaction of tetrazines with isonitriles has recently been 
applied to the imaging of cell surface glycans.37 In another study it was demonstrated that 
the tetrazine moiety possesses an intrinsic property that may provide an additional 
advantage for imaging applications, namely its ability to quench specifically conjugated 
Bodipy fluorophores.33 Cultured cells were treated with a trans-cyclooctene-modified taxol 
derivative and subsequently with Bodipy-functionalized tetrazine 1 (Figure 2.2) to visualize 
microtubule structures, the intracellular target of taxol. The Bodipy tag was revealed to be 
intrinsically only weakly fluorescent but turned brightly fluorescent upon reaction with the 
dienophile (2), which  strongly reduces background fluorescence and eliminates the need to 
wash out the excess of reagents prior to fluorescence imaging. More recently, other 
tetrazine-fluorophore conjugates were described for which the ‘turn-on’ ratio of 






Figure 2.2. Quenched Bodipy-tetrazine (1) that becomes strongly fluorescent after reaction with a dienophile (2). 
In synthetic organic chemistry the utility of chemical transformations is judged by their 
efficiency, so that at least the most elaborate or expensive reaction partner is transformed 
in (near) quantitative fashion, as well as their selectivity, so that unwanted side reactions are 
limited. Yield, the nature of (side) products and reaction kinetics are also parameters that 
should be considered when evaluating the merits of a bioorthogonal ligation. Whereas the 
kinetics of newly developed ligation reactions are frequently analyzed using isolated 
reagents, the efficiency of a particular ligation reaction is likely to be influenced by the 
nature of the biological sample, for example a cell extract or an intracellular environment, 
and the experimental conditions. A detailed study in which the copper(I)-catalyzed click 
reaction, strain-promoted click reaction and Staudinger-Bertozzi ligation were directly 
compared for the labeling of proteins in cell extracts and glycoproteins on live cell surfaces 
revealed that, as expected, the former reaction is superior in terms of efficiency but its use 
is restricted to in vitro experiments.9 The strain-promoted azide-alkyne cycloaddition and 
Staudinger ligation performed similarly well, with the efficiency of the latter reaction 
depending on the specific structure of the azide.  
The efficiency of bioorthogonal chemistry in the context of two-step profiling of 
enzymatic activity has been evaluated by making use of a trifunctional ABP (3, Figure 2.3A), 
which contains an electrophilic vinyl sulfone warhead to target the catalytically active 
subunits of the proteasome (β1, β2 and β5), a fluorescent Bodipy tag and also an azide as a 
ligation handle.39 Using this probe, endogenous proteasome activity was fluorescently 
labeled in cell extracts and subsequently reacted with biotin-phosphine 4. Visualization of 
the labeled proteins by SDS-PAGE revealed not only the fluorescent labeling of the three 
active proteasome subunits by ABP 3 but also a gel-shift of the fluorescent bands in those 
samples that were exposed to biotin-phosphine 4 (Figure 2.3B). This phenomenon is due to 
the increase in molecular weight of the labeled proteins (roughly 1 kDa) resulting from the 
reaction of the enzyme-bound ABP with the phosphine reagent. Hence, the efficiency of the 
ligation reaction can be determined from the ratio of fluorescence intensity between 





Figure 2.3. Staudinger-Bertozzi ligation in two-step labeling of proteasome activity. A) Structures of azide-
functionalized fluorescent proteasome ABP 3 and biotin-phosphine 4. B) Strategy to evaluate the efficiency of the 
Staudinger-Bertozzi ligation using ABP 3 and phosphine 4. Ligation with the phosphine reagent results in a 
concentration-dependent gel-shift of the fluorescently labeled proteasome subunits. SDS-PAGE: sodium dodecyl 
sulfate polyacrylamide gel electrophoresis. 
Bertozzi ligation, as compared to the corresponding lower-running bands. The ligation 
reaction was shown to reach completion, provided that a large excess of biotin-phosphine 4 
was added relative to ABP 3. The poor yield in terms of conversion of reagent 4 is most likely 
due to the inherent instability of the trivalent phosphine, which has been shown to be 
susceptible to aerobic and metabolic oxidation.40  
A similar approach was used to directly compare the efficiency of the strain-promoted 
azide-cyclooctyne cycloaddition with the Staudinger-Bertozzi ligation in addressing azide-
modified biomolecules in cell extracts. For this purpose, biotinylated cyclooctynes 6,18 721 
and 812 were applied to a two-step proteasome profiling assay using azide-functionalized 
and fluorescently labeled ABP 5 (Figure 2.4).41 The results were compared to those obtained 
after Staudinger ligation with 4, revealing that in these settings a quantitative 
transformation with respect to the azide is achieved with much lower concentrations of the 
cyclooctyne reagents than the phosphine. However, a shortcoming of all three strain-
promoted click reagents is that they suffered from considerable cross-reactivity, resulting in 
the appearance of numerous background protein bands. This is in agreement with 
previously reported observations of non- specific labeling with dibenzocyclooctyne reagents 





Figure 2.4. Reagents for two-step labeling of proteasome activity via strain-promoted click reaction. Structures of 
azide-functionalized fluorescent proteasome ABP 5 and biotin-functionalized cyclooctynes 6-8. 
that most of the azide-independent   labeling by cyclooctynes occurs via thiol-yne addition 
with cysteine residues.43 Consequently, while the use of functionalized cyclooctynes is an 
effective strategy for addressing cell surface azides, alkylation of free thiols appears to be 
requisite to limit background labeling when strain-promoted click chemistry is applied to 
complex biological samples such as cell extracts.  
After the first reports describing the use of the tetrazine ligation as a bioorthogonal 
ligation strategy had appeared, its efficiency and selectivity have quickly led to an increasing 
use of this reaction for in situ and in vivo applications instead of azide-cyclooctyne 
cycloadditions and the Staudinger-Bertozzi ligation. At the same time the development of 
ligation handles other than azides and alkynes has opened up a means to explore another 
aspect of bioorthogonal chemistry, namely the simultaneous use of multiple bioorthogonal 
ligations to study several biomolecules at the same time. Whereas it has been shown that 
samples tagged with both azide and alkyne groups can be efficiently labeled by step-wise 
click ligation,44,45 the cross-reactivity between the reagents precludes the simultaneous 
performance of both ligation reactions and also necessitates the use and efficient removal 
of large excesses of the reagents. The availability of reagents for bioorthogonal ligations that 
are orthogonal to azides enables the use of two or more individual ligation reactions at the 
same time. A first demonstration of a dual labeling strategy involved the simultaneous 
labeling of two different cell surface glycans by ketone-hydrazide ligation and Staudinger-
Bertozzi ligation.46 The use of ketones, however, restricts the application of this strategy to 
the labeling of molecules on the cell surface. In a later study it was shown that the Diels-
Alder [4+2] cycloaddition and the Staudinger-Bertozzi ligation can be used in tandem to label 
different proteolytic activities in cell lysates (see Chapter 3), although the reactivity of the 
dienophile towards cysteine residues forms severe limitations to the application and 




The selectivity of the inverse-electron-demand Diels-Alder reaction has stimulated the 
development of improved tandem labeling strategies. In a first report it was revealed that 
the reaction between tetrazine and trans-cyclooctene can be used concurrently with the 
strain-promoted azide-cyclooctyne cycloaddition for the simultaneous labeling of two 
different cell surface receptors (Figure 2.5).47 A co-culture of two cell lines was first treated 
with two different trans-cyclooctene- or dibenzocyclooctyne-modified antibodies and then 
labeled by reaction with azide- and tetrazine-functionalized fluorescent tags. A limitation of 
this strategy is that trans-cyclooctene reacts (albeit slowly) with azides and that some 
tetrazines display reactivity towards specific cyclooctynes,47,48 so that the proper reagents 
need to be carefully selected in order to minimize cross-reactivity. Related dual labeling 
strategies were used for cell surface glycan imaging in which ligation with tetrazine was 
accomplished by making use of cyclopropene or terminal alkene ligation handles instead of 
trans-cyclooctene.49-51 In addition, it has been demonstrated that properly substituted 
cyclopropenes enable orthogonal reactions with either tetrazines or nitrile imines52 and that 
the reaction of tetrazine with isonitriles is orthogonal to the azide-dibenzocyclooctyne 
cycloaddition,53 although in both cases no tandem bioorthogonal labeling experiments were 
performed. A triple ligation strategy that involves the copper(I)-catalyzed click reaction, the 
Staudinger-Bertozzi ligation and the inverse-electron-demand Diels-Alder reaction of 
tetrazine with norbornene was shown to enable the simultaneous labeling of three different 
enzymatic activities in cell extracts (Figure 2.6). Despite the fact that tetrazines revealed to 
be poorly compatible with click chemistry, the successive performance of these ligation 
reactions in the same sample proved to result in efficient and selective labeling of the 
intended target enzymes (see Chapter 4).54  
 
Figure 2.5. Schematic representation of a tandem bioorthogonal ligation strategy that involves combined strain-





Figure 2.6. Schematic representation of a triple ligation strategy involving copper(I)-catalyzed click reaction, 
Staudinger-Bertozzi ligation and tetrazine ligation for simultaneous labeling of three enzymatic activities. 
2.3 Bioorthogonal chemistry in ABPP 
An area of research that has benefited greatly from the development of bioorthogonal 
chemistry is activity-based protein profiling (ABPP), which aims to obtain information on the 
activity of an enzyme (family) within the larger context of the full biological system. 
Bioorthogonal ligation reactions are essential for a specific type of ABPP studies that make 
use of two-step ABPs, which in contrast to directly labeled ABPs are modified with a small 
ligation handle instead of a reporter group. In this way the structural modifications to the 
ABP core, which is frequently derived from a small molecule inhibitor, are kept as small as 
possible in order to limit the disadvantageous consequences that can be associated with the 
direct attachment of a reporter group. Furthermore, the temporal separation of an ABP and 
a tag also provides the opportunity to select different tags depending on the desired 
method of analysis while using a single ABP. Most two-step ABPP strategies make use of 
either azide- or alkyne-functionalized ABPs that can be labeled via azide-alkyne 
cycloaddition or Staudinger-Bertozzi ligation. The first report describing the use of 
bioorthogonal chemistry for ABPP involved the two-step profiling of enzymatic activity via 
copper(I)-catalyzed click reaction between an azide-functionalized ABP and an alkyne-
rhodamine tag.55 At the same time another study was reported in which the Staudinger-
Bertozzi-ligation was used to label enzymatic activity in cell extracts.56 In this strategy, again 
an azide-modified ABP was used but two-step labeling was achieved by reaction with a 
biotinylated phosphine. The efficacy of the tetrazine-norbornene cycloaddition for the 
labeling of enzymatic activities in cell extracts and in cultured cells has also been 
demonstrated.54 The relatively large size of the norbornene ligation handle may hinder its 
general application in activity-based profiling and in this respect the use of the much smaller 
cyclopropene tag forms an attractive alternative. Up till now, however, the tetrazine ligation 




The value of two-step protein profiling can be illustrated by the development of a 
subunit-specific ABP for one of the proteasome active sites, β1. The two-step ABP 9 (Figure 
2.7) was derived from a β1-subunit selective mechanism-based proteasome inhibitor by the 
installment of an azide and displayed selectivity similar to the parent compound.57 In 
contrast, a direct ABP that was synthesized from the azide-functionalized probe by reaction 
with an alkyne-modified fluorescent tag (10) showed cross-reactivity towards other 
proteolytically active proteasome subunits, demonstrating that the installment of the 
fluorescent tag had resulted in a loss of selectivity.58 An example of an enzyme class for 
which two-step labeling strategies appear to be indispensable is that of the exo-
glycosidases, which typically have a sterically confined active site so that modification of a 
substrate (analogue) with a large tag is usually not tolerated. This limitation is likely 
responsible for the fact that few ABPs have been developed for this class of enzymes. The 
first ABPs that were reported to target exo-glycosidases are based on 2-deoxy-2- 
fluoroglycosides, mechanism-based retaining exo-glycosidase inhibitors,59 in which the 
primary hydroxyl is substituted with an azide to enable two-step labeling of target enzymes. 
For instance, retaining β-galactosidase inhibitor 11 served as a basis for the development of 
the two-step ABP 12 (Figure 2.8).60 Even though this small modification resulted in some loss 
of affinity, the probe retained sufficient affinity to enable labeling of target enzymes via 
Staudinger-Bertozzi ligation with a tagged phosphine reagent. In an alternative approach, 
ABPs for retaining β-glucosidases were designed by making use of the potent irreversible 
retaining β-glucosidase inhibitor cyclophellitol (13)61,62 which contains an epoxide moiety 
with which it covalently binds its target enzymes. Substitution of the primary hydroxyl with 
an azide led to an equally potent two-step ABP (14).63 This probe can be used to label 
recombinant retaining β-glucosidases via copper(I)-catalyzed azide-alkyne cycloaddition.64 
Suprisingly, however, a direct ABP that was derived from 14 by installment of a Bodipy 
fluorophore (15) proved to label the human enzyme glucocerebrosidase with much higher 
potency than the azide-functionalized ABP.63 It was suggested that a hydrophobic pocket 
near the active site of the enzyme is responsible for tight binding of the hydrophobic 
fluorescent tag, thereby enhancing the affinity of the probe. 
 





Figure 2.8. Structures of retaining β-galactosidase inhibitor 11 and azide-functionalized analogue 12, retaining β-
glucosidase inhibitor cyclophellitol (13) and derivatives functionalized with an azide (14) or Bodipy fluorophore (15). 
2.4 Cleavable linkers in ABPP 
A conceptually different application of selective organic chemistry in chemical biology 
research involves the use of cleavable linker systems that allow mild cleavage under 
conditions orthogonal to functionalities present in the biological system at hand. A major 
application of these linkers in ABPP is their use in the purification of enzymes that are 
tagged by either direct or two-step labeling with a biotin tag. Affinity tags are regularly used 
for the enrichment of target proteins, for instance by pull-down with streptavidin-coated 
beads, to facilitate subsequent analysis. This approach often requires the release of 
captured proteins from the beads, which generally involves harsh conditions due to the 
strong affinity of streptavidin for biotin. Another drawback is that the purified samples may 
be contaminated with endogenously biotinylated proteins, non-specifically bound proteins 
and (denatured) streptavidin. To solve these issues, several cleavable linker systems have 
been designed that can be incorporated in an ABP or in a reagent for bioorthogonal ligation 
and that can be cleaved in a chemoselective manner after affinity pull-down in order to 
selectively release the target proteins. Examples include redox-cleavable linkers based on a 
disulfide (16)65,66 or a diazobenzene (17)67 moiety, bisaryl hydrazones (18)68 which are 
cleaved by transimination, and photocleavable linkers such as 19 (Figure 2.9A).69 Protecting 
groups used in organic synthesis have also served as a basis for the design of cleavable 
linkers, for instance acid-cleavable linker 2070 and levulinoyl derivative 21.71 The latter 
moiety can be cleaved by the addition of hydrazine, which results in imine formation and 
intramolecular cyclization with concomitant cleavage of the ester bond (Figure 2.9B). 
Alternatively, enzymatic hydrolysis can be used to achieve the selective release of target 
proteins, as exemplified by linker 22 (Figure 2.9A) which contains a peptide sequence that is 
specifically cleaved by TEV proteases.72 Recently, a linker containing a vicinal diol was 






Figure 2.9. A) Structures of commonly used cleavable linker systems for the enrichment of proteins from biological 
samples. Cleavage sites are indicated by dashed lines. B) Mechanism of hydrazine-mediated cleavage of levulinoyl-
based linker 21. 
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Two-step labeling of endogenous enzymatic 
activities by Diels-Alder ligation 
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ChemBioChem 2010, 11, 1769‐1781. 
3.1 Introduction 
A bioorthogonal reaction can be defined as a chemical transformation between two 
functional groups that takes place selectively within complex biological samples such as cell 
extracts, tissues or even living organisms. By allowing the temporal separation of a 
molecular probe and a reporter group, bioorthogonal chemistry creates the potential to 
selectively modify a specific biomolecule in the desired experimental setting. The power of 
this strategy was initially demonstrated by the cell surface labeling of N-glycoproteins by 
means of the Staudinger-Bertozzi ligation.1-3 The success of this strategy led to the 
development of many other bioorthogonal ligation reactions, of which the copper(I)-
catalyzed Huisgen [2+3] cycloaddition between an azide and an alkyne, referred to as ‘click’ 
reaction, is at present one of the most widely used bioconjugation methods.4,5 
Bioorthogonal ligation reactions have been applied to study a variety of biological processes, 
in particular those involving post-translational modifications.6-10 Another area of research 
that has benefited from bioorthogonal chemistry is two-step activity-based protein profiling 
(ABPP), in which it enables the temporal separation of an active site-directed chemical probe 




target enzyme may overcome problems associated with the direct introduction of a reporter 
group into an ABP such as interference with cell permeability, bioavailability, affinity for a 
target enzyme and/or selectivity over other enzymes. The value of bioorthogonal chemistry 
in ABPP was first demonstrated by the two-step activity-based profiling of serine hydrolases 
by making use of the copper(I)-catalyzed click reaction between an azide-functionalized ABP 
and an alkyne-modified fluorescent tag.11 At the same time, a two-step ABPP method based 
on the Staudinger-Bertozzi ligation was reported for the labeling of the 20S proteasome, a 
highly conserved protease complex responsible for degrading the majority of cellular 
proteins. The use of an azide-functionalized ABP and subsequent reaction with a biotin-
phosphine reagent enabled labeling of active proteasome subunits and also facilitated the 
direct identification of a novel subunit-specific inhibitor.12,13  
While the examples described above make use of either azides or alkynes as ligation 
handles, other small reactive groups also warrant consideration to complement the 
repertoire of two-step ABPP strategies. In view of its selectivity and efficiency under mild, 
aqueous conditions, the Diels-Alder [4+2] cycloaddition presents an attractive alternative. 
Several reports have described the use of the Diels-Alder ligation for bioconjugation, 
including the modification of oligonucleotides and DNA,14-21 surface immobilization of 
oligonucleotides,22,23 conjugation of carbohydrates and proteins,24,25 and the surface 
immobilization and site-specific ligation of peptides and proteins.26,27 Recently, a number of 
related strategies based on the inverse-electron-demand Diels-Alder reaction has been 
reported for the bioorthogonal labeling of proteins.28-30 None of these methods, however, 
has been applied to ABPP. The first part of this chapter describes the development of a 
Diels-Alder based ligation procedure for the profiling of endogenous enzymatic activities in 
complex biological samples. As outlined in Figure 3.1A, this approach involves the labeling of 
active enzymes with a diene-functionalized ABP followed by reaction with a dienophile 
containing a fluorescent tag to enable visualization of the labeled proteins. In the second 
part of this chapter, the potential use of a combined Diels-Alder and Staudinger-Bertozzi 
ligation strategy is examined in order to realize simultaneous two-step labeling of different 
enzymatic activities in a single experiment (Figure 3.1B). The application of the inverse-
electron-demand Diels-Alder reaction as a two-step ABPP strategy for the monitoring of 
endogenously expressed enzymes is described in Chapter 4.  
 




Figure 3.1. The Diels-Alder cycloaddition in activity-based protein profiling. Schematic representations of a two-step 
labeling strategy based on the Diels-Alder ligation (A) and the simultaneous labeling of two different catalytic 
activities in the same sample by successive Staudinger-Bertozzi ligation and Diels-Alder ligation (B). ABP: activity-
based probe. 
The validity of the Diels-Alder based ABPP strategy is evaluated by using the 20S 
proteasome as a model protein. This multi-subunit protein complex contains three 
catalytically active subunits (β1, β2 and β5) that each have a different substrate preference 
and can be targeted by either broad-spectrum or subunit-specific ABPs.13,31-34 In order to 
enable two-step labeling of the catalytically active proteasome β-subunits by Diels-Alder 
ligation, a panel of four diene-modified ABPs (1a-d) was designed as well as a maleimide-
functionalized fluorescent Bodipy tag (3) (Figure 3.2). The ABPs are based on the potent 
broad-spectrum proteasome inhibitor epoxomicin,35,36 extended at the N‐terminus with 
either a linear (1b, 1c) or a cyclic (1a, 1d) conjugated diene. The maleimide moiety is a very 
reactive dienophile which has been used successfully for Diels-Alder based ligation 
procedures on recombinant proteins.26,27 Besides the labeling of proteasome activity, the 
Diels-Alder approach is also applied to the labeling of another class of enzymes, lysosomal 
cysteine proteases of the cathepsin family. For this purpose a diene-functionalized 







Figure 3.2. Structures of target compounds: diene-functionalized proteasome ABPs 1a-d, cathepsin probe 2b and 
Bodipy-tagged maleimide 3.  
3.2 Results and discussion 
The synthesis of diene-derivatized proteasome ABPs 1a-d and Bodipy-tagged maleimide 
reagent 3 has been described elsewhere.38 The ability of the four epoxomicin derivatives 1a-
d to inhibit the activity of the 20S proteasome was established by performing a competition 
experiment against the fluorescent activity-based proteasome probe MV15132 in El-4 cell 
extracts (Figure 3.3). El-4 cells contain next to the constitutive proteasome also the 
immunoproteasome, in which the β1, β2 and β5 subunits are replaced by β1i, β2i and β5i 
subunits having slightly different substrate preferences.39-41 All six catalytically active 
subunits are targeted by MV151. Exposure of El-4 cell extracts to increasing concentrations 
of 1a-d followed by labeling of residual proteasome activity with MV151 revealed that all 
probes are able to block the fluorescent labeling of the six proteasome β-subunits with 
  
 
Figure 3.3. Inhibition of proteasome activity in vitro by probes 1a-d. El-4 cell lysates were treated with 0.05 - 1 µM 
of inhibitors 1a-d for 2 hrs, after which residual proteasome activity was labeled with 1 µM MV151 for 1 hr. Labeled 
proteins were resolved by 12.5% SDS-PAGE with fluorescent readout followed by coomassie brilliant blue staining. 
Proteasome β-subunits are designated on the basis of reported labeling by MV151.32 ‘M’: protein marker. 
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similar potency. This indicates that the epoxomicin derivatives, like epoxomicin itself, are 
covalent and irreversible inhibitors of the catalytically active proteasome β-subunits. 
Complete inhibition was observed at inhibitor concentrations of 0.5-1 μM and higher. 
As a first evaluation of the applicability of the synthesized probes in Diels-Alder ligation 
procedures, the Diels-Alder reaction of diene-derivatized probe 1c  with 1 equivalent of 
tagged maleimide 3 was performed in the absence of proteins. The reaction was monitored 
by LC/MS analysis at various time points (Figure 3.4), which demonstrated the formation of 
the predicted Diels-Alder adduct over time. Although significant product formation 
wasobserved after 24 hrs, the reaction did not reach complete conversion in 3 days. 
Considering the potential degradation of proteins in cell extracts when left for an extended 
period of time and in view of practical convenience, it was decided to use an overnight 
incubation for the ensuing Diels-Alder two-step labeling experiments in vitro with an excess 
of the dienophile to further promote product formation. 
The feasibility of the Diels-Alder ligation strategy for two-step profiling of enzymatic 
activity was demonstrated next. Cell extracts were exposed for 1 hr to ABP 1c using a 
concentration at which it completely blocks the active proteasome β-subunits (1 μM) and 
subsequently exposed to varying concentrations of Bodipy-maleimide 3 (1 - 50 μM) 
overnight (Figure 3.5A). Since maleimide 3 is a Michael acceptor that reacts readily with 
(cysteine) thiol groups and may thereby cause a substantial amount of non-specific 
background labeling, the proteins were denaturated and cysteine residues were masked 
with Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid), DTNB) after incubation with 1c 
and prior to addition of 3. In this protocol, a chloroform/methanol precipitation step is 
necessary to remove remaining thiol-containing reagents before the ligation reaction, which 
  
 
Figure 3.4. LC/MS analysis of Diels-Alder reaction of Bodipy-maleimide 3 with ABP 1c (ratio 1:1) at selected time 
points (t = 0, 24, 48, 72 hrs). Fragments of obtained spectra with peaks corresponding to both reagents and Diels-





Figure 3.5. Labeling of proteasome activity in cell extracts by Diels-Alder ligation. A) Labeling in EL-4 cell extracts by 
exposure to 1 μM of ABP 1c for 1 hr, denaturation, masking of cysteine residues and reaction with 1 - 50 µM of 
Bodipy-maleimide 3 overnight. B) Optimization of cysteine capping conditions by varying DTNB concentration (using 
25 µM of 3). Gels are 12.5% SDS-PAGE with fluorescent readout followed by coomassie brilliant blue staining as a 
loading control. ‘ctrl’: control sample labeled with 1 µM MV151. ‘ep’: 100 μM epoxomicin added to incubation with 
1c. ‘M’: protein marker. 
simultaneously provides the opportunity to redissolve the sample in a buffer optimal for 
Diels-Alder ligation (pH 6).26,27 A second precipitation step was used to quench the reaction 
and remove the excess of maleimide-tag 3. Analysis of the labeled proteins on gel (Figure 
3.5A) reveals, despite a considerable degree of background fluorescence, the specific 
fluorescent labeling of a number of bands which correspond to the proteasome β-subunits 
as labeled by MV151. Background fluorescence was not affected by the presence or absence 
of 1c, confirming that it results from non-specific reactions of the maleimide-functionalized 
tag (3) rather than the inhibitor. In line with this observation, the concentration of cysteine 
capping reagent (DTNB) proved to be of crucial importance for the amount of background 
labeling, with an optimum around 50 mM (Figure 3.5B). The observed reduction in specific 
labeling when using a higher DTNB concentration is possibly due to an insufficient removal 
of the excess of reagent by a single precipitation step, causing it to interfere with the 
subsequent ligation reaction.  
Next, the efficiency of the Diels-Alder ligation with the different dienes was assessed by 
performing the two-step labeling procedure in cell extracts with ABPs 1a-d (Figure 3.6). 
Specific labeling with Bodipy-maleimide 3 (25 μM) was observed for diene-derivatized 
epoxomicin analogues 1c, 1a and 1b but not for anthracenyl-derivative 1d, which is 
apparently not able to undergo efficient Diels-Alder ligation with maleimide 3 under these 
conditions. The specific fluorescent signals were completely blocked by adding an excess of 
the selective proteasome inhibitor epoxomicin, demonstrating that the observed bands 




Figure 3.6. Diels-Alder based proteasome labeling in cell extracts using ABPs 1a-d. EL-4 cell lysates were exposed to 
1 μM of 1a-d in the presence or absence of 100 μM epoxomicin for 1 hr, followed by denaturation, masking of 
cysteine residues and labeling with 25 μM Bodipy-maleimide 3 overnight. Labeled proteins were resolved by 12.5% 
SDS-PAGE with fluorescent readout followed by coomassie brilliant blue staining. ‘M’: protein marker.  
indeed reflect labeling of the catalytically active proteasome β-subunits. The ligation 
reaction proceeded most efficiently with the non-cyclic dienes in 1c and especially 1b. The 
lower efficiency of furyl-derivative 1a is somewhat surprising as this diene is fixed in the cis-
configuration which these reactants need to adopt for the Diels-Alder cycloaddition.  
Using the most reactive heptadienoyl-functionalized ABP 1b, efforts were then made to 
further improve the efficiency of the Diels-Alder ligation by varying the concentration of 
dienophile (Figure 3.7A) and the reaction time of the ligation step (Figure 3.7B). Maleimide 
concentrations between 10 and 25 μM appeared to give the best results in terms of signal 
intensity and ratio of specific to background fluorescence. Both non-specific and specific 
labeling were also dependent on the reaction time, giving the best results when Diels-Alder 
ligation was performed with 25 µM of maleimide 3 for 4 - 20 hrs. After overnight incubation 
the signal intensity of proteasome labeling was similar to that obtained by direct labeling 
with fluorescent ABP MV151. Hence, a reaction time of 20 hrs and a dienophile 
concentration of 25 μM were selected for the following labeling experiments.  
In a next experiment, the Diels-Alder approach was applied to the labeling of 
proteasome activity in situ. The cell-permeability of diene-functionalized probe 1b was first 
demonstrated by treating cultured EL-4 cells with increasing concentrations of the probe 
followed by cell lysis and labeling of residual proteasome activity with MV151 (Figure 3.8A). 
Having shown the ability of the diene-functionalized ABP to inhibit the active proteasome β-





Figure 3.7. Optimization of Diels-Alder labeling procedure in EL-4 cell extracts by exposure to 1 μM of ABP 1b for 1 
hr, denaturation, masking of cysteine residues and reaction with A) 1 - 50 µM of reagent 3 overnight, or B) 25 µM 3 
for 1 - 20 hrs. Gels are 12.5% SDS-PAGE with fluorescent readout followed by coomassie brilliant blue staining. ‘ctrl’: 
control sample labeled with 1 µM MV151. ‘ep’: 100 μM epoxomicin added to incubation with 1b. ‘M’: protein 
marker. 
subjected to the Diels-Alder labeling procedure with maleimide 3 (Figure 3.8B). Analysis of 
the fluorescent labeling on gel revealed the specific labeling of several bands that are not 
present in lysates from untreated cells and correspond to the proteasome β-subunits 
labeled by MV151. These results demonstrate that the Diels-Alder method can be applied to 
monitor enzymatic activity in living cells by in situ targeting with a diene-functionalized ABP 
and post-lysis labeling with a tagged maleimide reagent. 
 
 
Figure 3.8. Targeting of proteasome activity in situ by ABP 1b. Cultured EL-4 cells were exposed for 2 hrs to 0.1 - 10 
µM of probe 1b or 1 μM MV151 as a control (‘ctrl’) and then lysed. A) Residual proteasome activity in lysates was 
labeled with 1 µM MV151 for 1 hr. B) Lysates were subjected to denaturation, masking of cysteine residues and 
Diels-Alder ligation with 25 μM Bodipy-maleimide 3 overnight. Labeled proteins were resolved by 12.5% SDS-PAGE 
with fluorescent readout followed by coomassie brilliant blue staining. ‘nt’: non-treated control cells. ‘M’: protein 
marker. 
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Having established the applicability of the Diels-Alder strategy for two-step labeling of 
proteasome activity, attention was focused on using the approach to label a class of less 
abundant enzymes, cysteine proteases of the papain family (cathepsins). For this purpose a 
heptadienoyl-functionalized derivative of the irreversible cathepsin inhibitor DCG-0437 was 
synthesized (2b, Scheme 3.1). Standard solid-phase peptide chemistry was employed to 
obtain resin-bound peptide 4. The epoxysuccinate warhead 9 was synthesized from D-(-)-
diethyl tartrate (7) by using a slightly modified literature procedure.42 Briefly, the cis-diol 
was converted to a racemic mixture of trans-β-chloro alcohols which was then treated with 
DBU for epoxide formation (8), after which selective saponification of one of the ethyl esters 
afforded epoxysuccinate 9. Next, deprotection of the N‐terminal amine in peptide 4 
followed by condensation with 9 and cleavage from the resin with concomitant deprotection 
provided ethyl ester 5 as well as a side product in which the ester was hydrolyzed (6). The 
obtained mixture of peptides was not readily separable due to the presence of a free amine 
in both of the compounds and was therefore used as such for the final step, reaction of the 
lysine ε-amine in peptides 5 and 6 with succinimidyl ester 10.38 The two products could then 
easily be separated to provide diene-derivatized DCG-04 analogue 2b.  
 
Scheme 3.1 Synthesis of diene-functionalized DCG-04 derivative 2b 
 
Reagents and conditions: a) i) piperidine/NMP (1/4, v/v), rt, 30 min, ii) 9, DiPEA, BOP, NMP, rt, overnight, iii) 
TFA/TIS/H2O (95/2.5/2.5, v/v/v), rt, 2 hrs, 5 67%, 6 33%; b) 10, DiPEA, DCE/DMF, rt, overnight, 76% from 5; c) i) 33% 
HBr in AcOH, 0 °C  rt, overnight, ii) AcCl, EtOH, reflux, 3.5 hrs, iii) DBU, Et2O, 0 °C, 4.5 hrs, 56%; d) KOH, EtOH, 0 




The ability of the diene-functionalized DCG-04 derivative (2b) to irreversibly inhibit 
cathepsin activity was demonstrated by performing a competition assay against the 
fluorescent cysteine protease ABP N3-Bodipy(TMR)-DCG-04
43 in RAW cell extracts (Figure 
3.9A). Subsequently, two-step labeling of cathepsin activity was realized by treatment of cell 
extracts with ABP 2b, using a concentration at which it completely blocked fluorescent 
labeling by N3-Bodipy(TMR)-DCG-04, followed by Diels-Alder ligation with Bodipy-tagged 
maleimide 3 (Figure 3.9B). Despite the lower intensity of specific signals as compared to 
background fluorescence than was observed for the two-step labeling of proteasome 
activity, two bands are visible only in ABP-treated samples which thus represent proteins 
that are specifically labeled by means of the two-step Diels-Alder ligation procedure. These 
bands correspond to the proteins that are labeled by N3-Bodipy(TMR)-DCG-04. Moreover, 
the fluorescent labeling was blocked by adding an excess of DCG-04, which confirms the 
specific labeling of catalytically active cathepsins. On the basis of the apparent molecular 
weights and a previously reported DCG-04 labeling profile in RAW cell extracts,44 the labeled 




Figure 3.9. Diels-Alder based labeling of active cathepsins in cell extracts. RAW cell lysates were exposed to 0.05 - 
50 µM of diene-derivatized ABP 2b for 1 hr and then A) exposed to N3-Bodipy(TMR)-DCG-04 (0.5 μM) for 1 hr to 
label residual cathepsin activity, or B) subjected to denaturation, masking of cysteine residues and Diels-Alder 
ligation with 25 or 50 μM Bodipy-maleimide 3 overnight. Gels are 12.5% SDS-PAGE with fluorescent readout (A, B) 
followed by coomassie brilliant blue staining (B). ‘ctrl’: control sample labeled with 0.5 μM N3-Bodipy (TMR)-DCG-
04. ‘DC’: exposure to 2b in the presence of 25 μM DCG-04. ‘M’: protein marker. 
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In a final experiment the possibility was investigated to monitor different proteolytic 
activities in a single sample by combining Diels-Alder two-step labeling with the Staudinger-
Bertozzi ligation, another widely used bioorthogonal ligation reaction. For this purpose, the 
azide-derivatized proteasome probe 1145 was employed, which selectively targets the β1 
proteasome subunits and enables labeling via Staudinger-Bertozzi ligation with biotin-tagged 
phosphine 1246 (Figure 3.10). At the same time the β2 and β5 subunits can then be labeled 
by Diels-Alder ligation. The dual labeling procedure was performed in HEK cell extracts, 
which contain only the three constitutive active proteasome subunits β1, β2 and β5. Cell 
extracts were first exposed to azide-modified ABP 11 using a concentration at which it 
completely blocks β1 activity, and then to diene-equipped probe 1b to target the non-
occupied subunits β2 and β5. Next, Staudinger-Bertozzi ligation was effected by treatment 
with biotin-phosphine 12, after which denaturation, cysteine masking and Diels-Alder 
reaction with fluorescent maleimide 3 were performed as before. As shown in Figure 3.10, 
ligation with maleimide 3 in samples treated with both 1b and 11 resulted in the exclusive 
fluorescent labeling of the diene-modified subunits β2 and β5, while Staudinger ligation with 
phosphine 12 gave selective labeling of the β1 subunit on Western blot. Importantly, no 
cross-reactivity was observed and the labeling efficiency obtained by combining both 
ligation methods in the same sample was comparable to that of the separate ligation 
reactions. This experiment shows that the Diels-Alder ligation and Staudinger-Bertozzi 
ligation are mutually orthogonal and can be combined in the same sample to monitor 




Figure 3.10. Dual ligation strategy using Diels-Alder and Staudinger-Bertozzi ligation in the same sample. HEK cell 
extracts were exposed successively to azide-functionalized β1-selective proteasome probe 11 (5 μM) for 1 hr, 
diene-derivatized probe 1b (5 μM) for 1 hr, and biotin-phosphine 12 (100 μM) for 1 hr. After protein denaturation 
and masking of cysteine residues, Diels-Alder ligation was performed with Bodipy-maleimide 3 (25 μM) overnight. 
The labeled proteins were resolved by 12.5% SDS-PAGE with fluorescent readout followed by streptavidin Western 





The Diels-Alder [4+2] cycloaddition was used as a ligation reaction for two-step ABPP by 
incorporation of a conjugated diene into an ABP and subsequent labeling with a 
fluorescently tagged maleimide. The Diels-Alder method was applied to monitor the activity 
of endogenously expressed proteasome β-subunits and cathepsins in cellular extracts and 
forms a useful complement to Staudinger-Bertozzi and click ligation strategies. From the 
panel of four tested dienes, the heptadienoyl moiety in 1b proved to react most efficiently 
with maleimide 3 for proteasome labeling in vitro. The Diels-Alder approach is fully 
orthogonal with respect to the Staudinger-Bertozzi ligation and both reactions can be 
performed in the same sample, providing the possibility to modify two different 
biomolecules, for example two enzymatic activities or metabolites, with different labels to 
study them simultaneously. Limitations of the Diels-Alder procedure are the need to mask 
cysteine residues prior to dienophile addition which precludes in vivo applications, and 
significant background labeling by the maleimide reagent which might hamper the detection 
of proteins with low abundance or endogenous activity. The broad use of the Diels-Alder 
reaction as a bioorthogonal ligation method therefore requires a dienophile that is 
unreactive towards cysteine residues and other functionalities present in biological samples. 
During the completion of the labeling experiments described in this chapter, several related 
studies were reported on the in situ and in vivo imaging of small molecules by inverse-
electron-demand Diels-Alder reaction.48,49 The use of tetrazine as a diene and a strained 
alkene as a dienophile afforded very fast and selective labeling reactions and allowed the 
ligations to be performed in living cells. The application of a tetrazine ligation strategy for 




All reagents were commercial grade and were used as received unless stated otherwise. MeOH and NMP were 
obtained from Biosolve. Toluene, EtOAc and PetEt (Riedel-de Haën) used for column chromatography were of 
technical grade and distilled before use. DCE, DCM, DMF, THF and dioxane (Biosolve) were of analytical grade and 
when used under anhydrous conditions stored over flame-dried 4 Å molecular sieves. Reactions were monitored by 
TLC-analysis using DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm), spraying 
with a solution of (NH4)6Mo7O24∙4H2O (25 g/L) and (NH4)4Ce(SO4)4∙2H2O (10 g/L) in 10% aqueous sulfuric acid 
followed by charring at ~150 °C or spraying with an aqueous solution of KMnO4 (7%) and K2CO3 (2%). Column 
chromatography was performed on silica gel (Screening Devices BV, 0.040 - 0.063 mm, 60 Å). LC/MS analysis was 
performed on an LCQ Adventage Max (Thermo Finnigan) ion-trap spectrometer (ESI+) coupled to a Surveyor HPLC 
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system (Thermo Finnigan) equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 5μm particle size, Phenomenex). 
The applied buffers were A: H2O, B: ACN and C: 1 % aqueous TFA. Reported gradients represent the percentage of 
buffer B in buffer A with 10% buffer C. HRMS analysis was performed on an LTQ Orbitrap (Thermo Finnigan) mass 
spectrometer equipped with an electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 
10 mL min−1, capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z = 150 - 2000) 
and dioctylphtalate (m/z = 391.28428) as a "lock mass". The high resolution mass spectrometer was calibrated prior 
to measurements with a calibration mixture (Thermo Finnigan). 1H- and 13C-APT-NMR spectra were recorded on a 
Jeol JNM-FX-200 (200/50) or Bruker AV-400 (400/100 MHz). Chemical shifts are given in ppm (δ) relative to the 
solvent peak or to tetramethylsilane as internal standard. Coupling constants (J) are given in Hz. All presented 13C-
APT spectra are proton decoupled. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR experiments. 
Compounds 1a-d, 3 and 10 were described previously.38 
(2S,3S)-diethyl oxirane-2,3-dicarboxylate (8) 
D-(-)-diethyl tartrate (7) (29 g, 0.14 mol) was cooled to 0 °C, before a solution of 33% HBr in acetic acid (120 mL) 
was added dropwise over 45 min. After complete addition, the reaction mixture was stirred at 0 °C for 15 min and 
then at room temperature overnight. Next, the mixture was poored onto crushed ice/H2O (300 mL) and extracted 
with Et2O (3x). The combined organics were washed with H2O (3x), dried over anhydrous MgSO4, filtered and 
concentrated in vacuo. Remaining solvents were concentrated in the presence of toluene. The crude oil was 
dissolved in EtOH and acetyl chloride (5.1 mL, 70 mmol, 0.5 eq.) was added. The reaction mixture was stirred under 
reflux for 3.5 hrs, before being concentrated at a temperature of 30 °C. The remaining yellowish oil was dissolved in 
Et2O (175 mL), cooled to 0 °C and put under argon atmosphere. A solution of DBU (21 mL, 0.14 mol, 1.0 eq.) in Et2O 
(90 mL) was added dropwise over 100 min. The reaction mixture was then stirred at 0 °C for 1 hr, more DBU (2.1 
mL, 14 mmol, 0.1 eq.) was added and the reaction mixture was stirred for an additional 2 hrs, before being 
quenched with H2O. The mixture was washed with 1M KHSO4 solution and H2O and the organic layer was dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (PetEt → 15% EtOAc 
in PetEt) yielded title compound 8 (15 g, 79 mmol, 56% over 3 steps). 1H NMR (400 MHz, CDCl3): δ (ppm) 4.32-4.22 
(m, 4H), 3.66 (s, 2H), 1.32 (t, J = 7.15, 7.15 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ (ppm) 166.69, 62.14, 51.96, 13.96. 
(2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid (9) 
A solution of compound 8 (14 g, 76 mmol) in absolute EtOH (200 mL) was cooled to 0 °C and a solution of KOH (5.0 
g, 76 mmol, 1.0 eq.) in absolute EtOH (100 mL) was added dropwise over 20 min. Next, the reaction mixture was 
stirred at 0 °C for 3 hrs and then at room temperature for 2 hrs, before being concentrated in vacuo. H2O (200 mL) 
was added to the residue and the basic aqueous mixture was washed with DCM (1x 30 mL). The aqueous layer was 
then acidified with concentrated HCl (7.0 mL), NaCl (60 g) was added and the mixture was extracted with EtOAc (4x 
200 mL). The combined organics were dried over anhydrous MgSO4, filtered and concentrated in vacuo to give title 
compound 9 (11 g, 66 mmol, 86%). 1H NMR (400 MHz, CDCl3): δ (ppm) 6.24 (bs, 1H), 4.33-4.20 (m, 2H), 3.74-3.61 
(m, 2H), 1.32 (t, J = 7.10, 7.10 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) 168.54, 166.92, 61.95, 51.49, 51.42, 
13.38. 
MBHA-Rink amide-Lys(Boc)-Ahx-Tyr(tBu)-Leu(Fmoc) (4) 
4-methylbenzhydrylamine (MBHA) functionalized Rink amide resin (3.2 g, 0.64 mmol/g, 2.1 mmol) was washed with 
DCM and deprotected with 20% piperidine in NMP for 20 min. After washing with NMP (2x) and DCM (2x), the resin 
was coupled to Fmoc-Lys(Boc)-OH (2.4 g, 5.2 mmol, 2.5 eq.) in the presence of BOP (2.3 g, 5.2 mmol, 2.5 eq.) and 
DiPEA (1.1 mL, 6.2 mmol, 3.0 eq.) in NMP; the reaction mixture was shaken overnight, followed by washing with 




in the presence of DiPEA (3.6 mL, 21 mmol, 10 eq.) in DCM for 30 min. The resin was then washed with Et2O, dried 
in vacuo overnight and the loading of the resin was determined to be 0.30 mmol/g by spectrophotometric analysis 
(3.7 g, 1.1 mmol, 53%). The obtained resin (3.0 g, 0.90 mmol) was submitted to three cycles of standard Fmoc-
based solid phase peptide synthesis as follows: after deprotection with 20% piperidine in NMP for 30 min, the resin 
was washed with NMP (2x) and DCM (3x) and coupled to ε-Ahx-Fmoc (0.80 g, 2.3 mmol, 2.5 eq.) in the presence of 
BOP (1.0 g, 2.3 mmol, 2.5 eq.) and DiPEA (0.45 mL, 2.7 mmol, 3.0 eq.) in NMP for 3 days, followed by washing with 
NMP (3x) and DCM (3x). The second and third cycles were done in the same way, coupling to Fmoc-Tyr(tBu)-OH (1.0 
g, 2.3 mmol, 2.5 eq.) for 5 hrs and Fmoc-Leu-OH (0.80 g, 2.3 mmol, 2.5 eq.) overnight, respectively. Couplings were 
monitored for completion by the Kaiser test. Washing with Et2O and drying in vacuo overnight yielded resin-bound 
compound 4.  
(2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxyl-Leu-Tyr-Ahx-Lys.TFA (5) 
Resin-bound compound 4 (~0.90 mmol) was deprotected with 20% piperidine in NMP for 30 min. The resin was 
washed with NMP (2x) and DCM (3x) before being subjected to a condensation cycle with free acid 9 (0.36 g, 2.3 
mmol, 2.5 eq.) in the presence of BOP (1.0 g, 2.3 mmol, 2.5 eq.) and DiPEA (0.45 mL, 2.7 mmol, 3.0 eq.) in NMP; the 
reaction mixture was shaken overnight, followed by washing with NMP (3x) and DCM (3x). The condensation cycle 
was repeated after which the Kaiser test indicated complete coupling. Cleavage from the resin was then 
accomplished by treatment with TFA/TIS/H2O (95/2.5/2.5, v/v/v) for 2 hrs at room temperature. After filtration and 
concentration in vacuo in the presence of toluene, the residue was recrystallized first from acetone/MeOH/EtOAc 
and then from MeOH/Et2O, yielding a 2:1 mixture of fully deprotected ester 5 and free acid 6 (total yield 0.73 g, 
0.93 mmol, quant.) according to NMR analysis. LC/MS analysis: Rt 5.0 min (linear gradient 10 → 90% B in 15 min), 
m/z 677.4 [M+H]+, 1353.2 [2M+H]+. 1H NMR (400 MHz, MeOD): δ (ppm) 6.98 (d, J = 7.87 Hz, 2H), 6.66 (d, J = 7.76 Hz, 
2H), 4.44 (t, J = 7.23, 7.23 Hz, 1H), 4.37 (dd, J = 7.59, 5.82 Hz, 1H), 4.30 (dd, J = 7.96, 5.15 Hz, 1H), 4.26-4.16 (m, 1H), 
3.79-3.61 (m, 1H), 3.61-3.46 (m, 1H), 3.17-3.07 (m, 2H), 3.06-2.98 (m, 2H), 2.98-2.91 (m, 2H), 2.91-2.73 (m, 2H), 
2.20 (t, J = 6.87, 6.87 Hz, 2H), 1.66-1.63 (m, 2H), 1.59-1.31 (m, 9H), 1.26 (t, J = 6.99, 6.99 Hz, 3H), 1.23-1.13 (m, 2H), 
0.88 (d, J = 5.77 Hz, 3H), 0.84 (d, J = 5.75 Hz, 3H). 
(2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxyl-Leu-Tyr-Ahx-((N)-(E)-hepta-4,6-dienoyl)Lys-H2N (2b) 
A mixture of 5 and 6 (0.31 g, 0.39 mmol, non-hydrolyzed/hydrolyzed 2/1) was dissolved in DCE/DMF under argon 
atmosphere and made basic (pH 8.5) using DiPEA (0.13 mL, 0.78 mmol, 2.0 eq.), before a solution of OSu-ester 10 
(0.23 g, 1.0 mmol, 2.6 eq.) in DCE/DMF was added. After stirring overnight at room temperature under argon 
atmosphere, the reaction mixture was concentrated in vacuo. The residue was taken up in MeOH/acetone and the 
soluble fraction was purified by column chromatography (CHCl3 → 10% MeOH in CHCl3), yielding diene-modified 
title compound 2b (0.16 g, 0.20 mmol, 76% from non-hydrolyzed starting material 7). 1H NMR (400 MHz, dmso-d6): 
δ (ppm) 8.54 (d, J = 8.19 Hz, 1H), 8.11 (d, J = 8.24 Hz, 1H), 7.82-7.74 (m, 2H), 7.30 (s, 1H), 6.96 (d, J = 8.40 Hz, 2H), 
6.61 (d, J = 8.32 Hz, 2H), 6.28 (td, J = 17.03, 10.26, 10.26 Hz, 1H), 6.04 (dd, J = 15.16, 10.53 Hz, 1H), 5.74-5.64 (m, 
1H), 5.02 (dd, J = 50.10, 13.54 Hz, 2H), 4.37-4.28 (m, 2H), 4.23-4.08 (m, 3H), 3.73-3.69 (m, 1H), 3.62-3.57 (m, 1H), 
3.07-2.88 (m, 4H), 2.82 (dd, J = 13.69, 5.57 Hz, 1H), 2.67 (dd, J = 13.64, 8.85 Hz, 1H), 2.26 (dd, J = 14.23, 7.06 Hz, 2H), 
2.17-2.05 (m, 4H), 1.59 (td, J = 9.47, 6.89, 6.89 Hz, 1H), 1.54-1.26 (m, 12H), 1.23 (t, J = 7.10, 7.10 Hz, 3H), 1.20-1.12 
(m, 2H), 0.83 (dd, J = 14.79, 6.46 Hz, 6H). 
Diels-Alder reaction of maleimide-tag 3 with diene-functionalized probe 1c 
Fluorescent maleimide 3 (5 mM) was reacted with diene-derivatized probe 1c (5 mM) in a 1/1 (v/v) mixture of H2O 
and DMSO at room temperature. The reactions were monitored by LC/MS analysis at various time points (t = 0, 24, 
48, 72 hrs). LC/MS analysis (linear gradient 10 → 90% B in 15 min): Bodipy-maleimide 3: Rt 8.6 min, m/z 589.3 [M-
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F]+, 631.4 [M+Na]+, 1217.0 [2M+H]+; Probe 1c: Rt 9.3 min (linear gradient 10 → 90% B in 15 min), m/z 637.2 [M+H]+, 




EL-4 and HEK-293T cells were cultured in DMEM supplemented with 10% (v/v) FCS, 10 units/mL penicillin and 10 
μg/mL streptomycin in a 5% CO2 humidified incubator at 37 °C. Cells were harvested, washed with PBS (2x) and 
lysed in digitonin lysis buffer (50 mM Tris pH 7.5, 250 mM sucrose, 5 mM MgCl2, 1 mM DTT, 2 mM ATP, 0.025% 
digitonin) for 30 min on ice followed by sonication on ice for 3x 10 s. After centrifugation of the cells at 16,100 g for 
15 min at 4 °C, the supernatants were collected and the protein concentration was determined by Bradford assay. 
RAW cell lysates were prepared by incubating harvested RAW cells in MES lysis buffer (50 mM MES pH 5.5, 50 mM 
NaCl, 5 mM DTT, 0.013% digitonin) for 30 min on ice followed by sonication and centrifugation. Precipitation of 
proteins was done using a chloroform/methanol (c/m) precipitation protocol.50 SDS-PAGE analysis: in-gel 
fluorescence was measured on a Typhoon Variable Mode Imager (Amersham Biosciences) using Cy3/TAMRA 
settings (excitation wavelength 532 nm, emission wavelength 580 nm). As a loading control gels were stained with 
Coomassie Brilliant Blue. For Western blotting, the proteins were transferred onto a PVDF membrane using a Bio-
Rad Trans-Blot cell system. Membranes were blocked with 1% BSA in TBS-t(+) (0.1% Tween 20) for 1 hr at room 
temperature, hybridized with Streptavidin-HRP for 45 min at room temperature (1:10,000 in blocking buffer) 
(Molecular Probes, Life Technologies), washed with TBS-t(+) and TBS and then visualized using an ECL+ Western 
blotting detection kit (Amersham Biosciences). Markers used were Precision Plus Dual Color protein standard (Bio-
Rad) and Biotinylated protein marker (Bio-Rad). MV15132, N3-Bodipy(TMR)-DCG-0443, DCG-0437, 1145 and 1246 are 
described in literature. 
In vitro competition assay versus MV151 
EL-4 cell lysates (10 µg total protein per experiment) in lysis buffer (9 µL) were exposed to the indicated 
concentrations of 1a, 1b, 1c or 1d  (1 μL 10x solution in DMSO) for 2 hrs at 37 °C, after which the lysates were 
incubated with 1 μM MV151 (1 µL 10 µM in DMSO) for 1 hr at 37 °C. The reaction mixtures were then heated to 55 
°C for 20 minutes with 4 µL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 12.5% SDS-
PAGE. In-gel visualization of the fluorescent labeling was performed in the wet gel slabs directly. 
In vitro competition assay versus N3-Bodipy(TMR)-DCG-04 
RAW cell lysates (50 µg total protein per experiment) in MES lysis buffer (9 µL) were exposed to the indicated 
concentrations of 2b (1 μL 10x solution in DMSO) for 1 hr at 37 °C, prior to incubation with 0.5 μM N3-Bodipy(TMR)-
DCG-04 (1 µL 5 µM in DMSO) for 1 hr at 37 °C. The reaction mixtures were boiled for 3 minutes with 4 µL 4x 
Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 12.5% SDS-PAGE. In-gel visualization of the 
fluorescent labeling was performed in the wet gel slabs directly. 
Diels-Alder based proteasome labeling in vitro 
In a typical experiment, EL-4 cell lysates (50 µg total protein per experiment) in lysis buffer (9 µL) were exposed to 1 
μM 1a, 1b, 1c or 1d (1 μL 10 μM DMSO) for 1 hr at 37 °C in the presence or absence of 100 μM epoxomicin (1 μL 1 
mM in DMSO). Control samples were labeled with 1 µM MV151. The proteins were then denatured for 15 min at 
room temperature in 8 M urea (80 µL 9 M in H2O), after which cysteine residues were reduced with 5 mM DTT (5 µL 
100 mM in H2O) for 30 min at 55 °C and capped with 50 mM DTNB (5 µL 1 M in DMSO) for 3.5 hrs at room 




Alder buffer (5 mM NaH2PO4, 20 mM NaCl, 0.2 mM MgCl2, pH 6.0) containing 6 M urea, diluted to 2 M urea by 
addition of 10 µL Diels-Alder buffer and then exposed to the indicated concentrations of Bodipy-maleimide 3 (1.7 
μL 10x solution in DMSO) overnight at 37 °C. Where indicated, reaction times were reduced to 1, 2 or 4 hrs. After 
quenching by c/m precipitation, proteins were taken up in 10 µL Laemmli’s sample buffer containing 2-
mercaptoethanol, heated to 55 °C for 15 minutes and resolved on 12.5% SDS-PAGE. In-gel visualization of the 
fluorescent labeling was performed in the wet gel slabs directly. 
Diels-Alder based cathepsin labeling in vitro 
RAW cell lysates (50 µg total protein per experiment) in MES lysis buffer (9 µL) were exposed to 5 μM of ABP 2b (0.5 
μL 100 μM DMSO) for 1 hr at 37 °C in the presence or absence of 25 μM DCG-04 (1.3 μL 200 μM in DMSO). Control 
samples were labeled with 0.5 μM N3-Bodipy(TMR)-DCG-04. Then the proteins were subjected to denaturation, 
cysteine capping and Diels-Alder ligation with Bodipy-maleimide 3 (25 or 50 µM) using the same procedure as 
described for Diels-Alder based proteasome labeling.  
Diels-Alder based proteasome labeling in situ  
Some 1*106 EL-4 cells per experiment were grown overnight in 5.5 mL of medium and exposed to the indicated 
concentrations of 1b for 2 hrs at 37 °C in a total volume of 6 mL medium containing 0.25% DMSO. As a control, cells 
were exposed to 1 μM MV151, 0 µM probe (DMSO control) or no compound at all (non-treated control). The cells 
were then harvested, washed with PBS (2x) and lysed in digitonin lysis buffer.  
Competition experiment. Lysates (10 µg total protein per experiment in 9 µL lysis buffer) were incubated with 1 μM 
MV151 (1 µL 10 µM in DMSO) for 1 hr at 37 °C. The reaction mixtures were then heated to 55 °C for 20 minutes 
with 4 µL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 12.5% SDS-PAGE. In-gel 
visualization of the fluorescent labeling was performed in the wet gel slabs directly. 
Diels‐Alder ligation. Lysates from cells treated with 5 μM 1b (20 µg total protein per experiment in 10 µL lysis 
buffer) were subjected to denaturation, cysteine capping and Diels-Alder ligation with 25 µM Bodipy-maleimide 3 
using the same procedure as described for in vitro Diels-Alder based proteasome labeling.  
Combined Diels-Alder and Staudinger ligation for labeling of proteasome β-subunits  
HEK cell lysates (50 µg total protein per experiment) in lysis buffer (9 µL) were exposed to 5 μM 11 (1 μL 50 μM 
DMSO) for 1 hr at 37 °C, followed by exposure to 5 μM 1b (1 μL 50 μM DMSO) for 1 hr at 37 °C. Next, 100 μM of 
biotin-phosphine 12 was added (1.2 μL 1 mM in DMF) and the lysates were again incubated for 1 hr at 37 °C. The 
proteins were then denatured for 15 min at room temperature in 8 M urea (80 µL 9 M in H2O), after which cysteine 
residues were reduced with 5 mM DTT (5 µL 100 mM in H2O) for 30 min at 55 °C and capped with 50 mM DTNB (5 
µL 1 M in DMSO) for 3.5 hrs at room temperature. Next, the mixtures were subjected to c/m precipitation and the 
proteins were taken up in 5 µL Diels-Alder buffer (5 mM NaH2PO4, 20 mM NaCl, 0.2 mM MgCl2, pH 6.0) containing 6 
M urea, diluted to 2 M urea by addition of 10 µL Diels-Alder buffer and then exposed to 25 µM Bodipy-maleimide 3 
(1.7 μL 250 µM in DMSO) overnight at 37 °C. After quenching by c/m precipitation, the proteins were taken up in 10 
µL Laemmli’s sample buffer containing 2-mercaptoethanol, heated to 55 °C for 15 minutes and resolved on 12.5% 
SDS-PAGE. In-gel visualization of the fluorescent labeling was performed in the wet gel slabs directly, after which 
biotinylated proteins were detected by streptavidin Western blotting.  
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Triple bioorthogonal ligation strategy  
for simultaneous labeling 
of multiple enzymatic activities 
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4.1 Introduction 
Bioorthogonal chemistry plays an important role in chemical biology research by creating 
the means to carry out selective chemical transformations in complex biological samples. A 
ligation reaction classifies as being bioorthogonal when it can be performed in a biological 
sample in a chemoselective manner without any interference with the biological system. 
Initially applied to the labeling of cell-surface glycoproteins,1-3 nowadays bioorthogonal 
reactions are being used to study a wide variety of biological processes, for example those 
involving post-translational modifications.4 The most widely used bioorthogonal ligation 
strategies include the Staudinger-Bertozzi ligaton, in which an azide is reacted with a 
phosphine reagent,1,2 the azide-alkyne Huisgen [2+3] cycloaddition (also termed ‘click’ 
reaction), either catalyzed by copper(I)5-7 or driven by ring strain,8 and the inverse-electron-
demand Diels-Alder reaction of tetrazine with a strained alkene.9,10 Continuing efforts are 
being made to develop ligations that are more selective and efficient than existing methods. 




multiple targets simultaneously, creating a need for ligation reactions that are orthogonal 
with respect to each other and can thus be used concurrently in a single experiment. Over 
the past decade, a number of tandem ligation strategies for use in bioconjugation has been 
described in literature.11-17 In addition it has been demonstrated that the ligation of ketones 
with hydrazides can be performed together with the Staudinger-Bertozzi ligation for the 
simultaneous imaging of two different types of glycans on cell surfaces.18 The first reported 
use of a tandem bioorthogonal ligation procedure in complex biological samples (cell 
lysates) is outlined in Chapter 3.19 This strategy, which involves ensuing Staudinger-Bertozzi 
ligation and Diels-Alder [4+2] cycloaddition, utilizes mutually orthogonal reagents but suffers 
from the need to mask free thiols prior to the ligation step in order to avoid non-specific 
labeling. More recently it was reported that the copper-free azide-cyclooctyne cycloaddition 
can be used concurrently with an inverse-electron-demand Diels-Alder reaction between 
tetrazine and trans-cyclooctene for the simultaneous labeling of two different receptors on 
cell surfaces, provided that the proper reagents are carefully selected so that cross-reactivity 
is minimized.20  
In this chapter a triple ligation strategy is described that employs the tetrazine ligation, 
Staudinger-Bertozzi ligation and copper(I)-catalyzed click reaction for the selective and 
simultaneous labeling of three different targets in a single experiment. To demonstrate the 
feasibility of this approach the triple ligation is applied to two-step activity-based protein 
profiling (ABPP), an area of research in which bioorthogonal chemistry is used to introduce a 
reporter group onto an enzyme active-site directed chemical probe (or activity-based probe, 
ABP) after binding of the probe to a target enzyme (Figure 4.1). The temporal separation of 
the ABP and the reporter entity which is thereby achieved is of particular interest when the 
presence of the tag interferes with selectivity, affinity, cell-permeability or bioavailability of 
the probe. A further advantage of two-step ABPP strategies as compared to direct labeling 
by a tagged ABP is the option to use different reporter groups depending on the 
experimental settings and the desired method of analysis while using a single ABP. Several 
examples of two-step ABPP strategies based on click chemistry21 and Staudinger-Bertozzi 
ligation22 have been described previously. The tetrazine ligation, however, has thus far not 
been used for this purpose.  
The first part of this chapter describes the development of a tetrazine ligation strategy 
for two-step ABPP, in which an ABP functionalized with norbornene as a ligation handle is 
used to target a specific enzymatic activity after which reaction with a tetrazine reagent 
conjugated to a reporter group enables detection and analysis of the labeled proteins 
(Figure 4.1A). Similar to the development of the Diels-Alder ligation method described in 
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Chapter 3, the 20S proteasome is used as a model system. The 20S proteasome is a multi-
subunit protein complex containing three catalytically active subunits (β1, β2 and β5) that 
have different substrate preferences and can be targeted by either broad-spectrum or 
subunit-specific ABPs.23-27 Based on previously reported mechanism-based inhibitors, two 
proteasome ABPs were designed that are functionalized with norbornene as a ligation 
handle (1 and 2, Figure 4.2). ABP 1 is derived from the pan-reactive proteasome inhibitor 
epoxomicin28,29 while ABP 2 has a different scaffold based on a β5 subunit-selective 
proteasome inhibitor.27 In addition, three tetrazine reagents were designed that are 
functionalized with different fluorescent tags, BodipyTMR (3a) and BodipyFL (3b), or a biotin 
tag (3c). With these probes, the use of the tetrazine ligation for the profiling of endogenous 
proteasome activity in cell extracts and cultured cells is demonstrated. In the second part of 
this chapter the developed tetrazine labeling procedure is combined with two established 
ligation methods in a tandem ligation strategy for the simultaneous labeling of three 
different enzymatic activities in the same sample (Figure 4.1B). 
 
 
Figure 4.1. The tetrazine ligation in activity-based protein profiling. A) Schematic representation of a two-step 
labeling strategy based on the tetrazine-norbornene cycloaddition. B) Schematic representation of a triple 
bioorthogonal ligation strategy involving tetrazine ligation, Staudinger-Bertozzi ligation and copper(I)-catalyzed click 





Figure 4.2. Structures of target compounds: norbornene-functionalized proteasome ABPs 1 and 2 and tetrazines 
derivatized with two different Bodipy fluorophores (3a, 3b) or a biotin tag (3c).  
4.2 Results and discussion 
The synthetic routes towards norbornene-functionalized epoxomicin derivative 1 and 
vinyl sulfone 2 are depicted in Schemes 4.1 and 4.2, respectively. It was envisioned that an 
alkyne-functionalized norbornene moiety would enable facile coupling of the ligation handle 
to the respective azide-functionalized inhibitors by copper(I)-catalyzed click reaction. Hence, 
the synthetic strategy commenced with the conversion of commercially available 
norbornene-carboxylic acid 4 into succinimidyl ester 5 (Scheme 4.1). The endo and exo 
isomers of the acid (4) and the OSu ester (5) could not be separated. However, reaction of 5 
with propargylamine resulted in a mixture of alkyne-functionalized products 6 (endo) and 7 
(exo) that proved to be easily separable by column chromatography. The major isomer, 
endo-norbornene-alkyne 6, was then used for a copper(I)-catalyzed click reaction with 
previously reported azide-modified inhibitor 9,30 which was in turn obtained from 
tetrapeptide epoxyketone 8,31 to provide ABP 1. As a starting point for the synthesis of 
putative β5-selective proteasome ABP 2 the previously described tripeptide vinyl sulfone 12 
was used (Scheme 4.2).27  Norbornene-alkyne 6 was first coupled via a copper(I)-catalyzed 
click reaction to azido-naphthalenyl-acetic acid 10,32 after which the resulting norbornene 
building block 11 was condensed with the deprotected vinyl sulfone tripeptide to give 
norbornene-functionalized probe 2. It should be noted that compound 6 consists of two 
enantiomers so that norbornene-equipped probes 1 and 2 are both obtained as a mixture of 
two diastereomers. No attempts were made to separate these isomers as it was assumed 
that the stereochemistry at this position would not profoundly affect the inhibitory potency 
of the probes or the ligation efficiency with tetrazine. 
Triple bioorthogonal ligation strategy  
61 
 
Scheme 4.1 Synthesis of norbornene-functionalized proteasome ABP 1 
 
Reagents and conditions: a) N-HOSu, EDC.HCl, DCE, rt, overnight, 74%; b) propargyl amine, DiPEA, DCE, rt, 3 hrs, 6 
65%, 7 13%; c) i) TFA, rt, 30 min, ii) 2-azidoacetyl-OSu, DiPEA, DCE, rt, 4 hrs, 88 %; d) 6, CuSO4.H2O, sodium 
ascorbate, tBuOH/H2O/toluene (1/1/1, v/v/v), 80 °C, overnight, 47%. 
The key step in the route towards tetrazine reagents 3a-c is the generation of the 
1,2,4,5-tetrazine moiety. The synthesis of asymmetrically substituted tetrazines can be 
accomplished by reaction of two appropriately substituted nitriles with hydrazine, resulting 
in the formation of a dihydrotetrazine intermediate via several condensation and 
elimination steps, followed by oxidation with sodium nitrite in acetic acid to afford the 
tetrazine product.33,34 Generally the yield of these reactions is rather low, which is at least  
 
Scheme 4.2 Synthesis of norbornene-functionalized proteasome ABP 2 
 
Reagents and conditions: a) 6, CuSO4.H2O, sodium ascorbate, DMF, 80 °C, overnight, 59%; b) i) TFA/DCM (1/1, v/v), 




partly due to the formation of symmetrically substituted byproducts. In a first attempt to 
synthesize tetrazines 3a-c, a mixture of 4-aminomethylbenzonitrile (13) and 2-
cyanopyrimidine (14) was refluxed with hydrazine hydrate in ethanol and then oxidized by 
careful addition of sodium nitrite in aqueous acetic acid (Scheme 4.3). Instead of compound 
15, however, an unexpected product was isolated in which the primary amine had been 
converted into a hydroxyl group (16). A possible explanation for this conversion is that the 
primary amine, upon addition of the acidic solution of sodium nitrite to the dihydrotetrazine 
intermediate, reacts with NO+ and forms a diazonium species which is then susceptible to 
nucleophilic attack by a water molecule. In line with this hypothesis, other tetrazine 
products isolated after this reaction included the symmetrical dihydroxy tetrazine as well as 
acetyloxy-substituted tetrazine products resulting from reaction of the diazonium species 
with acetic acid. It was found that these side reactions could be prevented by first dissolving 
the dihydrotetrazine intermediate in acetic acid before addition of the oxidizing reagent, in 
which case alcohol 16 was not detected and amine-functionalized tetrazine 15 was formed 
instead. In order to further minimize side reactions and also facilitate purification 
procedures, the primary amine in 13 was protected with a Boc group (17) prior to tetrazine 
formation. Reaction of 17 with 14 and an excess of hydrazine hydrate followed by oxidation 
with sodium nitrite in acetic acid provided Boc-protected tetrazine 18. After deprotection, 
the free amine was reacted with BodipyTMR-OSu,25 BodipyFL-OSu35 or biotin-OSu to afford 
the tagged tetrazines 3a-c. 
 
Scheme 4.3 Synthesis of Bodipy-tagged tetrazines 3a and 3b and biotinylated tetrazine 3c 
 
Reagents and conditions: a) i) H2NNH2.H2O, EtOH, 80 °C, overnight, ii) NaNO2, AcOH/H2O (1/1, v/v), 0 °C, 15 min, 15 
0%, 16 5%; b) Boc2O, Et3N, DCM, rt, overnight, quant.; c) i) 14, H2NNH2.H2O, EtOH, 70 °C, 24 hrs, ii) AcOH, then 
NaNO2, H2O, 0 °C, 15 min, 11%; d) i) TFA/DCM (1/1, v/v), rt, 15 min, ii) BodipyTMR-OSu (a), BodipyFL-OSu (b) or 
biotin-OSu (c), DiPEA, DCE/DMF, rt, overnight, 3a 79%, 3b 63%, 3c 49%. 
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Before using the synthesized probes in two-step labeling experiments, the ability of the 
norbornene-functionalized ABPs 1 and 2 to inhibit the activity of the 20S proteasome in cell 
extracts and cultured cells was evaluated. HEK cell extracts were exposed to increasing 
concentrations of probes 1 and 2, after which the residual proteasome activity was labeled 
with MV151,25 a fluorescently labeled ABP that targets the catalytically active proteasome β-
subunits β1, β2 and β5 (Figure 4.3A). The fluorescent labeling was completely abolished by 
preincubation with 1 µM of ABP 1, revealing that this probe is an irreversible inhibitor of all 
three proteolytically active proteasome β-subunits. ABP 2, on the other hand, only blocked 
the fluorescent labeling of a single band corresponding to β5, which indicates that this probe 
is a β5-subunit selective proteasome inhibitor. Similar results were obtained by treatment of 
cultured HEK cells with 1 or 2 followed by cell lysis and labeling with MV151 (Figure 4.3B). 
Both norbornene-functionalized probes were able to inhibit proteasome activity in situ and 
are thus cell-permeable. As before, ABP 1 reduced the fluorescent labeling of all three 
catalytically active proteasome β-subunits, although no complete inhibition was reached up 
to a concentration of 50 µM. ABP 2 appeared to inhibit β5 completely at the lowest 
concentration tested (1 µM) and did not affect the labeling of the other proteasome β-
subunits. 
Having established the inhibitory potency of the norbornene-derivatized ABPs, the 
applicability of the tetrazine ligation for two-step labeling of endogenous proteasome 
activity in vitro and in situ was examined. HEK cell extracts were treated with norbornene-
functionalized ABP 1 at a concentration at which it completely inhibits proteasome activity, 
and subsequently reacted with varying concentrations of one of the tetrazine reagents 3a-c 
for 1 hr at 37 °C (Figures 4.4A-C). Ligation with all three tetrazine reagents resulted in the  
 
 
Figure 4.3. Inhibition of proteasome activity by probes 1 and 2. A) HEK cell lysates labeled with 1 µM MV151 for 1 
hr after preincubation with 0.05 - 1 µM of compounds 1 or 2 for 1 hr. B) Cultured HEK cells were treated with 1 - 50 
µM of compounds 1 or 2 for 4 hrs. After cell lysis residual proteasome activity was labeled with 1 µM MV151 for 1 
hr. Gels are 12.5% SDS-PAGE with fluorescent readout followed by coomassie brilliant blue staining. Proteasome β-








Figure 4.4. In vitro and in situ labeling of proteasome activity by tetrazine ligation. A-C) HEK cell extracts were 
exposed to 1 μM of ABP 1 for 1 hr and then incubated with 5 - 100 µM of tetrazines 3a-c for 1 hr. D-F) Cultured HEK 
cells were exposed to 10 μM of ABP 1 for 3 hrs, incubated with 1 - 50 µM of tetrazines 3a-c for 1 hr and lysed. 
Proteins were resolved by 12.5% SDS-PAGE and detected by in-gel fluorescent readout in Cy3 (3a, panels A and D) 
and Cy2 (3b, panels B and E) channels or by streptavidin Western blotting (3c, panels C and F). Coomassie brilliant 
blue staining was used as a loading control (A, B, D, E). ‘ctrl’: control extracts or cells labeled with 1 µM MV151. 
‘ep’: 100 μM epoxomicin added to incubation with ABP 1. ‘M’: protein marker.  
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labeling of the three catalytically active proteasome β-subunits in a concentration-
dependent manner.36 The high selectivity and specificity of the ligation reaction is apparent 
from the absence of proteasome labeling and low degree of background labeling in the 
absence of the norbornene-functionalized ABP (1) and when proteasome activity is inhibited 
by an excess of epoxomicin. Comparison of the labeling intensity in samples treated with 
tetrazine 3a to that obtained by direct labeling with the fluorescent ABP MV151, which 
contains the same Bodipy(TMR) tag as 3a, revealed that under these conditions the ligation 
reaction appears to reach completion at a tetrazine concentration of 50 µM and higher 
(Figure 4.4A). Ligation with tetrazine-BodipyFL 3b appeared to proceed with similar 
efficiency as with 3a (Figure 4.4B). In case of biotinylated tetrazine 3c, however, the 
relatively low labeling intensity after treatment with 50 µM of the probe as compared to 
reaction with 100 µM of the reagent indicates that this reagent reacts less efficiently than 
the fluorescently labeled tetrazines (Figure 4.4C).  
Next, the efficacy of the tetrazine ligation inside living cells was evaluated. Cultured HEK 
cells were incubated with ABP 1, washed and subsequently exposed to varying 
concentrations of tetrazines 3a-c for 1 hr. After cell lysis the labeled proteins were analyzed 
by SDS-PAGE (Figures 4.4D-F). In situ tetrazine ligation with fluorescently labeled tetrazines 
3a and 3b resulted in efficient labeling of the active proteasome β-subunits, with labeling 
visible at tetrazine concentrations as low as 1 μM. This demonstrates that the tetrazine 
probes are cell-permeable and that the ligation reaction can be performed successfully 
inside living cells. Furthermore, the ligation proceeded with very high selectivity and even 
less non-specific labeling than in cell lysates. A reduced cell-permeability of the biotin-
functionalized tetrazine reagent (3c) as compared to the fluorescently labeled tetrazines is 
presumably at the basis of its lower labeling efficiency.  
In an attempt to further improve the tetrazine-mediated labeling in cell extracts, the 
reaction time and temperature of the ligation step were varied (Figures 4.5A and 4.5C). In 
addition, the compatibility of the tetrazine ligation with buffers of various pH values ranging 
from pH 4 to pH 8 was tested (Figure 4.5B). When using 50 µM of tetrazine 3a, labeling of 
the active proteasome β-subunits was visible within 30 minutes and appeared to be 
complete within 1-2 hrs. No marked effects of pH on reaction efficiency or selectivity were 
found. Similarly, no profound differences were detected when performing the reaction at 
room temperature instead of 37 °C. However, at higher temperature (50 °C) or a prolonged 
reaction time (overnight) an enhanced degree of non-specific labeling was observed. 






Figure 4.5. Optimization of in vitro tetrazine ligation conditions. Labeling in HEK cell extracts using 1 μM of ABP 1 
followed by reaction with A) 50 µM of tetrazine 3a for 0.5 - 20 hrs (37 °C, pH 7.5), B) 10 µM 3a for 1 hr in buffers of 
varying pH (37 °C), or C) 50 µM 3a for 1 hr at 20 - 50 °C (pH 7.5). Gels are 12.5% SDS-PAGE with fluorescent readout 
followed by coomassie brilliant blue staining. ‘ctrl’: control sample labeled with 1 µM MV151. ‘M’: protein marker. 
In a next set of experiments the tetrazine ligation was compared to three other 
commonly used ligation methods, the Staudinger-Bertozzi ligation, the copper(I)-catalyzed 
click reaction and the strain-promoted click reaction, by applying the four different ligation 
reactions to the two-step labeling of proteasome activity in cell extracts. For this purpose 
two epoxomicin derivatives were designed that are similar to norbornene-functionalized 
ABP 1 but are equipped with either an azide or an alkyne as the ligation handle (compounds 
9 and 19, respectively, Figure 4.6). Azide-modified ABP 9 is a known inhibitor of the three  
 
 
Figure 4.6. Structures of azide- and alkyne-functionalized proteasome ABPs 9 and 19, Bodipy-tagged azide (20) and 
alkyne (21) reagents for copper(I)-catalyzed click reaction, biotin-phosphine 22 for Staudinger-Bertozzi ligation, 
biotin-dibenzocyclooctyne 23 for strain-promoted click reaction, and azide-derivatized β1-selective proteasome 
ABP 24. 
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Scheme 4.4 Synthesis of alkyne-functionalized proteasome ABP 19 and azido-BodipyFL 20 
 
Reagents and conditions: a) i) TFA, rt, 30 min, ii) 6-heptynoyl-OSu, DiPEA, DCE, rt, overnight, 87%; b) i) NaN3, DMF, 
rt, overnight, ii) BodipyFL-OSu, DiPEA, DCE/DMF, rt, 5 hrs, 99%. 
proteolytically active proteasome β-subunits30 and was generated in the synthetic route 
towards ABP 1 (see Scheme 4.1). Alkyne-functionalized ABP 19 was synthesized from 
tetrapeptide epoxyketone 8 by deprotection and subsequent reaction of the primary amine 
with the succinimidyl ester of 6-heptynoic acid37 (Scheme 4.4). A competition experiment 
confirming the ability of ABP 19 to inhibit the catalytically active proteasome β-subunits in 
HEK cell extracts is shown in Figure 4.7. In addition to the ABPs, a number of Bodipy- and 
biotin-tagged reagents was selected to enable two-step labeling via the various ligation 
reactions (20-23, Figure 4.6). Reagents 21,30 2238 and 2339 have been reported previously. 
Azido-BodipyFL 20 was synthesized in two steps from 3-bromopropanamine (25) in near 
quantitative yield (Scheme 4.4). 
With all probes in hand, two-step labeling experiments were carried out by exposure of 
cell extracts to ABPs 1, 9 or 19 followed by reaction with one of the ligation reagents 3b-c or 
20-23 (Figure 4.8). Labeling via tetrazine ligation with norbornene-derivatized ABP 1 and 
biotinylated tetrazine 3c gave similar results in terms of selectivity and efficiency to  
 
 
Figure 4.7. Inhibition of proteasome activity by probe 19. HEK cell lysates were treated with 0.05 - 10 µM of 
compound 19 for 1 hr and then labeled with 1 µM MV151 for 1 hr. Proteins were resolved by 12.5% SDS-PAGE and 





Figure 4.8. Comparison of various ligation strategies. HEK cell extracts were exposed to 1 μM of ABPs 1, 9 or 19 for 
1 hr and then reacted with 5 - 50 µM of tetrazines 3b or 3c, Bodipy-azide 20, Bodipy-alkyne 21, biotin-phosphine 
22, or biotin-dibenzocyclooctyne 23 for 1 hr. Copper(I)-catalyzed click reactions with 20 and 21 were performed in 
the presence of 1 mM CuSO4, 1 mM TCEP and 100 μM TBTA. Proteins were resolved by 12.5% SDS-PAGE and 
detected by A) in-gel fluorescent readout (3b, 20, 21) followed by coomassie brilliant blue staining or B) streptavidin 
Western blotting (3c, 22, 23). 
Staudinger-Bertozzi ligation with azide-functionalized ABP 9 and biotin-phosphine 22. 
Additionally, tetrazine ligation with Bodipy(FL)-tetrazine 3b appeared to proceed with 
comparable efficiency to the copper(I)-catalyzed click procedures with either ABP 9 and 
Bodipy-alkyne 21 or ABP 19 and Bodipy-azide 20. A remarkable difference between the two 
copper-catalyzed click reactions is the degree of background fluorescence, as the 
combination of azide-functionalized ABP 9 and alkyne-Bodipy 21 gave more background 
labeling than the click procedure using alkyne-ABP 19 and azido-Bodipy 20. Attempts to 
label proteasome activity via strain-promoted click reaction with biotinylated 
dibenzocyclooctyne 23 resulted in a very high amount of background labeling in which 
specific signals were not detectable. This result confirms previous findings that strain-
promoted click procedures are poorly compatible with cell extracts.40 
Having established the utility of the tetrazine ligation strategy for two-step profiling of 
endogenous proteasome activity, the final part of this chapter focuses on the development 
of a triple ligation strategy. First, the orthogonality of the tetrazine ligation with respect to 
the Staudinger-Bertozzi ligation and the copper(I)-catalyzed click reaction was 
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demonstrated. Potential cross-reactivity between norbornene-, azide- and alkyne-tagged 
proteasome ABPs (1, 9 and 19, respectively) and azide, alkyne, phosphine and tetrazine 
reagents (20, 21, 22 and 3b, respectively) was evaluated by performing two-step 
proteasome labeling experiments in cell extracts with different combinations of the probes 
(Figure 4.9A). As before, labeling of the catalytically active proteasome β-subunits was 
obtained by exposure of cell extracts to ABP 1 followed by reaction with 3b, as well as by 
making use of probes 19 and 20, 9 and 21 or 9 and 22. No cross-reactivity could be detected 
when any of the other probe combinations was used, which opens up the possibility to 
perform all three ligation reactions simultaneously. However, it was found that background 
fluorescence caused by the fluorescently labeled tetrazine reagent is drastically increased 
when it is mixed with the click cocktail for copper(I)-catalyzed click reactions, to such an 
extent that specific labeling is no longer detectable (Figure 4.9B). An investigation of the 
compatibility of tetrazine labeling with the separate click reagents revealed that the high 
degree of background fluorescence is caused by the presence of copper sulfate. As a result, 
the tetrazine ligation and the copper(I)-catalyzed click reaction can not be performed at the 
same time. Nevertheless a triple ligation experiment can be designed in which these two 
reactions are carried out consecutively so that the copper catalyst does not interfere with 




Figure 4.9. Orthogonality of tetrazine ligation, Staudinger-Bertozzi ligation and copper(I)-catalyzed click reaction. A) 
Labeling in HEK cell extracts using 1 μM of ABPs 1, 9 or 19 followed by reaction with 50 µM of tetrazine 3b, azide 
20, alkyne 21 or phosphine 22 for 1 hr. Click reactions with 20 and 21 were performed in the presence of 1 mM 
CuSO4, 1 mM TCEP and 100 μM TBTA. B) Tetrazine ligation in HEK cell extracts using 1 μM of ABP 1 followed by 
reaction with 50 μM of tetrazine 3a in the presence of 1 mM CuSO4, 1 mM TCEP and/or 100 μM TBTA. Labeled 
proteins were resolved by 12.5% SDS-PAGE and detected by in-gel fluorescent readout in Cy3 (3a) and Cy2 (3b, 20, 
21) channels or by streptavidin Western blotting (22). Coomassie brilliant blue staining was used as a loading 




In a seminal experiment, a triple ligation strategy that combines the tetrazine ligation, 
the Staudinger-Bertozzi ligation and the copper(I)-catalyzed click reaction was used to label 
the three proteolytically active proteasome β-subunits each with a different tag via one of 
the different ligation reactions. In order to enable separate labeling of the β-subunits, the 
β5-subunit selective norbornene-functionalized ABP 2 was used together with the β1-
selective azide-functionalized proteasome probe 2432 (Figure 4.6). After exposure of cell 
extracts to probes 2 and 24, alkyne-derivatized ABP 19 was added which could then only 
bind to the non-occupied proteasome β2-subunits. This sequence of addition should lead to 
the selective tagging of β1-subunits with an azide, β2-subunits with an alkyne and β5-
subunits with a norbornene moiety. Next, the lysates were exposed to tetrazine-BodipyTMR 
3a and biotin-phosphine 22 for 1 hr, after which the excess of the reagents was removed by 
buffer exchange and lastly copper(I)-catalyzed click ligation was performed with azido-
BodipyFL 20 for 1 hr. In this procedure, the washing step in between the ligation reactions is 
necessary to remove both the excess of tetrazine before addition of the copper catalyst as 
well as the excess of phosphine which might otherwise react with the azido-Bodipy reagent 
and thereby interfere with the click reaction. The use of two different Bodipy fluorophores 
and a biotin tag enables the separate visualization of the proteins labeled by each of the 
ligation reactions by using in-gel fluorescence scanning with two different scanner settings 
followed by streptavidin Western blotting. As shown in Figure 4.10, the three ligation 
reactions each resulted in the selective labeling of a single proteasome subunit. Tetrazine-
BodipyTMR 3a selectively labeled the proteasome β5-subunits by reaction with norbornene-
ABP 2, while β1-subunits were labeled by Staudinger-Bertozzi ligation of azido-ABP 24 with 
biotin-phosphine 22 and β2-subunits were labeled by copper(I)-catalyzed click reaction of 
alkyne-ABP 19 and azido-Bodipy 20. The results obtained by performing all ligation reactions 
in the same sample were similar to those of the separate ligation reactions, demonstrating 
the value of the tandem labeling strategy for the selective labeling of three different 
catalytic activities in a single experiment. 
  




Figure 4.10. Triple ligation strategy. HEK cell extracts were exposed to 1 μM of β5-selective proteasome ABP 2 and 
5 µM of β1-selective ABP 24 followed by 1 µM of ABP 19, treated with 25 µM of tetrazine 3a and 100 µM of 
phosphine 22 and subsequently reacted with 25 µM of azide 20 in the presence of 1 mM CuSO4, 1 mM TCEP, and 
100 μM TBTA. Proteins were resolved by 12.5% SDS-PAGE with fluorescent readout in Cy3 (3a) and Cy2 (20) 
channels followed by streptavidin Western blotting (22). ‘M’: protein marker.  
4.3 Conclusion 
A two-step ABPP strategy was developed that is based on the inverse-electron-demand 
Diels-Alder reaction of tetrazine with norbornene. Incorporation of norbornene into an ABP 
that targets the catalytically active proteasome β-subunits enabled the labeling of 
endogenous proteasome activity by reaction with fluorescently labeled or biotin-tagged 
tetrazines. The tetrazine ligation proceeds with high selectivity in cell extracts and inside 
living cells and forms a valuable complement to existing two-step ABPP methods. The 
reagents used for the tetrazine ligation were shown to be orthogonal to those used in 
Staudinger-Bertozzi ligation and copper(I)-catalyzed click reactions. Although tetrazines are 
not directly compatible with copper-catalyzed click chemistry, this drawback can easily be 
overcome by a simple washing step between the two ligation reactions which allows their 
consecutive use in the same experiment. A triple ligation strategy combining the tetrazine 
ligation, the Staudinger-Bertozzi ligation and the copper(I)-catalyzed click reaction was used 
for the simultaneous labeling of three enzymatic activities with different tags in a single 
experiment. This tandem ligation strategy will not only be useful for application in ABPP but 
also for the study of other biological processes such as post-translational modifications, 
enabling the selective monitoring of multiple targets at the same time in complex biological 
samples. Moreover, the possibility to perform both tetrazine and Staudinger-Bertozzi 
ligations inside living cells22,41 and in living animals3,42 should enable the use of tandem 







All reagents were commercial grade and were used as received unless stated otherwise. MeOH was obtained from 
Biosolve. Toluene, EtOAc and PetEt (Riedel-de Haën) used for column chromatography were of technical grade and 
distilled before use. DCE, DCM, DMF, and THF (Biosolve) were of analytical grade and when used under anhydrous 
conditions stored over flame-dried 4 Å molecular sieves. Reactions were monitored by TLC-analysis using DC-
alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm), spraying with a solution of 20% 
H2SO4 in EtOH or a solution of (NH4)6Mo7O24∙4H2O (25 g/L) and (NH4)4Ce(SO4)4∙2H2O (10 g/L) in 10% aqueous sulfuric 
acid followed by charring at ~150 °C or by spraying with an aqueous solution of KMnO4 (7%) and K2CO3 (2%). 
Column chromatography was performed on silica gel (Screening Devices BV, 0.040 - 0.063 mm, 60 Å). LC/MS 
analysis was performed on an LCQ Adventage Max (Thermo Finnigan) ion-trap spectrometer (ESI+) coupled to a 
Surveyor HPLC system (Thermo Finnigan) equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 5μm particle size, 
Phenomenex). The applied buffers were A: H2O, B: ACN and C: 1 % aqueous TFA. Reported gradients represent the 
percentage of buffer B in buffer A with 10% buffer C. HRMS analysis was performed on an LTQ Orbitrap (Thermo 
Finnigan) mass spectrometer equipped with an electronspray ion source in positive mode (source voltage 3.5 kV, 
sheath gas flow 10 mL min−1, capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z 
= 150 - 2000) and dioctylphtalate (m/z = 391.28428) as a "lock mass". The high resolution mass spectrometer was 
calibrated prior to measurements with a calibration mixture (Thermo Finnigan). 1H- and 13C-APT-NMR spectra were 
recorded on a Brüker AV-400 (400/100MHz) or a Bruker DMX600 (600/150 MHz) instrument with a cryoprobe. 
Chemical shifts are given in ppm (δ) relative to the solvent peak or to tetramethylsilane as internal standard. 
Coupling constants (J) are given in Hz. All presented 13C-APT spectra are proton decoupled. Peak assignments are 
based on 2D 1H-COSY and 13C-HSQC NMR experiments.  
5-Norbornene-2-carboxylic acid succinimidyl ester (5) 
To a solution of 5-norbornene-2-carboxylic acid 4 (mixture of endo and exo, predominantly endo) (10 mmol, 1.25 
mL) in DCE under argon atmosphere was added EDC.HCl (40 mmol, 7.7 g, 4.0 eq.) and N-HOSu (40 mmol, 4.6 g, 4.0 
eq.). The reaction mixture was stirred overnight at room temperature, washed with 1 M HCl (3x), dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography 
(PetEt → PetEt/EtOAc 2/1 (v/v)), yielding succinimidyl ester 5 (mixture of endo and exo) as a white powder (1.75 g, 
7.4 mmol, 74%). Rf 0.4 (PetEt/EtOAc 2/1). 1H NMR (400 MHz, CDCl3): δ (ppm) 6.26-6.20 (m, 1H), 6.16-6.12 (m, 1H), 
3.42-3.40 (m, 1H), 3.27-3.23 (m, 1H), 3.00-2.98 (m, 1H), 2.84-2.81 (m, 4H), 2.07-1.99 (m, 1H), 1.56-1.44 (m, 2H), 
1.36-1.33 (m, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 169.91, 169.29, 138.48, 138.07, 135.20, 132.09, 49.58, 47.06, 
46.37, 46.33, 42.44, 41.70, 40.53, 40.21, 30.90, 29.49, 25.54, 25.51. 
N-(2-propynyl)-5-norbornene-2-carboxamide (6 and 7) 
To a solution of norbornene-OSu 5 (mixture of endo and exo) (2.0 mmol, 0.47 g) in DCE under argon atmosphere 
was added propargyl amine (2.0 mmol, 0.11 g, 1.0 eq.) and DiPEA (5.0 mmol, 0.87 mL, 2.5 eq.). The reaction mixture 
was stirred at room temperature for 3 hrs before being concentrated in vacuo. The crude product was purified by 
column chromatography (PetEt → 15% EtOAc in PetEt), followed by recrystallization from EtOAc/PetEt to give 6 and 
7 separately as white crystals. Based on the endo/exo ratio in the starting material, the larger product batch was 
designated the endo product 6 (0.24 g, 1.3 mmol, 65%) and the smaller batch the exo product 7 (43 mg, 0.25 mmol, 
13%). Rf 6 0.25/7 0.4 (PetEt/EtOAc 4/1). 1H NMR (400 MHz, CDCl3) 6: δ (ppm) 6.25-6.23 (m, 1H), 6.00-5.98 (m, 2H), 
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4.00 (dd, J = 5.2, 2.4 Hz, 2H), 3.17-3.16 (m, 1H), 2.92-2.88 (m, 2H), 2.22 (t, J = 2.4 Hz, 1H), 1.97-1.90 (m, 1H), 1.47-
1.44 (m, 1H), 1.40-1.36 (m, 1H), 1.31-1.29 (m, 1H). 1H NMR (400 MHz, CDCl3) 7: δ (ppm) 6.16-6.14 (m, 1H), 6.11-6.09 
(m, 1H), 5.88 (s, 1H), 4.07 (dd, J = 5.2, 2.4 Hz, 2H), 2.96-2.93 (m, 2H), 2.24 (t, J = 2.4 Hz, 1H), 2.05-2.01 (m, 1H), 1.95-
1.90 (m, 1H), 1.72-1.70 (m, 1H), 1.37-1.31 (m, 2H). 13C NMR (100 MHz, CDCl3) 6: δ (ppm) 173.96, 137.72, 132.00, 
79.81, 71.13, 49.86, 46.09, 44.44, 42.58, 29.59, 28.96. 13C NMR (100 MHz, CDCl3) 7: δ (ppm) 175.28, 138.28, 135.85, 
79.75, 71.44, 47.03, 46.28, 44.41, 41.50, 30.41, 29.25. LC/MS analysis: 6: Rt 5.0 min (linear gradient 10 → 90% B in 
15 min), m/z 176.0 [M+H]+, 350.8 [2M+H]+; 7: Rt 5.7 min (linear gradient 10 → 90% B in 15 min), m/z 175.9 [M+H]+. 
HRMS: calcd. for [C12H14NO]+ 176.10699, found 6 176.10684, 7 176.10682. 
N-(2-azidoacetyl)-Ile-Ile-Thr-leucinyl-2-methyloxirane (9) 
Tetrapeptide epoxyketone 831 (0.33 g, 0.50 mmol) was deprotected with TFA for 30 min at room temperature 
before being concentrated in the presence of toluene. The TFA salt of the deprotected compound was redissolved 
in DCE under argon atmosphere and DiPEA (0.17 mL, 1.0 mmol, 2.0 eq.) and 2-azidoacetyl-OSu (0.10 g, 0.50 mmol, 
1.0 eq.) were added. The reaction mixture was stirred at room temperature for 4 hrs, concentrated in vacuo and 
the crude product was purified by column chromatography (DCM  4% MeOH in DCM) to yield azide-modified 
epoxyketone 9 (0.26 g, 0.44 mmol, 88%). 1H NMR (400 MHz, CDCl3/CD3OD): δ (ppm) 7.80 (d, J = 8.4 Hz, 1H), 7.53 (d, 
J = 7.6 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 8.8 Hz, 1H), 4.39-4.35 (m, 1H), 4.26-4.18 (m, 2H), 4.14-4.10 (m, 
1H), 3.92-3.88 (m, 1H), 3.83 (s, 2H), 3.13 (d, J = 4.8 Hz, 1H), 2.75 (d, J = 4.8 Hz, 1H), 1.67-1.61 (m, 2H), 1.51-1.47 (m, 
1H), 1.36 (s, 3H), 1.41-1.30 (m, 3H), 1.19-1.08 (m, 2H), 0.98-0.94 (m, 5H), 0.81-0.70 (m, 18H). 13C NMR (100 MHz, 
CDCl3/CD3OD): δ (ppm) 207.52, 174.63, 171.38, 171.12, 167.36, 66.81, 59.03, 57.94, 57.29, 52.24, 51.90, 50.59, 
50.50, 39.14, 37.13, 36.62, 24.95, 24.74, 24.60, 22.99, 20.78, 17.85, 16.52, 14.92, 10.76, 10.69. LC/MS analysis: Rt 
8.0 min (linear gradient 10 → 90% B in 15 min), m/z 582.1 [M+H]+, 1185.0 [2M+Na]+. 
N-((4-(N-(5-norbornene-2-carbonyl)aminomethyl)-1H-1,2,3-triazol-1-yl)acetyl)-Ile-Ile-Thr-leucinyl-2-
methyloxirane (1) 
Azide-functionalized probe 9 (60 μmol, 35 mg) and alkyne 6 (60 μmol, 10 mg, 1.0 eq.) were dissolved in a mixture of 
tBuOH/toluene/H2O (2/2/1, v/v/v) (2 mL). After adding CuSO4.H2O (6 μmol, 0.5 mL 12 mM in H2O, 10 mol%) and 
sodium ascorbate (9 μmol, 0.5 mL 18 mM in H2O, 15 mol%), the mixture was stirred at 80 °C overnight before being 
concentrated in vacuo. Purification by column chromatography (2x; DCM → 6% MeOH in DCM, then EtOAc → 15% 
MeOH in EtOAc) yielded norbornene-functionalized peptide epoxyketone 1 (21 mg, 28 μmol, 47%) as a racemic 
mixture of diastereomers. Rf 0.3 (10% MeOH in DCM). 1H NMR (600 MHz, CD3OD): δ (ppm) 8.25-8.23 (m, 1H), 8.19-
8.16 (m, 2H), 7.98-7.96 (m, 1H), 7.84 (s, 1H), 6.18-6.17 (m, 1H), 5.91-5.89 (m, 1H), 5.22 (2xd, J = 16 Hz, 2H), 4.60-
4.57 (m, 1H), 4.42-4.41 (m, 2H), 4.37-4.27 (m, 3H), 4.07-4.06 (m, 1H), 3.28 (d, J = 4.8 Hz, 1H), 3.18-3.17 (m, 1H), 
2.96-2.93 (m, 2H), 2.90-2.89 (m, 1H), 1.89-1.85 (m, 3H), 1.75-1.72 (m, 1H), 1.58-1.50 (m, 3H), 1.49 (s, 3H), 1.42-1.31 
(m, 5H), 1.21-1.20 (m, 1H), 1.18 (d, J = 6.0 Hz, 3H), 0.97-0.89 (m, 18H). 13C NMR (150 MHz, CD3OD): δ (ppm) 207.37, 
174.87, 171.53, 170.17, 165.76, 145.00, 136.42, 130.95, 123.70, 66.53, 57.96, 57.76, 57.43, 57.35, 50.94, 50.76, 
49.77, 48.66, 45.47, 43.21, 41.86, 38.25, 36.12, 35.83, 33.67, 27.80, 27.79, 24.09, 23.89, 23.79, 21.63, 19.36, 17.90, 
14.89, 13.80, 8.50. LC/MS analysis: Rt 7.8 min (linear gradient 10 → 90% B in 15 min), m/z 757.3 [M+H]+, 1513.3 
[2M+H]+. HRMS: calcd. for [C39H61N8O8]+ 757.46069, found 757.46120; calcd. for [C39H60N8O8Na]+ 779.44263, found 
779.44285.  
(S)-2-(4-(N-(5-norbornene-2-carbonyl)aminomethyl)-1H-1,2,3-triazol-1-yl)-2-(naphthalen-2-yl)acetic acid (11) 
(S)-2-azido-2-(naphthalen-2-yl)acetic acid (10)32 (1.0 mmol, 0.23 g) and alkyne 6 (1.0 mmol, 0.18 g, 1.0 eq.) were 
dissolved in DMF. After adding CuSO4.H2O (0.1 mmol, 0.1 mL 1 M in H2O, 10 mol%) and sodium ascorbate (0.15 




vacuo. The crude product was purified by column chromatography (DCM → 10% MeOH in DCM with 1% AcOH), 
then recrystallized from DCM and finally resuspended in 1 M HCl after which the norbornene-functionalized acid 11 
was collected as white crystals (0.24 g, 0.59 mmol, 59%). Rf 0.3 (10% MeOH in DCM with 1% AcOH). 1H NMR (400 
MHz, DMSO-d6): δ (ppm) 8.11-7.94 (m, 5H), 7.81 (d, J = 5.6 Hz, 1H), 7.60-7.56 (m, 3H), 6.90 (s, 1H), 5.99-5.94 (m, 
1H), 5.69-5.58 (m, 1H), 4.29-4.16 (m, 2H), 3.09-3.06 (m, 1H), 2.79-2.76 (m, 2H), 1.71-1.65 (m, 1H), 1.28-1.20 (m, 3H). 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 172.90, 169.18, 145.43, 136.79, 132.81, 132.61, 132.08, 131.98, 131.82, 
128.71, 128.10, 127.63, 127.06, 126.81, 125.99, 122.73, 65.43, 49.35, 45.57, 43.19, 42.06, 34.27, 28.27. LC/MS 
analysis: Rt 7.9 min (linear gradient 0 → 90% B in 15 min), m/z 403.2 [M+H]+, 805.1 [2M+H]+, 827.3 [2M+Na]+. 




Boc-protected vinyl sulfone 1227 (0.10 mmol, 62 mg) was treated with TFA/DCM (1/1, v/v) for 30 min and then 
concentrated in vacuo in the presence of toluene. The residue was dissolved in DMF under argon atmosphere and 
DiPEA (0.20 mmol, 35 μL, 2.0 eq.), acid 11 (0.10 mmol, 40 mg, 1.0 eq.) and HCTU (0.15 mmol, 62 mg, 1.5 eq.) were 
added. The reaction mixture was stirred for 5 hrs at room temperature before DCM was added and the mixture was 
washed with H2O. The aqueous layer was extracted with DCM and the combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography (2x; DCM → 
3% MeOH in DCM, then toluene → toluene/acetone 2/1 (v/v)), yielding the norbornene-functionalized peptide vinyl 
sulfone 2 (54 mg, 60 μmol, 60%) as a racemic mixture of diastereomers. Rf 0.4 (5% MeOH in DCM). 1H NMR (400 
MHz, CD3OD): δ (ppm) 7.87-7.66 (m, 5H), 7.55-7.47 (m, 2H), 7.26-7.14 (m, 6.5H), 7.00 (d, J = 8.4 Hz, 0.5H), 6.86-6.84 
(m, 1.5H), 6.67-6.57 (m, 1.5H), 6.41 (d, J = 7.6 Hz, 1H), 5.99-5.93 (m, 2H), 5.74-5.56 (m, 1H), 4.89-4.85 (m, 1H), 4.64-
4.59 (m, 2H), 4.37-4.31 (m, 2H), 3.75-3.67 (2xs, 1.5H), 3.50 (s, 1.5H), 3.05-2.96 (m, 4H), 2.87 (s, 3H), 2.84-2.72 (m, 
3H), 1.81-1.73 (m, 1H), 1.66-1.52 (m, 1H), 1.35-1.20 (m, 5H), 0.92-0.79 (m, 6H). 13C NMR (100 MHz, CD3OD): δ (ppm) 
170.78, 170.58, 170.47, 170.40, 166.43, 166.25, 158.02, 157.71, 146.20, 146.09, 144.43, 136.41, 136.34, 135.58, 
135.53, 132.61, 132.29, 130.83, 130.78, 130.55, 130.33, 130.31, 129.36, 129.19, 128.32, 128.21, 128.16, 128.08, 
127.40, 127.36, 127.28, 127.25, 126.80, 126.77, 126.65, 126.59, 125.77, 125.74, 123.95, 123.85, 122.22, 122.14, 
113.07, 112.84, 65.40, 54.21, 53.94, 53.70, 53.65, 48.72, 48.66, 47.08, 45.39, 45.33, 45.30, 43.11, 41.74, 41.25, 
41.15, 37.13, 37.03, 36.94, 36.21, 33.67, 33.62, 29.61, 27.78, 27.73, 21.36, 21.29, 20.17, 20.11. LC/MS analysis: Rt 
9.3 min (linear gradient 10 → 90% B in 15 min), m/z 900.4 [M+H]+, 1800.3 [2M+H]+. 
4-(6-(2-pyrimidinyl)-1,2,4,5-tetrazin-3-yl)benzylhydroxide (16) 
To a solution of 4-(aminomethyl)benzonitrile.HCl (13) (12 mmol, 2.0 g) and 2-cyanopyrimidine (14) (15 mmol, 1.6 g, 
1.3 eq.) in EtOH was added H2NNH2.H2O (150 mmol, 7.3 mL, 12.5 eq.) and the reaction mixture was stirred under 
reflux (80 °C) overnight. Then, more H2NNH2.H2O (10 eq.) was added and the reaction mixture was stirred for an 
additional 4 hrs at 80 °C, after which it was allowed to cool to temperature and concentrated in vacuo. A solution of 
NaNO2 (150 mmol, 10 g, 12.5 eq.) in H2O/AcOH 1/1 (v/v, 30 mL) was then added slowly to the residue at 0 °C. The 
resulting pink mixture was stirred for 15 min at 0 °C, diluted with H2O and extracted with DCM (3x) until the water 
layer was colourless. The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in 
vacuo. The crude product was purified by column chromatography (2x; toluene → 25% acetone in toluene, then 
DCM → 12% MeOH in DCM), followed by trituration with a mixture of toluene and acetone to give tetrazine 16 as a 
purple solid (0.15 g, 0.55 mmol, 5%). Rf 0.3 (acetone/DCM 1/1). 1H NMR (400 MHz, CD3OD): δ (ppm) 9.14 (d, J = 4.8 
Hz, 2H), 8.69 (d, J = 8.0 Hz, 2H), 7.78 (t, J = 4.8 Hz, 1H), 7.67 (d, J = 8.4 Hz, 2H), 4.76 (d, J = 8.0 Hz, 2H). 13C NMR (100 
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MHz, CD3OD): δ (ppm) 163.93, 159.70, 159.20, 149.01, 129.72, 129.22, 128.58, 128.05, 124.40, 64.59. HRMS: calcd. 
for [C13H11N6O]+ 267.09834, found 267.09945. 
4-(Boc-aminomethyl)benzonitrile (17) 
4-(Aminomethyl)benzonitrile.HCl (13) (30 mmol, 5.0 g) was coevaporated with toluene (3x) and dissolved in DCM 
under argon atmosphere. After addition of Et3N (75 mmol, 11 mL, 2.5 eq.) and Boc2O (33 mmol, 7.4 g, 1.1 eq.) the 
reaction mixture was stirred at room temperature overnight before being concentrated in vacuo. The crude 
product was purified by column chromatography (PetEt → 20% EtOAc in PetEt), followed by recrystallization from 
EtOAc/PetEt to yield Boc-protected benzonitrile 17 as a white solid (7.0 g, 30 mmol, quant.). Rf 0.9 (10% MeOH in 
DCM). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.62 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 5.06 (s, 1H), 4.37 (d, J = 6.0 
Hz, 2H), 1.46 (s, 9H). 13C NMR (100 MHz, CDCl3): δ (ppm) 155.79, 144.61, 132.33, 127.71, 118.74, 110.97, 79.99, 
44.10, 28.28. LC/MS analysis: Rt 7.7 min (linear gradient 10 → 90% B in 15 min), m/z 132.9 [M-Boc+H]+, 232.9 
[M+H]+.  
Boc-4-(6-(2-pyrimidinyl)-1,2,4,5-tetrazin-3-yl)benzylamine (18)  
To a solution of 4-(N-Boc-aminomethyl)benzonitrile 17 (30 mmol, 7.0 g) and 2-cyanopyrimidine 14 (60 mmol, 6.3 g, 
2.0 eq.) in EtOH was added H2NNH2.H2O (300 mmol, 15 mL, 10 eq.) and the reaction mixture was stirred under 
reflux (70 °C) overnight. Then, more 2-cyanopyrimidine 14 (1.5 eq.) and H2NNH2.H2O (5.0 eq.) were added and the 
reaction mixture was stirred for an additional 7 hrs at 70 °C, after which it was allowed to cool to temperature and 
concentrated in vacuo. The residue was dissolved in AcOH (100 mL) and cooled to 0 °C before a solution of NaNO2 
(300 mmol, 21 g, 10 eq.) in H2O (50 mL) was added dropwise. The pink mixture was stirred for 15 min at 0 °C, 
diluted with H2O and extracted with DCM (3x). The combined organic layers were dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by column chromatography (2x; EtOAc, then 
DCM → 10% acetone in DCM), followed by recrystallization from EtOAc/PetEt to yield Boc-protected tetrazine 18 as 
purple crystals (1.3 g, 3.4 mmol, 11%). Rf 0.6 (25% acetone in DCM). 1H NMR (400 MHz, CDCl3): δ (ppm) 9.14 (d, J = 
4.8 Hz, 2H), 8.70 (d, J = 8.0 Hz, 2H), 7.60 (t, J = 4.8 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 5.11 (s, 1H), 4.47 (d, J = 6.0 Hz, 
2H), 1.49 (s, 9H). 13C NMR (100 MHz, CDCl3): δ (ppm) 164.30, 163.01, 159.51, 158.39, 155.91, 144.98, 130.19, 
129.07, 128.12, 122.45, 79.83, 44.34, 28.36. LC/MS analysis: Rt 7.1 min (linear gradient 10 → 90% B in 15 min), m/z 
366.1 [M+H]+, 730.9 [2M+H]+. HRMS: calcd. for [C18H20N7O2]+ 366.16730, found 366.16728. 
N-BodipyTMR-4-(6-(2-pyrimidinyl)-1,2,4,5-tetrazin-3-yl)benzylamine (3a) 
Boc-protected tetrazine 18 (0.1 mmol, 37 mg) was treated with TFA/DCM (1/1, v/v) for 15 min and then 
concentrated in vacuo in the presence of toluene. The residue was dissolved in DCE/DMF under argon atmosphere 
and DiPEA (0.2 mmol, 35 μL, 2.0 eq.) and BodipyTMR-OSu25 (0.1 mmol, 50 mg, 1.0 eq.) were added. The reaction 
mixture was stirred at room temperature overnight before being concentrated in vacuo. The crude product was 
purified by column chromatography (DCM → 2% MeOH in DCM), followed by recrystallization from DCM/n-hexane 
to yield BodipyTMR-tetrazine 3a as dark purple crystals (51 mg, 79 μmol, 79%). Rf 0.7 (10% MeOH in DCM). 1H NMR 
(400 MHz, CDCl3): δ (ppm) 9.12 (d, J = 4.8 Hz, 2H), 8.57 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 8.8 Hz, 2H), 7.58 (t, J = 4.8 Hz, 
1H), 7.40 (d, J = 8.0 Hz, 2H), 7.05 (s, 1H), 6.96 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 4.4 Hz, 1H), 6.53 (d, J = 4.4 Hz, 1H), 6.08 
(t, J = 5.6 Hz, 1H), 4.49 (d, J = 5.6 Hz, 2H), 3.85 (s, 3H), 2.80 (t, J = 7.2 Hz, 2H), 2.52 (s, 3H), 2.37 (t, J = 7.2 Hz, 2H), 
2.15 (s, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) 171.69, 164.21, 162.98, 160.36, 159.50, 158.86, 158.37, 155.82, 
144.00, 139.77, 134.98, 134.50, 130.69, 130.65, 130.29, 129.07, 128.47, 128.12, 125.37, 122.89, 122.49, 118.49, 
113.69, 55.25, 43.25, 36.29, 19.99, 13.15, 9.58. LC/MS analysis: Rt 8.6 min (linear gradient 10 → 90% B in 15 min), 
m/z 624.2 [M-F]+, 668.2 [M+Na]+, 1291.0 [2M+H]+, 1313.1 [2M+Na]+. HRMS: calcd. for [C34H30BF2N9O2Na]+ 





Boc-protected tetrazine 18 (0.1 mmol, 37 mg) was treated with TFA/DCM (1/1, v/v) for 15 min and then 
concentrated in vacuo in the presence of toluene. The residue was dissolved in DCE/DMF under argon atmosphere 
and DiPEA (0.2 mmol, 35 μL, 2.0 eq.) and BodipyFL-OSu35 (0.1 mmol, 39 mg, 1.0 eq.) were added. The reaction 
mixture was stirred at room temperature overnight before being concentrated in vacuo. The crude product was 
purified by column chromatography (DCM → 2% MeOH in DCM), followed by recrystallization from DCM/n-hexane 
to yield BodipyFL-tetrazine 3b as purple crystals (34 mg, 63 μmol, 63%). Rf 0.8 (10% MeOH in DCM). 1H NMR (400 
MHz, CDCl3): δ (ppm) 9.13 (d, J = 4.8 Hz, 2H), 8.58 (d, J = 8.0 Hz, 2H), 7.59 (t, J = 4.8 Hz, 1H), 7.36 (d, J = 8.4 Hz, 2H), 
7.10 (s, 1H), 6.89 (d, J = 4.0 Hz, 1H), 6.36 (s, 1H), 6.32 (d, J = 4.0 Hz, 1H), 6.06 (s, 1H), 4.52 (d, J = 5.6 Hz, 2H), 3.32 (t, J 
= 7.2 Hz, 2H), 2.78 (t, J = 7.2 Hz, 2H), 2.52 (s, 3H), 2.23 (s, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) 171.56, 164.31, 
163.05, 160.55, 159.59, 158.39, 156.69, 144.31, 144.21, 135.35, 134.10, 130.04, 128.94, 128.41, 128.20, 123.81, 
122.45, 120.50, 117.58, 43.12, 35.89, 24.77, 14.91, 11.32. LC/MS analysis: Rt 7.9 min (linear gradient 10 → 90% B in 
15 min), m/z 520.2 [M-F]+, 1079.1 [2M+H]+. HRMS: calcd. for [C27H24BFN9O]+ 520.21754, found 520.21767.  
N-biotin-4-(6-(2-pyrimidinyl)-1,2,4,5-tetrazin-3-yl)benzylamine (3c) 
Boc-protected tetrazine 18 (0.1 mmol, 37 mg) was treated with TFA/DCM (1/1, v/v) for 15 min and then 
concentrated in vacuo in the presence of toluene. The residue was dissolved in DCE/DMF under argon atmosphere 
and DiPEA (0.2 mmol, 35 μL, 2.0 eq.) and biotin-OSu (0.1 mmol, 34 mg, 1.0 eq.) were added. The reaction mixture 
was stirred at room temperature overnight before being concentrated in vacuo. The crude product was purified by 
column chromatography (DCM → 10% MeOH in DCM), followed by recrystallization from a mixture of DCM/MeOH 
(1/1, v/v) and n-hexane to yield biotin-tetrazine 3c as purple crystals (24 mg, 49 μmol, 49%). Rf 0.7 (20% MeOH in 
DCM). 1H NMR (400 MHz, CD3OD): δ (ppm) 9.14 (d, J = 4.8 Hz, 2H), 8.69 (d, J = 8.0 Hz, 2H), 7.67 (t, J = 4.8 Hz, 1H), 
7.57 (d, J = 8.4 Hz, 2H), 4.59-4.49 (m, 3H), 4.32-4.29 (m, 1H), 3.20-3.15 (m, 1H), 2.93 (dd, J = 13.0, 4.8 Hz, 1H), 2.74 
(d, J = 12.8 Hz, 1H), 2.31 (t, J = 7.2 Hz, 2H), 1.78-1.63 (m, 4H), 1.51-1.44 (m, 2H). 13C NMR (100 MHz, CD3OD): δ 
(ppm) 173.90, 164.33, 163.87, 162.52, 158.93, 158.27, 144.50, 129.93, 128.87, 128.33, 122.66, 61.72, 59.93, 55.32, 
42.80, 40.14, 35.43, 28.15, 27.86, 25.27. LC/MS analysis: Rt 5.2 min (linear gradient 10 → 90% B in 15 min), m/z 
492.2 [M+H]+, 983.1 [2M+H]+, 1473.9 [3M+H]+. HRMS: calcd. for [C23H26N9O2S]+ 492.19247, found 492.19228; calcd. 
for [C23H25N9O2SNa]+ 514.17441, found 514.17417. 
N-(6-heptynoyl)-Ile-Ile-Thr-leucinyl-2-methyloxirane (19) 
Fully protected peptide epoxyketone 831 (15 μmol, 10 mg) was treated with TFA for 30 min and then concentrated 
in vacuo in the presence of toluene. The residue was dissolved in DCE under argon atmosphere and DiPEA (45 μmol, 
8.0 μL, 3.0 eq.) and 6-heptynoic acid succinimidyl ester37 (15 μmol, 3.3 mg, 1.0 eq.) were added. The reaction 
mixture was stirred overnight at room temperature before being concentrated in vacuo. The crude product was 
purified by column chromatography (DCM → 2% MeOH in DCM) and then redissolved in DCM and washed with H2O 
(3x), dried over MgSO4, filtered and concentrated in vacuo to give alkyne-functionalized peptide epoxyketone 19 as 
a white powder (8.0 mg, 13 μmol, 87%). Rf 0.4 (5% MeOH in DCM). 1H NMR (400 MHz, CDCl3): δ (ppm) 8.37 (bs, 1H), 
7.89 (bs, 1H), 7.77 (bs, 1H), 7.12 (bs, 1H), 4.75-4.71 (m, 2H), 4.61-4.59 (m, 2H), 4.12-4.11 (m, 1H), 3.30 (s, 1H), 2.91 
(s, 1H), 2.36-2.19 (m, 4H), 1.94 (s, 1H), 1.77-1.69 (m, 6H), 1.60-1.53 (m, 8H), 1.41-1.30 (m, 1H), 1.11 (d, J = 4.8 Hz, 
3H), 1.10-1.03 (m, 1H), 0.92-0.83 (m, 18H).13C NMR (100 MHz, CDCl3): δ (ppm) 208.19, 172.79, 171.96, 171.87, 
170.63, 83.94, 68.60, 67.11, 59.19, 57.61, 57.27, 56.98, 52.36, 50.69, 39.27, 38.01, 37.64, 35.82, 27.88, 25.21, 25.15, 
25.02, 24.85, 23.28, 21.17, 18.13, 17.30, 16.82, 15.29, 15.25, 11.42. LC/MS analysis: Rt 8.5 min (linear gradient 10 → 
90% B in 15 min), m/z 607.5 [M+H]+, 629.6 [M+Na]+, 1213.5 [2M+H]+, 1235.5 [2M+Na]+. 
 




To a solution of 3-bromopropylamine.HBr (25) (1.0 mmol, 0.22 g) in DMF was added sodium azide (1.0 mmol, 65 
mg, 1.0 eq.) and the mixture was stirred overnight at room temperature. Then, 1/20 part of this solution (50 μmol, 
3.0 eq.) was added to a solution of BodipyFL-OSu35 (17 μmol, 6.6 mg, 1.0 eq.) and DiPEA (100 μmol, 17 μL, 6.0 eq.) 
in DCE under argon atmosphere. The reaction mixture was stirred at room temperature for 5 hrs before DCM was 
added and the mixture was washed with a saturated aqueous NaHCO3 solution and 1 M HCl (3x). The combined 
aqueous layers were extracted with DCM and all organic layers were combined, dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by column chromatography (chloroform) 
yielding azido-BodipyFL 20 (6.3 mg, 17 μmol, 99%). Rf 0.7 (5% MeOH in DCM). 1H NMR (400 MHz, CD3OD): δ (ppm) 
7.43 (s, 1H), 7.00 (s, 1H), 6.32 (s, 1H), 6.21 (s, 1H), 3.31-3.20 (m, 6H), 2.61 (t, J = 7.2 Hz, 2H), 2.51 (s, 3H), 2.28 (s, 3H), 
1.74-1.71 (m, 2H). 13C NMR (100 MHz, CD3OD): δ (ppm) 174.75, 161.40, 158.37, 145.88, 136.56, 134.87, 129.55, 
125.78, 121.36, 117.68, 49.99, 37.69, 36.05, 29.66, 25.62, 14.86, 11.17. LC/MS analysis: Rt 8.2 min (linear gradient 
10 → 90% B in 15 min), m/z 355.3 [M-F]+, 375.0 [M+H]+, 397.1 [M+Na]+, 749.1 [2M+H]+, 771.1 [2M+Na]+. 
B. Biochemistry 
General 
HEK-293T cells were cultured in DMEM supplemented with 10% (v/v) FCS, 10 units/mL penicillin and 10 μg/mL 
streptomycin in a 5% CO2 humidified incubator at 37 °C. Cells were harvested, washed with PBS (2x) and lysed in 
digitonin lysis buffer (50 mM Tris pH 7.5, 250 mM sucrose, 5 mM MgCl2, 1 mM DTT, 2 mM ATP, 0.025% digitonin) 
for 30 min on ice. After centrifugation of the cells at 16,100 g for 20 min at 4 °C, the supernatants were collected 
and the protein concentration was determined by Bradford assay. Precipitation of proteins was done using a 
chloroform/methanol (c/m) precipitation protocol.44 SDS-PAGE analysis: in-gel fluorescence was measured on a 
Typhoon Variable Mode Imager (Amersham Biosciences) using Cy3/TAMRA settings (excitation wavelength 532 nm, 
emission wavelength 580 nm) or Cy2/Blue FAM settings (excitation wavelength 488 nm, emission wavelength 520 
nm). As a loading control gels were stained with Coomassie Brilliant Blue. For Western blotting, the proteins were 
transferred onto a PVDF membrane using a Bio-Rad Trans-Blot cell system. Membranes were blocked with 1% BSA 
in TBS-t(+) (0.1% Tween 20) overnight at room temperature, hybridized with Streptavidin-HRP for 1 hr at room 
temperature (1:10,000 in blocking buffer) (Molecular Probes, Life Technologies), washed with TBS-t(+) and TBS and 
then visualized using an ECL+ Western blotting detection kit (Amersham Biosciences). Markers used were Precision 
Plus Dual Color protein standard (Bio-Rad) and Biotinylated protein marker (Bio-Rad). MV15125, 2130, 2238, 2339 and 
2432 are described in literature. 
In vitro competition assay versus MV151 
HEK cell lysates (20 μg total protein per experiment) in lysis buffer (9 μL) were exposed to the indicated 
concentrations of ABP 1, 2 or 19 (1 μL 10x solution in DMSO) for 1 hr at 37 °C, after which the lysates were 
incubated with 1 μM MV151 (1.1 µL 10 µM in DMSO) for 1 hr at 37 °C. The reaction mixtures were then boiled for 5 
min at 100 °C with 4 μL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 12.5% SDS-
PAGE. In-gel visualization of the fluorescent labeling was performed in the wet gel slabs directly using Cy3/TAMRA 
settings. 
In situ competition assay versus MV151 
HEK cells (~1x106 cells per experiment) were seeded in 6 cm petri dishes and grown overnight, after which the 
medium was removed and the cells were exposed to the indicated concentrations of ABP 1 or 2 (2 μL 1000x 




for 5 min at 1200 rpm and washed with PBS (2x), before flash freezing the cell pellets in liquid nitrogen and cell lysis 
in 50 μL lysis buffer. The lysates (10 μg total protein per experiment) in lysis buffer (9 μL) were exposed to 1 μM 
MV151 (1 μL 10 μM in DMSO) for 1 hr at 37 °C, boiled for 5 min at 100 °C with 4 μL 4x Laemmli’s sample buffer 
containing 2-mercaptoethanol and resolved on 12.5% SDSPAGE. In-gel visualization of the fluorescent labeling was 
performed in the wet gel slabs directly using Cy3/TAMRA settings. 
General procedure for tetrazine ligation in vitro 
HEK cell lysates (20 μg total protein per experiment) in lysis buffer (9 μL) were exposed to 1 μM ABP 1 or 2 (1 μL 10 
μM in DMSO) for 1 hr at 37 °C in the presence or absence of 100 μM epoxomicin (1 μL 1 mM in DMSO), followed by 
addition of the indicated concentrations of tetrazine 3a, 3b or 3c (1.1 μL 10x solution in DMSO) and incubation for 1 
hr at 37 °C. Control samples were labeled with 1 µM MV151. After quenching by c/m precipitation, proteins were 
taken up in 10 μL Laemmli’s sample buffer containing 2-mercaptoethanol, boiled for 5 min at 100 °C and resolved 
on 12.5% SDS-PAGE. Fluorescent labeling was visualized in the wet gel slabs directly using Cy3/TAMRA settings (3a, 
MV151) or Cy2/Blue FAM settings (3b). Biotinylated proteins (3c) were detected by streptavidin Western blotting.  
Optimisation of tetrazine ligation conditions. Tetrazine ligation was performed for 0.5, 1, 2, 3 or 20 hrs at 37 °C or 
for 1 hr at 20, 37 or 50 °C. Alternatively, the pH of the reaction mixture was adjusted by addition of a citric 
acid/phosphate buffer (9 μL) (pH 4, 5, 6, 7, or 8) prior to addition of tetrazine 3a. 
Compatibility with click conditions. One or more of the following reagents were added to the tetrazine ligation 
reaction mixture: 1 mM CuSO4 (1 μL 10 mM in H2O), 1 mM TCEP (1 μL 10 mM in H2O) and 100 μM TBTA (1 μL 1 mM 
in DMSO). 
Cross-reactivity. ABPs 1, 9 and 19 (1 μM ) were used for reaction with tetrazine 3b (50 μM). 
General procedure for tetrazine ligation in situ 
HEK cells (~1x106 cells per experiment) were seeded in 6 cm petri dishes and grown overnight, after which the 
medium was removed and the cells were exposed to 10 μM ABP 1 (2 μL 10 mM in DMSO) in 2 mL fresh medium for 
3 hrs at 37 °C. Control cells were exposed to MV151 (1 μM) for 3 hrs at 37 °C. After removal of the medium, the 
cells were washed with 3 mL fresh medium for 30 min at 37 °C and then exposed to the indicated concentrations of 
tetrazine 3a, 3b, or 3c (2 μL 1000x solution in DMSO) in 2 mL fresh medium for 1 hr at 37 °C. Next, the cells were 
harvested by scraping, centrifuged for 5 min at 1200 rpm and washed with PBS (2x), before flash freezing the cell 
pellets in liquid nitrogen and cell lysis in 50 μL lysis buffer. The lysates (20 μg total protein per experiment) were 
boiled for 5 min at 100 °C with Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 12.5% SDS-
PAGE. Fluorescent labeling was visualized in the wet gel slabs directly using Cy3/TAMRA settings (3a, MV151) or 
Cy2/Blue FAM settings (3b). Biotinylated proteins (3c) were detected by streptavidin Western blotting. 
Staudinger-Bertozzi ligation and copper-free strain-promoted click ligation in vitro 
HEK cell lysates (20 μg total protein per experiment) in lysis buffer (9 μL) were exposed to 1 μM ABP 9 (1 μL 10 μM 
in DMSO) for 1 hr at 37 °C, followed by addition of the indicated concentrations of phosphine 22 or 
dibenzocyclooctyn 23 (1.1 μL 10x solution in DMSO) and incubation for 1 hr at 37 °C. After quenching by c/m 
precipitation, proteins were taken up in 10 μL Laemmli’s sample buffer containing 2-mercaptoethanol, boiled for 5 
min at 100 °C and resolved on 12.5% SDS-PAGE. Biotinylated proteins were detected by streptavidin Western 
blotting.  
Cross-reactivity. ABPs 1, 9 and 19 (1 μM ) were used for reaction with phosphine 22 (50 μM). 
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Copper(I)-catalyzed click ligation in vitro 
HEK cell lysates (20 μg total protein per experiment) in lysis buffer (9 μL) were exposed to 1 μM ABP 9 or 19 (1 μL 
10 μM in DMSO) for 1 hr at 37 °C. The mixtures were then diluted with an additional 9 μL lysis buffer containing 2 
mM CuSO4, 2 mM TCEP and 200 μM TBTA and exposed for 1 hr at 37 °C to the indicated concentrations of azide 20 
(reaction with 19) or alkyne 21 (reaction with 9) (1 μL 20x solution in DMSO). After quenching by c/m precipitation, 
proteins were taken up in 10 μL Laemmli’s sample buffer containing 2-mercaptoethanol, boiled for 5 min at 100 °C 
and resolved on 12.5% SDS-PAGE. Fluorescent labeling was visualized in the wet gel slabs directly using Cy2/Blue 
FAM settings. 
Cross-reactivity. ABPs 1, 9 and 19 (1 μM ) were used for reaction with azide 20 and/or alkyne 21 (50 μM). 
Triple ligation procedure in vitro 
HEK cell lysates (30 μg total protein per experiment) in lysis buffer (9 μL) were exposed to 1 μM ABP 2 and 5 μM 
ABP 24 (0.5 μL 20x solution in DMSO each) for 1 hr at 37 °C, and then to 1 μM ABP 19 (0.5 μL 20 μM in DMSO) for 1 
hr at 37 °C. After diluting the mixtures with an additional 9 μL lysis buffer, 25 μM BodipyTMR-tetrazine 3a and 100 
μM biotin-phosphine 22 (0.5 μL 40x solution in DMSO each) were added and the mixtures were incubated for 1 hr 
at 37 °C. Next, the excess of reagents was removed by a buffer exchange to 50 mM Tris pH 7.5 using Millipore 
Amicon centrifugal filters (3 kDa MWCO). Samples were washed twice with 300 μL Tris buffer and concentrated to a 
final volume of 40 μL per sample, prior to addition of 1 mM CuSO4, 1 mM TCEP and 100 μM TBTA (0.6 μL 100x 
solution each). The mixtures were then reacted with 25 μM BodipyFL-azide 20 (1.5 μL 1 mM in DMSO) for 1 hr at 37 
°C. After quenching by c/m precipitation, proteins were taken up in 10 μL Laemmli’s sample buffer containing 2-
mercaptoethanol, boiled for 5 min at 100 °C and resolved on 12.5% SDS-PAGE. Fluorescent labeling was visualized 
in the wet gel slabs directly using Cy3/TAMRA settings (3a) and Cy2/Blue FAM settings (20) after which biotinylated 
proteins (22) were detected by streptavidin Western blotting. 
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Synthesis of epoxide- and aziridine-based 
probes to target retaining galactosidases 
  
5.1 Introduction 
Glycosidases are hydrolytic enzymes responsible for the hydrolysis of glycosidic bonds in 
(oligo)saccharides and glycoconjugates and are crucial for the breakdown of 
glyco(sphingo)lipids in lysosomes. They can be classified according to the nature of their 
substrate and the mechanism of substrate hydrolysis, which generally involves cleavage with 
either retention or inversion of anomeric stereochemistry. For example, retaining β-
glucosidases recognize β-linked glucoside substrates and hydrolyze the glycosidic bond with 
retention of stereochemistry at the anomeric position. The catalytic mechanism of retaining 
glycosidases is a two-step process that generally involves a double displacement mechanism 
as depicted schematically in Figure 5.1A.1 In the first step the catalytic nucleophile, usually 
an aspartic or glutamic acid residue, attacks the anomeric center to cleave the glycosidic 
bond with inversion of configuration and thereby creates a covalent enzyme-substrate 
intermediate. Cleavage of the substrate aglycon is assisted by another glutamic or aspartic 
acid residue that acts as a general acid and protonates the leaving group. In the next step 
this residue, now acting as a general base, deprotonates a water molecule that hydrolyzes 
the glycosyl-enzyme intermediate, thereby releasing the glycoside from the active site. The 





Figure 5.1. Mechanism of substrate hydrolysis by retaining β-glucosidases (A), N-acetylhexosaminidases (B) and 
inverting β-glucosidases (C). D) Proposed mechanism of cyclophellitol binding to retaining β-glucosidases.  
alternative mechanism for hydrolysis with retention of configuration can occur when the 
substrate carries an acetamide substituent at C2 that assists in the cleavage of the glycosidic 
bond by acting as a nucleophile. This mechanism, for example used by N-
acetylhexosaminidases, does not involve a covalent substrate-enzyme intermediate (Figure 
5.1B).2 The same holds true for the class of inverting glycosidases. These enzymes employ a 
one-step mechanism involving two carboxylic acid residues in the active site that act as a 
general base and a general acid.1 The first carboxylic acid residue deprotonates a water 
molecule during its attack on the anomeric center, while the second residue protonates the 
leaving aglycon (Figure 5.1C).  
Many covalent and irreversible mechanism-based glycosidase inhibitors have been 
described in literature.3 These can generally be divided into two types: compounds that 
release a reactive aglycon after hydrolytic cleavage which then reacts with another residue 
in the active site, and inhibitors that contain a reactive electrophile that is attacked by the 
active site nucleophile to create a stable covalent bond. The latter class includes epoxide- 
and aziridine-based inhibitors as well as glycosides that are functionalized with one or more 
fluorine substituents at C2 and/or C5.4-14 Of these, especially the fluorosugars have received 
considerable attention. Drawbacks of these inhibitors are their modest potency and the 
reversibility of binding, although the covalent enzyme-probe intermediate is usually 
sufficiently stable to enable analysis of the adducts. In contrast, the epoxide based inhibitors 
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have proven to enable very potent and selective irreversible inhibition of specific 
glycosidases. Cyclophellitol (1) is a naturally occurring β-glucosidase inhibitor that was first 
isolated in 1990 from the mushroom Phellinus sp. (Figure 5.2A).5,6 In a follow-up study it was 
demonstrated that cyclophellitol is a selective and potent mechanism-based irreversible 
inhibitor of several retaining β-glucosidases.7 The β-glucopyranose-configured inhibitor is 
thought to bind in the active site by mimicking a β-linked glucoside substrate and to enable 
covalent bond formation through reaction of the epoxide with the catalytic nucleophile 
(Figure 5.1D). In later studies, the α-epoxide stereoisomers (1R,6S)- and (1R,2S,6S)-
cyclophellitol (2 and 3, Figure 5.2A) were shown to be irreversible inhibitors of retaining α-
glucosidases and α-mannosidases, respectively,8,9 while the β-epoxide isomer of inhibitor 3 
was synthesized as a putative β-mannosidase inhibitor.10 Conduritol B epoxide (5), although 
structurally related to cyclophellitol, is less potent and also less selective as a result of its 
structural symmetry, resulting in the inhibition of both retaining β- and α-glucosidases.11,12 
Two galactopyranose-configured isomers, conduritol C epoxides 6 and 7, have been 
identified as irreversible inhibitors of several retaining α- and β-galactosidases, 
respectively.13 In addition to the epoxide-based inhibitors, a few aziridine derivatives have 
been synthesized. For example, the aziridine analogue of cyclophellitol (4) is an inhibitor of 
  
 
Figure 5.2. A) Irreversible glycosidase inhibitors (1-8). B) ABPs for retaining β-exoglucosidases (9-10). C) Target 




retaining β-glucosidases9 and conduritol B aziridine (8) inhibits a number of retaining α- and 
β-glucosidases.14 The remarkable selectivity and potency of cyclophellitol, in combination 
with the highly conserved catalytic mechanism of this class of enzymes, opens up the 
potential to develop selective inhibitors for different retaining glycosidases by altering the 
configuration of the inhibitor to that of the natural substrates of the target enzyme. For 
example, galactopyranose-configured epoxides may enable specific targeting of catalytically 
active retaining galactosidases. In the same line, the structure of these inhibitors can be 
exploited for the design of ABPs that target a specific class of glycosidases. Cyclophellitol has 
already served as a basis to develop a number of epoxide- and aziridine-based probes for 
retaining β-exoglucosidases (e.g. 9 and 10, Figure 5.2B).15,16 Surprisingly, other than the 
glucosidase and mannosidase inhibitors described above, no differently configured isomers 
of cyclophellitol or ABPs 9 and 10 have been reported. It would therefore be desirable to 
develop new synthetic strategies that enable the synthesis of such compounds. This chapter 
describes the synthesis of two series of galactopyranose-configured ABPs (12-16 and 18-22, 
Figure 5.2C) for retaining α- and β-galactosidases, respectively, with the electrophilic 
aziridine and epoxide moieties in either an α- or a β-configuration17 to allow attack by the 
respective catalytic nucleophiles. The ABPs are functionalized with a fluorescent Bodipy tag, 
a biotin tag or an azide that can be used for two-step labeling. In addition, the epoxide-
based inhibitors 11 and 17 are synthesized as α- and β-galactopyranose-configured 
cyclophellitol isomers. 
5.2 Results and discussion 
All target compounds were synthesized from a single precursor, dibenzylated compound 
27, that was prepared in 3 steps from aldehyde 2418 following conditions similar to those 
described in literature (Scheme 5.1).19 Dibutylboryl triflate mediated reaction of 24 with 
oxazolidinone 2320 resulted in the stereoselective formation of syn-aldol adduct 25, which 
after removal of the Evans template (26) was subjected to ring-closing metathesis to provide 
cyclohexene 27. The synthetic route towards α- and β-epoxides 11 and 17 and their azide-
modified derivatives 12 and 18 is depicted in Scheme 5.2. The azide moiety was installed at 
C6 (carbohydrate numbering) by selective tosylation of the primary alcohol in 27 followed by 
substitution with sodium azide to give 28. Next, the benzyl groups were removed with BCl3 
and the free hydroxyl groups benzoylated (29) in order to enable facile deprotection after 
formation of the epoxide. Epoxidation was performed with mCPBA to give the α- and β-
epoxides (30) in a ratio of approximately 4:1. After final deprotection with sodium 
methoxide the isomers could be separated by column chromatography to give 
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Scheme 5.1 Synthesis of dibenzylated cyclohexene 27 
 
Reagents and conditions: a) Bu2BSO3CF3, Et3N, DCM, -78 °C  -15 °C, 3.5 hrs, 63%; b) LiBH4, THF/H2O, 0 °C  rt, 2 
hrs, 85%; c) Grubbs II, DCM, 40 °C, overnight, 78%. 
enantiomerically pure azide-functionalized α- and β-epoxides 12 and 18. The same strategy 
of deprotection, benzoylation and epoxidation was used to synthesize the non-tagged 
epoxide inhibitors 11 and 17. In this case it proved impossible to separate the mixture of α- 
and β-epoxides (ratio 1:1) in the protected (32) or deprotected (33) stage. However, 
acetylation of 33 was found to give a separable mixture of mainly tri-acetylated β-epoxide 
34β1, a small amount of  fully acetylated β-epoxide 34β2, and fully acetylated α-epoxide 
34α. After separation of the isomers by column chromatography, deprotection yielded the 
enantiomerically pure α- and β-epoxides 11 and 17. In order to synthesize the Bodipy- and 
 
Scheme 5.2 Synthesis of α- and β-galactopyranose-configured epoxides (11, 17) and azide-modified derivatives (12, 
18) 
 
Reagents and conditions: a) i) pTsCl, Et3N, DCM, rt, 4 days, ii) NaN3, DMF, 60 °C, overnight, 63%; b) i) BCl3, DCM, -78 
°C, 4 hrs, ii) BzCl, pyridine, rt, overnight, 29 85%, 31 76%; c) mCPBA, DCM, rt, 4-8 days, 30 53%, 32 62%; d) NaOMe, 
MeOH, rt, 1.5 hrs, 18 8% + 12 42%, 33 76%; e) Ac2O, pyridine, rt, 4 hrs, 34α 38% + 34β1 20% + 34β2 2%; f) NaOMe, 




biotin-tagged epoxide ABPs, their azide-functionalized precursors 12 and 18 were subjected 
to copper(I)-catalyzed azide-alkyne cycloadditions (‘click’ reactions) with Bodipy-alkyne 3521 
or biotin-alkyne 3622 (Scheme 5.3). The click reactions proceeded smoothly to provide the 
fluorescently labeled α-epoxide 13 and biotinylated probe 14 as well as their β-epoxide 
isomers 19 and 20. 
The strategy towards β-aziridine ABPs 21 and 22 is based on the previously reported 
procedure to synthesize β-glucosidase probe 10 and relies on the stereocontrolled 
formation of a β-aziridine with the aid of the primary alcohol at C6 (Scheme 5.4).16 Briefly, 
the primary hydroxyl in 27 was selectively transformed into the trichloroacetimidate which 
was then subjected to iodocyclization. Acidic hydrolysis of the intermediate imidate was 
followed by the addition of base to effect nucleophilic displacement of the iodine by the 
amine, providing aziridine 39. In case of the α-aziridine ABPs 15 and 16 it might be possible 
to apply a similar procedure by creating an imidate with the hydroxyl group at C2 in order to 
achieve iodocyclization below the plane of the cyclohexane ring. However, such a strategy 
would require a number of additional protection and deprotection steps in order to 
selectively unmask this hydroxyl group. Therefore another route was evaluated to 
synthesize the α-aziridine probes, commencing with the formation of fully benzylated β-
epoxide 42. Although an α/β mixture was formed by mCPBA-mediated epoxidation of 41, 
the most prevalent product was β-epoxide 42 with only a small amount of the 
corresponding α epoxide (ratio 6:1). Moreover, the two isomers could easily be separated by 
column chromatography. Next, the β-epoxide was opened with sodium azide and lithium 
perchlorate as a Lewis acid to give a mixture of azido-alcohols (43).23 Treatment of 43 with  
 
Scheme 5.3 Synthesis of biotin- and Bodipy-functionalized epoxide ABPs (13, 14, 19, 20) and Bodipy-spacer 38 
 
Reagents and conditions: a) Bodipy-alkyne 35 or biotin-alkyne 36, CuSO4.5H2O, sodium ascorbate, DMF, rt, 
overnight, 13 88%, 14 68%, 19 90%, 20 68%; b) Bodipy-alkyne 35, CuSO4.5H2O, sodium ascorbate, DMF, 80 °C, 4.5 
hrs, 87%. 
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Scheme 5.4 Synthesis of α- and β-galactopyranose-configured aziridine ABPs (15, 16, 21) 
 
Reagents and conditions: a) i) CCl3CN, DBU, DCM, 0 °C, 1.5 hrs, ii) I2, NaHCO3, H2O, rt, overnight, iii) HCl, MeOH, rt, 
3.5 hrs, iv) HCl, dioxane, 60 °C, 1 hr, v) NaHCO3, MeOH, rt, 4 days, 52%; b) Li, NH3 (l), THF, -60 °C, 45 min; c) 37 or 
38, EEDQ, DMF, 0 °C, 90 min, 15 14%, 16 15%; d) NaH, BnBr, TBAI, DMF, rt, overnight, 85%; e) mCPBA, DCM, rt, 
overnight, 63%; f) NaN3, LiClO4, ACN, 80 °C, overnight, 73%; g) Ph3P, ACN, 80 °C, 2 hrs, 26%. 
triphenylphosphine led to the formation of the α-aziridine moiety (44) via an intramolecular 
Staudinger-like ring closure.24 The yield of this reaction was rather low, partly due to the fact 
that it proved difficult to remove the formed triphenylphosphine oxide. In addition, it might 
be possible that the intramolecular rearrangement of the iminophosphorane intermediate is 
hindered by steric factors or ring strain, resulting in reduction of the azide to an amine 
during workup. Nonetheless, the α-aziridine 44 could be obtained in enantiomerically pure 
form in four steps starting from 27. It proved impossible to synthesize β-aziridine 39 using 
the same strategy since no product was formed by opening of the benzylated epoxide (the 
α-isomer of 42) under the same conditions as described above, nor under acidic 
‘nonchelating’ conditions (NaN3, MeOH/1.2 M NH4Cl (4:1), 80 °C)
23 or with the use of phase 
transfer conditions (NaN3, Bu4NCl, ACN/H2O, 80 °C). 
 The final stage in the synthetic route towards the aziridine ABPs involved deprotection 
of the benzyl groups in 39 and 44 by Birch reduction and acylation of the aziridine nitrogen 
with an azide- or Bodipy-functionalized spacer (37, 38) using EEDQ as the coupling reagent 
(Scheme 5.4).16 In case of the α-aziridine 44, deprotection and subsequent acylation 
followed by HPLC purification provided the azide- and Bodipy-tagged products 15 and 16. 
After deprotection of the β-aziridine 39, however, some byproduct formation was observed 




spacer 37 were unsuccessful since 1H NMR analysis indicated significant degradation and 
almost complete disappearance of the aziridine proton peaks after HPLC purification and 
ensuing lyophilization. Further analysis by LC/MS revealed that the aziridine was opened 
with HCl, despite the fact that no acids were used during purification. Instability of the 
acylated aziridine moiety is a recurring problem during the synthesis of such ABPs and 
opening of the aziridine was also repeatedly observed with the α-galactosidase ABPs and the 
β-glucosidase ABPs described previously.16 Hence, care has to be taken that the acylation 
reaction as well as ensuing HPLC purification and lyophilization are performed in the 
absolute absence of any traces of acid. It appears that the β-aziridine moiety is very unstable 
even under these conditions and consequently the β-aziridine ABP 21 could not be isolated.  
The diastereomeric configuration of the α- and β-epoxides 11 and 17 was determined by 
1H NMR analysis and was supported by a comparison of the experimental coupling constants 
with the corresponding values obtained from DFT calculations (Table 5.1). The optimized 
structures obtained by these calculations are shown in Figure 5.3. The assignment of the 
diastereomeric configuration of epoxides 12, 18 and 42 could be deduced from epoxides 11 
and 17. In all cases a characteristic configuration-dependent pattern of epoxide proton 
peaks was observed in which the H1 and H7 peaks (carbohydrate numbering) of the β-
epoxides are consistently closer together than those of the α-epoxides. Moreover, the H1-
H2 coupling is smaller and the H5-H7 coupling larger for the β-isomers than the α-isomers. 
The correct configuration of β-epoxide 42 was further supported by the fact that it leads to 
α-aziridine 44, which can in turn be confirmed by comparison with β-aziridine 39 of which 
the configuration is known. 
 
 
Table 5.1. Comparison of experimental and calculated coupling constants for epoxides 11 and 17  
α-epoxide 11 J exp. (Hz) J calc. (Hz) β-epoxide 17 J  exp. (Hz) J  calc. (Hz) 
H1-H7 4.0 3.7 H1-H7 3.7 3.4 
H1-H2 2.5 2.2 H1-H2 n.d. (a) 0.04 
H2-H3 8.6 6.9 H2-H3 8.6 6.6 
H3-H4 1.9 1.8 H3-H4 n.d. (b) 2.7 
H4-H5 3.6 4.0 H4-H5 4.0 3.5 
H5-H7 n.d. (a) 0.04 H5-H7 1.7 1.5 
H4-H7 1.8 1.1 H4-H7 n.d. (a) 0.8 
Coupling constants obtained from DFT calculations (‘calc.’) as compared to experimental data from 1H NMR analysis 
(‘exp.’). n.d.: values were not determined because of a) very small coupling constants (J < 1 Hz) or b) peak overlap. 




Figure 5.3. Optimized structures of α-epoxide 11 (left) and β-epoxide 17 (right) obtained by DFT calculations. 
In the synthetic strategies described here, the formation of both α- and β-epoxides by 
mCPBA-mediated epoxidation is favorable, as long as the two isomers can be separated at 
some point in the route of synthesis. In other cases, however, it may be desirable to obtain 
only one isomer and for that purpose other oxidation methods should be evaluated. It is 
worth noting that the fully benzoylated compound 31 gives a 1:1 ratio of α- and β-epoxides 
whereas an α:β ratio of 4:1 was obtained with the C6-azide-functionalized analogue 29. Full 
benzylation (41) on the other hand leads to more β-selectivity during epoxidation (α:β 1:6). 
These results indicate that formation of the β-epoxide is favored in the absence of chelating 
effects and that the presence of a benzoyl group at either the allylic (C2) or homoallylic (C6) 
position can enhance α- or β-selectivity, respectively. As expected, deprotection of either 29 
or 31 prior to epoxidation led to the formation of mainly the α-epoxide (α:β > 15:1) due to 
strong coordination of the allylic OH to mCPBA. 
5.3 Conclusion 
Two sets of galactopyranose-configured glycosidase probes were synthesized that are 
equipped with an electrophilic α- or β-configured epoxide moiety in order to enable 
targeting of retaining α- and β-galactosidases, respectively. Each set consists of a non-tagged 
inhibitor (11, 17), an ABP for two-step labeling with an azide as a ligation handle (12, 18), 
and two ABPs that are functionalized with a fluorescent Bodipy tag (13, 19) or a biotin tag 
(14, 20). Next to the epoxide-based ABPs, efforts were undertaken to synthesize analogous 
probes with an aziridine as the electrophile in which an azide or Bodipy tag is installed via 
acylation of the aziridine moiety. Whereas the α-aziridine ABPs 15 and 16 were successfully 
obtained, it proved impossible to isolate β-aziridine probe 21 since even the use of a 
completely acid-free purification procedure resulted in opening of the labile acylated 
aziridine. Hence, other methods or a different probe design will be necessary to realize the 
synthesis of aziridine-based β-galactosidase ABPs. Evaluation of the inhibitory potency of the 
synthesized α- and β-configured probes as well as their application for the labeling of human 






All reagents were commercial grade and were used as received unless stated otherwise. DCM, DCE, DMF and THF 
(Biosolve) were of analytical grade and when used under anhydrous conditions stored over flame-dried 3 Å 
molecular sieves. EtOAc (Riedel-de Haën) used for column chromatography was of technical grade and distilled 
before use. Reactions were monitored by TLC-analysis using DC-alufolien (Merck, Kieselgel60, F254) with detection 
by UV-absorption (254/366 nm), spraying with 20% H2SO4 in ethanol or a solution of (NH4)6Mo7O24.4H2O (25 g/L) 
and (NH4)4Ce(SO4)4.2H2O (10 g/L) in 10% aqueous sulfuric acid followed by charring at ∼150 °C or by spraying with 
an aqueous solution of KMnO4 (7%) and K2CO3 (2%). Column chromatography was performed on silica gel 
(Screening Devices BV, 0.040 - 0.063 mm, 60 Å). LC/MS analysis was performed on an LCQ Adventage Max (Thermo 
Finnigan) ion-trap spectrometer (ESI+) coupled to a Surveyor HPLC system (Thermo Finnigan) equipped with a C18 
column (Gemini, 4.6 mm x 50 mm, 5μm particle size, Phenomenex). The applied buffers were A: H2O, B: ACN and C: 
1 % aqueous TFA. Reported gradients represent the percentage of buffer B in buffer A with 10% buffer C. 
Alternatively, where indicated LC/MS analysis was performed using an API 3000 ESI (Q1) mass spectrometer 
(Applied Biosystems) coupled to a Jasco (900 series) HPLC system. The applied buffers were A: H2O, B: ACN and C: 
100 mM NH4OAc in H2O. Reported gradients represent the percentage of buffer B in buffer A with 10% buffer C. 
HRMS analysis was performed on an LTQ Orbitrap (Thermo Finnigan) mass spectrometer equipped with an 
electronspray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10 mL min−1, capillary 
temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z = 150 - 2000) and dioctylphtalate (m/z = 
391.28428) as a "lock mass". The high resolution mass spectrometer was calibrated prior to measurements with a 
calibration mixture (Thermo Finnigan). For reversed-phase HPLC purification an automated HPLC system equipped 
with a C18 semiprep column (Gemini C18, 250 mm x 10 mm, 5μm particle size, 110 Å pore size, Phenomenex) was 
used. 1H- and 13C-APT-NMR spectra were recorded on a Brüker AV-400 (400/100MHz) or a Bruker DMX600 
(600/150 MHz) instrument with a cryoprobe. Chemical shifts are given in ppm (δ) relative to the solvent peak or to 
tetramethylsilane as internal standard. Coupling constants (J) are given in Hz. All presented 13C-APT spectra are 
proton decoupled. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR experiments. 
(S)-3-((2S,3S,4S,5S)-4,5-bis(benzyloxy)-3-hydroxy-2-vinylhept-6-enoyl)-4-isopropyloxazolidin-2-one (25) 
Note: Solutions of aldehyde 2418 and oxazolidinone 2320 in DCM were put under argon atmosphere and dried over 
activated 4Å molsieves for at least 1 hr prior to use. Et3N was distilled over CaH2 and stored on activated 4Å 
molsieves under argon atmosphere. 
A solution of oxazolidinone 23 (32 mmol, 6.3 g, 2.0 eq.) in DCM under argon atmosphere was cooled to -78 °C with 
the use of a cryostate before addition of Bu2BSO3CF3 (32 mmol, 32 mL 1 M in DCM, 2.0 eq.) and Et3N (35 mmol, 4.9 
mL, 2.2 eq.). The reaction mixture was stirred at -78 °C for 1 hr, then at 0 °C (ice bath) for 15 min and subsequently 
cooled back to -78 °C. A solution of aldehyde 24 (16 mmol, 4.7 g, 1.0 eq.) in DCM under argon atmosphere was 
added via canula after which the temperature was allowed to rise to -20 °C over 2 hrs and maintained at -15 °C for 
1.5 hrs. Next, the mixture was removed from the cold bath and put in an ice bath of -5 °C. After quenching with PBS 
(20 mL), H2O2 (30% aqueous solution) was added dropwise while keeping the temperature of the mixture below 5 
°C, until no more rise in temperature was observed. At this point the mixture was stirred for another 45 min while 
slowly warming to room temperature after which aqueous saturated NaHCO3 was added and the aqueous layer was 
extracted with DCM (3x). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (pentane → 10% EtOAc in pentane) to afford the aldol 
adduct 25 (4.9 g, 10 mmol, 63%). 1H  NMR (400 MHz, CDCl3): δ (ppm) 7.39-7.25 (m, 10H), 6.06 (ddd, J = 18.5, 9.7, 7.1 
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Hz, 1H), 5.92 (ddd, J = 17.3, 10.1, 8.8 Hz, 1H), 5.45-5.37 (m, 3H), 5.29 (dd, J = 10.2, 1.6 Hz, 1H), 5.02 (dd, J = 9.0, 7.2 
Hz, 1H), 4.69 (dd, J = 11.5, 4.0 Hz, 2H), 4.55-4.40 (m, 3H), 4.29 (dd, J = 7.3, 3.9 Hz, 1H), 4.03 (dt, J = 8.6, 3.5 Hz, 1H), 
3.84 (dd, J = 9.0, 3.0 Hz, 1H), 3.58 (dd, J = 8.3, 3.9 Hz, 1H), 3.39 (bs, 1H), 3.26 (t, J = 8.8 Hz, 1H), 2.26-2.14 (m, 1H), 
0.75 (dd, J = 18.8, 7.0 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ (ppm) 172.53, 153.53, 138.01, 137.76, 134.55, 133.56, 
128.17, 128.00, 127.64, 127.53, 127.32, 127.09, 120.43, 119.14, 81.78, 79.90, 73.04, 71.12, 70.66, 62.38, 57.94, 
50.06, 27.96, 17.75, 14.41. 
(2R,3S,4S,5S)-4,5-bis(benzyloxy)-2-vinylhept-6-ene-1,3-diol (26) 
Oxazolidinone 25 (13.8 mmol, 6.8 g) was dissolved in THF (100 mL) at 0 °C after which H2O (8 mL) and LiBH4 (35 
mmol, 17.5 mL 2 M in THF, 2.5 eq.) were added. The reaction mixture was stirred at 0 °C for 1 hr and then at room 
temperature for 1 hr, before being quenched with 2 M NaOH. The resulting mixture was extracted with Et2O (2x) 
and the combined organic layers were washed with aqueous saturated NaHCO3 and Brine, dried over MgSO4 and 
concentrated in vacuo. Purification by column chromatography (pentane → 40% EtOAc in pentane) yielded alcohol 
26 as a white solid (4.3 g, 12 mmol, 85%).1H NMR (400 MHz, CDCl3): δ (ppm) 7.45-7.21 (m, 10H), 6.14-5.94 (m, 2H), 
5.49-5.33 (m, 2H), 5.26 (dd, J = 10.4, 2.1 Hz, 1H), 5.13 (dd, J = 17.5, 2.2 Hz, 1H), 4.67 (d, J = 11.8 Hz, 1H), 4.57 (d, J = 
11.1 Hz, 1H), 4.48 (d, J = 11.1 Hz, 1H), 4.39 (d, J = 11.8 Hz, 1H), 4.21 (dd, J = 7.0, 3.8 Hz, 1H), 4.05 (d, J = 9.1 Hz, 1H), 
3.77-3.64 (m, 2H), 3.51 (dd, J = 9.1, 3.7 Hz, 1H), 3.39 (bs, 1H), 2.58 (ddt, J = 7.9, 5.7, 2.9 Hz, 1H), 2.20 (bs, 1H). 13C 
NMR (100 MHz, CDCl3): δ (ppm) 137.75, 137.26, 135.28, 133.85, 128.55, 128.36, 127.93, 127.86, 127.80, 119.51, 
119.05, 79.58, 78.97, 73.08, 72.53, 70.97, 65.58, 47.33. 
(3S,4S,5S,6R)-6-(hydroxymethyl)-3,4-dibenzyloxy-5-hydroxy-cyclohex-1-ene (27) 
To a solution of 26 (7.8 mmol, 2.9 g) in DCM under argon atmosphere was added second generation Grubbs catalyst 
(0.4 mmol, 0.34 g, 5 mol%). The reaction mixture was stirred at 40 °C in the dark for 20 hrs, DMSO (40 mmol, 2.8 
mL, 100 eq. with respect to catalyst) was added and the mixture was stirred overnight at room temperature before 
being concentrated in vacuo. Purification by column chromatography (pentane → pentane/EtOAc 1/1 (v/v)) gave 
cyclohexene 27 (7.2 mmol, 2.5 g, 92%). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.38-7.28 (m, 10 H), 5.84 (d, J = 10.4 Hz, 
1H), 5.55 (d, J = 10.1 Hz, 1H), 4.71 (d, J = 8.5 Hz, 4H), 4.33-4.31 (m, 2H), 3.82-3.80 (m, 2H), 3.65 (d, J = 7.4 Hz, 1H), 
2.95 (bs, 2H), 2.45 (d, J = 6.1 Hz, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 138.45, 137.93, 128.45, 128.32, 127.85, 
127.75, 127.57, 127.43, 126.75, 81.80, 77.31, 76.58, 72.15, 41.87. 
(3S,4S,5S,6R)-6-(azidomethyl)-3,4-dibenzyloxy-5-hydroxy-cyclohex-1-ene (28) 
A solution of (3S,4S,5S,6R)-6-(hydroxymethyl)-3,4-dibenzyloxy-5-hydroxy-cyclohex-1-ene (27) (0.76 mmol, 0.26 g) in 
DCM under argon atmosphere was cooled to 0 °C before pTsCl (0.84 mmol, 0.16 g, 1.1 eq.) and Et3N (1.4 mmol, 
0.19 mL, 1.8 eq.) were added. The reaction mixture was stirred overnight at room temperature, after which TLC 
analysis indicated incomplete reaction. Therefore another 0.5 eq. of pTsCl (75 mg) and 1.8 eq. of Et3N (0.19 mL) 
were added after 24 hrs and again after 48 hrs. The mixture was stirred for a total of 4 days, after which 1 M 
aqueous HCl was added and the aqueous layer was extracted with Et2O (3x). The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. The crude tosylated product was then redissolved in DMF 
under argon atmosphere and NaN3 (7.6 mmol, 0.50 g, 10 eq.) was added. The reaction mixture was heated to 60 °C, 
stirred overnight and concentrated in vacuo. The residue was then redissolved in EtOAc and washed with 1 M 
aqueous HCl (1x), aqueous saturated NaHCO3 (1x) and Brine (1x), dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography (pentane → 12% EtOAc in pentane in steps of 2%) gave the 
dibenzylated azide 28 (0.17 g, 0.48 mmol, 63% over two steps). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.46-7.31 (m, 
10H), 5.86 (dt, J = 10.2, 2.6 Hz, 1H), 5.48 (dd, J = 9.6, 1.6 Hz, 1H), 4.81-4.73 (m, 4H), 4.40-4.27 (m, 2H), 3.70 (dd, J = 




(m, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 138.51, 138.03, 128.56, 128.44, 127.96, 127.92, 127.86, 127.70, 
125.50, 82.12, 76.80, 72.42, 72.26, 67.58, 51.77, 40.63. HRMS: calcd. for [C21H24O3N3]+ 366.18122, found 366.18143; 
calcd. for [C21H23O3N3Na]+ 388.16316, found 388.16322. [α]D20 (c = 0.1, CHCl3): +118°. 
(3S,4R,5S,6R)-6-(azidomethyl)-3,4,5-tribenzoyloxy-cyclohex-1-ene (29) 
A solution of dibenzylated azide 28 (0.47 mmol, 0.17 g) in DCM was cooled to -78 °C under argon atmosphere 
before addition of BCl3 (4.8 mmol, 4.8 mL 1 M in DCM, 10 eq.). The reaction mixture was stirred at -78 °C for 4 hrs, 
quenched with MeOH, concentrated in vacuo and coevaporated with toluene (3x). The deprotected product was 
then dissolved in pyridine, BzCl was added (4.7 mmol, 0.55 mL, 10 eq.) and the mixture was stirred overnight at 
room temperature. After quenching with aqueous saturated NaHCO3 the mixture was extracted with DCM (3x) and 
the combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The product was purified 
by column chromatography (pentane → 7.5% EtOAc in pentane) to yield the tribenzoylated product 29 (0.20 g, 0.40 
mmol, 85% over two steps). 1H NMR (400 MHz, CDCl3): δ (ppm) 8.19-7.86 (m, 6H), 7.66-7.28 (m, 9H), 6.21-6.12 (m, 
1H), 6.12-6.07 (m, 1H), 6.03 (dt, J = 10.3, 2.7 Hz, 1H), 5.89-5.82 (m, 1H), 5.71 (dd, J = 8.6, 2.3 Hz, 1H), 3.52 (dd, J = 
12.1, 7.7 Hz, 1H), 3.42 (dd, J = 12.1, 7.8 Hz, 1H), 3.10-3.08 (m, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 166.11, 
165.84, 165.51, 133.75, 133.55, 133.28, 133.21, 130.17, 129.78, 129.76, 129.72, 129.46, 129.20, 129.17, 128.66, 
128.46, 128.40, 128.31, 127.48, 126.55, 73.14, 70.49, 69.85, 51.46, 39.87. HRMS: calcd. for [C28H23O6N3Na]+ 
520.14791, found 520.14724. [α]D20 (c = 0.2, CHCl3): +265°. 
(2S,3S,4S,5S)-5-(azidomethyl)-2,3,4-tribenzoyloxy-7-oxabicyclo[4.1.0]heptane (30) 
Tribenzoylated azide 29 (0.40 mmol, 0.20 g) was dissolved in DCM under argon atmosphere and 3-
chloroperoxybenzoic acid (1.2 mmol, 0.27 g, 3.0 eq.) was added. The reaction mixture was stirred at room 
temperature for a total of 4 days, concentrated in vacuo and purified by column chromatography (pentane → 10% 
EtOAc in pentane) giving the azido-epoxide 30 as a mixture of α- and β-isomers (ratio 4:1) (0.11 g, 0.21 mmol, 53%). 
1H NMR (400 MHz, CDCl3): δ (ppm) 8.12-7.81 (m, 6H α + 6H β), 7.68-7.25 (m, 9H α + 9H β), 6.04 (dd, J = 9.3, 2.3 Hz, 
1H α), 5.93-5.86 (m, 1H α + 1H β), 5.75 (d, J = 9.4 Hz, 1H β), 5.60 (dd, J = 9.3, 1.9 Hz, 1H α), 5.53 (dd, J = 9.3, 2.6 Hz, 
1H β), 3.88 (dd, J = 3.9, 2.3 Hz, 1H α), 3.68-3.42 (m, 2H α + 4H β), 3.35 (dd, J = 3.9, 1.7 Hz, 1H α), 2.80-2.74 (m, 1H α 
+ 1H β). 13C NMR (100 MHz, CDCl3): δ (ppm) 166.25, 165.68, 165.65, 165.54, 165.47, 165.26, 134.59, 133.66, 133.62, 
133.53, 133.48, 133.36, 133.30, 130.88, 129.80, 129.79, 129.76, 129.73, 129.71, 129.64, 129.01, 128.96, 128.92, 
128.89, 128.83, 128.67, 128.64, 128.58, 128.56, 128.49, 128.43, 128.33, 128.32, 72.17, 70.85, 70.32, 70.18, 68.47, 
66.77, 54.44, 54.14, 53.67, 52.04, 49.77, 49.75, 39.01, 38.27. LC/MS analysis: Rt 9.3 min (linear gradient 10 → 90% B 
in 15 min), m/z 514.1 [M+H]+, 1026.7 [2M+H]+. HRMS: calcd. for [C28H24O7N3]+ 514.16088, found 514.16066; calcd. 
for [C28H23O7N3Na]+ 536.14282, found 536.14242. [α]D20 (c = 0.2, CHCl3): +189°. 
(2R,3S,4S,5R)-5-(azidomethyl)-2,3,4-trihydroxy-7-oxabicyclo[4.1.0]heptane: α-epoxide 12 and β-epoxide  18 
Epoxide 30 (0.19 mmol, 96 mg) was dissolved in MeOH (2.5 mL) and deprotected with NaOMe (38 µmol, 6.8 µL 5.6 
M in MeOH, 20 mol%) for 1.5 hrs at room temperature. The reaction mixture was then quenched by addition of 
Amberlite-H+ IR-200, filtered and concentrated in vacuo. The product was purified by multiple rounds of column 
chromatography (DCM → 3% MeOH in DCM in steps of 0.5%) to separate the α-epoxide 12 (16 mg, 80 µmol, 42%) 
and β-epoxide 18 (3.0 mg, 15 µmol, 8%) (yield of mixed α/β product 7.0 mg, 35 µmol, 18%). 1H NMR (600 MHz, 
MeOD) α-epoxide 12: δ (ppm) 4.07 (dd, J = 8.6, 2.5 Hz, 1H), 3.78 (dd, J = 3.4, 1.8 Hz, 1H), 3.59 (dd, J = 12.2, 8.0 Hz, 
1H), 3.48 (dd, J = 12.3, 8.3 Hz, 1H), 3.39 (dd, J = 8.5, 1.9 Hz, 1H), 3.32 (dd, J = 3.9, 2.4 Hz, 1H), 2.97 (dd, J = 3.9, 1.8 
Hz, 1H), 2.09 (td, J = 8.2, 3.5 Hz, 1H). 13C NMR (150 MHz, MeOD) α-epoxide 12: δ (ppm) 73.56, 72.15, 70.53, 58.08, 
55.29, 51.73, 41.83. 1H NMR (600 MHz, MeOD) β-epoxide 18: δ (ppm) 3.92 (dd, J = 8.7, 0.7 Hz, 1H), 3.82 (ddd, J = 
4.1, 2.5, 1.3 Hz, 1H), 3.70 (dd, J = 12.1, 8.2 Hz, 1H), 3.63 (dd, J = 12.1, 7.2 Hz, 1H), 3.33 (dd, J = 8.6, 2.6 Hz, 1H), 3.26-
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3.22 (m, 1H), 3.17 (d, J = 3.7 Hz, 1H), 2.28 (dddd, J = 8.2, 7.2, 4.1, 1.8 Hz, 1H). 13C NMR (150 MHz, MeOD) β-epoxide 
18: δ (ppm) 76.39, 70.36, 69.50, 58.03, 55.21, 51.58, 40.43. [α]D20 (c = 0.1 (β)/0.3 (α), MeOH): 12 +81°, 18 +64°. 
 (3S,4R,5S,6R)-6-(benzoyloxymethyl)-3,4,5-tribenzoyloxy-cyclohex-1-ene (31) 
A solution of (3S,4S,5S,6R)-6-(hydroxymethyl)-3,4-dibenzyloxy-5-hydroxy-cyclohex-1-ene (27) (0.5 mmol, 0.17 g) in 
DCM under argon atmosphere was cooled to -78 °C before BCl3 was added (5 mmol, 5 mL 1M in DCM, 10 eq.). The 
reaction mixture was stirred under argon at -78 °C for 4 hrs and then quenched with MeOH, concentrated in vacuo 
and coevaporated with toluene (3x). Purification by column chromatography (10% MeOH in EtOAc → 20% MeOH in 
EtOAc) afforded the fully deprotected compound, which was redissolved in pyridine and cooled to 0 °C. Next, 
benzoyl chloride was added (5 mmol, 0.6 mL, 10 eq.) and the mixture was stirred overnight at room temperature 
before being quenched with a saturated aqueous NaHCO3 solution. The aqueous layer was extracted with DCM (3x) 
and the combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (pentane → 10% EtOAc in pentane) yielded the fully benzoylated product 31 (0.22 g, 0.38 mmol, 
76% over two steps). 1H NMR (400 MHz, CDCl3): δ (ppm) 8.00-7.88 (m, 8H), 7.62-7.30 (m, 12H), 6.23-6.18 (m, 2H), 
6.09-6.06 (m, 1H), 5.88 (dd, J = 1.2, 10.4 Hz, 1H), 5.78 (dd, J = 2.2, 8.6 Hz, 1H), 4.59 (dd, J = 6.4, 10.8 Hz, 1H), 4.32 
(dd, J = 8.8, 10.8 Hz, 1H), 3.44-3.40 (m, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 166.23, 166.14, 165.87, 165.51, 
133.71, 133.42, 133.26, 133.20, 133.13, 129.80, 129.77, 129.74, 129.68, 129.51, 129.35, 129.24, 128.60, 128.47, 
128.39, 128.31, 126.86, 126.81, 73.10, 70.60, 69.30, 63.05, 39.47. LC/MS analysis: Rt 10.1 min (linear gradient 10 → 
90% B in 15 min), m/z 599.1 [M+Na]+, 1174.9 [2M+Na]+. HRMS: calcd. for [C35H29O8]+ 577.18569, found 577.18602; 
calcd. for [C35H28O8Na]+ 599.16764, found 599.16727. [α]D20 (c = 0.1, CHCl3): +250°. 
(2R,3S,4S,5R)-5-(benzoyloxymethyl)-2,3,4-tribenzoyloxy-7-oxabicyclo[4.1.0]heptane (32) 
To a solution of 31 (0.42 mmol, 0.24 g) in DCM was added 3-chloroperoxybenzoic acid (1.1 mmol, 0.24 g, 2.5 eq.) 
and the reaction mixture was stirred for 4 days at room temperature. Then, an additional 1 eq. of 3-
chloroperoxybenzoic acid was added and the reaction mixture was stirred again for 4 days at room temperature, 
before being concentrated in vacuo. Purification by column chromatography (pentane → 15% EtOAc in pentane) 
yielded a mixture of the α- and β-epoxides 32 in a 1:1 ratio (0.15 g, 0.26 mmol, 62%). 1H NMR (400 MHz, CDCl3): δ 
(ppm) 8.19-7.76 (m, 8H α + 8H β), 7.68-7.20 (m, 12H α + 12H β), 6.14-5.98 (m, 2H α + 1H β), 5.78 (d, J = 9.4 Hz, 1H 
β), 5.68 (dd, J = 1.8, 9.2 Hz, 1H α), 5.61 (dd, J = 2.6, 9.4 Hz, 1H β), 4.78 (dd, J = 6.7, 11.1 Hz, 1H β), 4.70-4.62 (m, 1H 
α), 4.52-4.46 (m, 1H α + 1H β), 3.92 (dd, J = 2.3, 3.7 Hz, 1H α), 3.50 (s, 2H β), 3.43 (dd, J = 1.5, 3.8 Hz, 1H α), 3.21-
3.01 (m, 1H α + 1H β). 13C NMR (100 MHz, CDCl3): δ (ppm) 166.28, 165.69, 165.58, 133.59, 133.50, 133.44, 133.25, 
133.20, 133.16, 130.00, 129.86, 129.77, 129.68, 129.12, 129.08, 129.01, 128.68, 128.58, 128.47, 128.40, 128.28, 
72.13, 70.85, 70.30, 69.87, 68.71, 66.25, 61.92, 61.79, 54.17, 53.98, 53.42, 51.73, 38.59, 37.75. LC/MS analysis: Rt 
9.7 min (linear gradient 10 → 90% B in 15 min), m/z 593.1 [M+H]+, 1206.9 [2M+Na]+. HRMS: calcd. for [C35H29O9]+ 
593.18061, found 593.18073; calcd. for [C35H28O9Na]+ 615.16255, found 615.16184. [α]D20 (c = 0.1, CHCl3): +130°. 
(2R,3S,4S,5R)-5-(hydroxymethyl)-7-oxabicyclo[4.1.0]heptane-2,3,4-triol: mix of α- and β-epoxide (33) 
A solution of tetrabenzoylated epoxides 32 (α- and β-epoxides in 1:1 ratio) (0.30 mmol, 180 mg) in MeOH was 
treated with sodium methoxide (0.12 mmol, 21 µL 5.6 M in MeOH, 0.4 eq.) at room temperature for 1.5 hrs. After 
neutralization with Amberlite-H+ IR-200 the reaction mixture was filtered and concentrated in vacuo. Purification by 
column chromatography (10% MeOH in DCM → 15% MeOH in DCM) yielded the fully deprotected product 33 (α- 
and β-epoxides in 1.5:1 ratio) (40 mg, 0.23 mmol, 76%). 1H NMR (400 MHz, CDCl3): δ (ppm) 4.07 (dd, J = 2.4, 8.4 Hz, 
1H α), 3.91 (d, J = 8.4 Hz, 1H β), 3.87-3.82 (m, 3H α + 3H β), 3.38 (dd, J = 1.6, 8.4 Hz, 1H α), 3.32-3.29 (m, 1H α + 2H 





Separation of α- and β-epoxides by acetylation-deacetylation (11 + 17) 
An α/β mixture of deprotected epoxides 33 (0.26 mmol, 45 mg) was coevaporated with toluene before being 
dissolved in pyridine under argon atmosphere. After addition of acetic anhydride (10 mmol, 0.9 mL, 38 eq.) the 
mixture was stirred at room temperature for 4 hrs, then concentrated in vacuo and coevaporated with toluene (3x). 
After purification by column chromatography (DCM → 0.6% MeOH in DCM in steps of 0.1%) three different 
products were isolated: the tetra-acetylated form of the α-isomer 34α (0.10 mmol, 35 mg, 38%), a small amount of 
tetra-acetylated β-isomer 34β2 (4.4 µmol, 1.5 mg, 2%) and tri-acetylated β-isomer 34β1 (53 µmol, 16 mg, 20%). 1H 
NMR (400 MHz, CDCl3) 34α: δ (ppm) 5.52-5.41 (m, 2H), 5.00 (dd, J = 9.6, 1.8 Hz, 1H), 4.24-4.07 (m, 2H), 3.59 (dd, J = 
4.0, 2.4 Hz, 1H), 3.10 (dd, J = 4.0, 1.6 Hz, 1H), 2.68 (td, J = 8.1, 3.7 Hz, 1H), 2.13 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 2.00 
(s, 3H). 1H NMR (400 MHz, CDCl3) 34β2: δ (ppm) 5.52-5.45 (m, 1H), 5.26 (d, J = 9.4 Hz, 1H), 4.95 (dd, J = 9.6, 2.0 Hz, 
1H), 4.35-4.20 (m, 2H), 3.26-3.17 (m, 2H), 2.78-2.74 (m, 1H), 2.12 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 1.96 (s, 3H). 1H 
NMR (400 MHz, CDCl3) 34β1: δ (ppm) 5.35 (d, J = 9.1 Hz, 1H), 4.90 (dd, J = 9.1, 2.6 Hz, 1H), 4.46-4.38 (m, 2H), 3.99 
(d, J = 9.3 Hz, 1H), 3.44-3.37 (m, 1H), 3.30 (d, J = 3.6 Hz, 1H), 2.54 (tdd, J = 7.6, 3.5, 1.3 Hz, 1H), 2.46 (d, J = 11.0 Hz, 
1H), 2.13 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H). The β-isomers 34β1 and 34β2 were then combined and deprotected 
separately from 34α by treatment with sodium methoxide (30 µmol, 5 µL 5.6 M in MeOH, 0.3 eq. for 34α and 17 
µmol, 3 µL 5.6 M in MeOH, 0.3 eq. for 34β) in MeOH at room temperature for 2 hrs. The mixtures were neutralized 
with Amberlite-H+ IR-200, filtered and concentrated in vacuo. The crude products were finally purified by column 
chromatography (10% MeOH in DCM → 15% MeOH in DCM) to give α-epoxide 11 (17 mg, 94 µmol, 94%) and β-
epoxide 17 (8.5 mg, 48 µmol, 84%). 1H NMR (600 MHz, MeOD) α-isomer 11: δ (ppm) 4.09 (dd, J = 8.5, 2.5 Hz, 1H), 
3.85 (ddd, J = 3.6, 1.8, 1.8 Hz, 1H), 3.78 (dd, J = 11.0, 6.6 Hz, 1H), 3.74 (dd, J = 11.0, 8.0 Hz, 1H), 3.41 (dd, J = 8.6, 1.9 
Hz, 1H), 3.33 (dd, J = 4.0, 2.5 Hz, 1H), 3.10 (dd, J = 4.0, 1.7 Hz, 1H), 2.04 (ddd, J = 8.0, 6.6, 3.5 Hz, 1H). 13C NMR (150 
MHz, MeOD) α-epoxide 11: δ (ppm) 73.76, 72.77, 70.79, 62.28, 58.10, 55.46, 44.34. 1H NMR (600 MHz, MeOD) β-
isomer 17: δ (ppm) 3.93 (d, J = 8.6 Hz, 1H), 3.88-3.82 (m, 3H), 3.33-3.31 (m, 2H), 3.17 (d, J = 3.7 Hz, 1H), 2.18 (tdd, J 
= 7.3, 4.0, 1.7 Hz, 1H). 13C NMR (150 MHz, MeOD) β-epoxide 17: δ (ppm) 76.72, 70.76, 69.96, 61.87, 57.76, 55.36, 
42.82. [α]D20 (c = 0.2, MeOH): 11 +85°, 17 +67°. 
(1R,2R,3S,4S,5R,6S)-5-((Bodipy-triazolyl)methyl)-2,3,4-trihydroxy-7-oxabicyclo[4.1.0]heptane (13) 
Azido-epoxide 12 (25 µmol, 5.0 mg) and Bodipy-alkyne 3521 (25 µmol, 12 mg, 1.0 eq.) were dissolved in DMF (0.5 
mL) under argon atmosphere. After addition of copper(II)sulfate pentahydrate (5 µmol, 5 µL 1 M in H2O, 0.2 eq.) 
and sodium ascorbate (10 µmol, 10 µL 1 M in H2O, 0.4 eq.) the reaction mixture was stirred at room temperature 
overnight. The mixture was then concentrated in vacuo and purified by column chromatography (DCM → 3% MeOH 
in DCM) to yield Bodipy-epoxide 13 as a purple solid (15 mg, 22 µmol, 88%). 1H NMR (400 MHz, MeOD): δ (ppm) 
7.89-7.82 (m, 4H), 7.78 (s, 1H), 7.43 (d, J = 4.4 Hz, 2H), 7.01-6.94 (m, 4H), 6.70 (d, J = 4.3 Hz, 2H), 4.60-4.53 (m, 2H), 
4.13 (dd, J = 8.5, 2.4 Hz, 1H), 3.85 (s, 6H), 3.66-3.61 (m, 1H), 3.42 (dd, J = 8.5, 1.8 Hz, 1H), 3.37-3.34 (m, 1H), 3.07-
3.02 (m, 2H), 2.97 (dd, J = 3.9, 1.8 Hz, 1H), 2.79-2.75 (m, 2H), 2.55 (td, J = 8.2, 3.5 Hz, 1H), 1.88-1.83 (m, 4H). 13C 
NMR (100 MHz, MeOD): δ (ppm) 160.77, 157.39, 145.31, 136.08, 130.71, 127.03, 125.10, 119.66, 115.98, 113.22, 
72.03, 70.53, 69.06, 56.67, 54.41, 53.30, 49.13, 41.27, 32.86, 29.58, 29.00, 24.48. LC/MS analysis: Rt 10.4 min (linear 
gradient 10 → 50% B in 15 min), m/z 666.3 [M-F]+, 685.9 [M+H]+, 1371.0 [2M+H]+. HRMS: calcd. for [C36H39O6N5BF2]+ 
686.29560, found 686.29599; calcd. for [C36H38O6N5BF2Na]+ 708.27754, found 708.27719. 
(1R,2R,3S,4S,5R,6S)-5-((biotin-triazolyl)methyl)-2,3,4-trihydroxy-7-oxabicyclo[4.1.0]heptane (14) 
Azido-epoxide 12 (25 µmol, 5.0 mg) and biotin-alkyne 3622 (25 µmol, 7.0 mg, 1.0 eq.) were dissolved in DMF (0.5 
mL) under argon atmosphere. After addition of copper(II)sulfate pentahydrate (5 µmol, 5 µL 1 M in H2O, 0.2 eq.) 
and sodium ascorbate (10 µmol, 10 µL 1 M in H2O, 0.4 eq.) the reaction mixture was stirred at room temperature 
overnight. The mixture was then concentrated in vacuo and purified by column chromatography (DCM → 30% 
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MeOH in DCM) to yield biotin-epoxide 14 as a white solid (8.0 mg, 17 µmol, 68%). 1H NMR (400 MHz, MeOD): δ 
(ppm) 7.97 (s, 1H), 4.65-4.60 (m, 2H), 4.52 (ddd, J = 8.0, 5.0, 1.0 Hz, 1H), 4.47 (s, 2H), 4.32 (dd, J = 7.9, 4.5 Hz, 1H), 
4.14 (dd, J = 8.6, 2.4 Hz, 1H), 3.66 (dt, J = 3.7, 1.8 Hz, 1H), 3.43 (dd, J = 8.6, 1.8 Hz, 1H), 3.37-3.36 (m, 1H), 3.22 (ddd, 
J = 8.9, 5.9, 4.4 Hz, 1H), 3.02 (dd, J = 4.0, 1.8 Hz, 1H), 2.96 (dd, J = 12.8, 5.0 Hz, 1H), 2.74 (d, J = 12.7 Hz, 1H), 2.58 (td, 
J = 8.1, 3.5 Hz, 1H), 2.27 (t, J = 7.3 Hz, 2H), 1.78-1.57 (m, 4H), 1.48-1.42 (m, 2H). 13C NMR (100 MHz, MeOD): δ (ppm) 
174.63, 145.05, 123.62, 72.00, 70.51, 69.03, 61.95, 60.23, 56.70, 55.59, 53.32, 49.23, 41.34, 39.66, 35.14, 34.20, 
28.28, 28.05, 25.29. LC/MS analysis: Rt 3.6 min (linear gradient 10 → 50% B in 15 min), m/z 483.3 [M+H]+, 965.1 
[2M+H]+, 1446.9 [3M+H]+. HRMS: calcd. for [C20H31O6N6S]+ 483.20203, found 483.20176; calcd. for [C20H30O6N6SNa]+ 
505.18397, found 505.18347. [α]D20 (c = 0.1, MeOH): +48°. 
(1R,2R,3S,4S,5R,6S)-5-((Bodipy-triazolyl)methyl)-2,3,4-trihydroxy-7-oxabicyclo[4.1.0]heptane (19) 
Azido-epoxide 18 (25 µmol, 5.0 mg) and Bodipy-alkyne 3521 (25 µmol, 12 mg, 1.0 eq.) were dissolved in DMF (0.5 
mL) under argon atmosphere. After addition of copper(II)sulfate pentahydrate (5 µmol, 5 µL 1 M in H2O, 0.2 eq.) 
and sodium ascorbate (10 µmol, 10 µL 1 M in H2O, 0.4 eq.) the reaction mixture was stirred at room temperature 
overnight. The mixture was then concentrated in vacuo and purified by column chromatography (DCM → 3% MeOH 
in DCM) to yield Bodipy-epoxide 19 as a purple solid (15 mg, 22 µmol, 90%). 1H NMR (400 MHz, MeOD): δ (ppm)  
1.91-7.82 (m, 4H), 7.77 (s, 1H), 7.44 (d, J = 4.4 Hz, 2H), 7.03-6.93 (m, 4H), 6.70 (d, J = 4.3 Hz, 2H), 4.70 (d, J = 7.8 Hz, 
2H), 3.97 (d, J = 8.5 Hz, 1H), 3.86 (s, 6H), 3.66-3.58 (m, 1H), 3.42-3.40 (m, 1H), 3.18 (d, J = 3.7 Hz, 1H), 3.11-2.97 (m, 
3H), 2.86-2.76 (m, 2H), 2.73 (ddt, J = 7.6, 4.3, 2.2 Hz, 1H), 1.91-1.82 (m, 4H).  13C NMR (100 MHz, MeOD): δ (ppm) 
160.78, 157.38, 136.09, 130.79, 127.03, 125.11, 123.06, 119.63, 113.22, 74.73, 68.51, 67.89, 56.77, 54.41, 53.27, 
48.74, 39.84, 32.86, 29.59, 29.02, 24.46. LC/MS analysis: Rt 10.5 min (linear gradient 10 → 50% B in 15 min), m/z 
666.3 [M-F]+, 686.0 [M+H]+, 1371.0 [2M+H]+. HRMS: calcd. for [C36H39O6N5BF2]+ 686.29560, found 686.29615; calcd. 
for [C36H38O6N5BF2Na]+ 708.27754, found 708.27725. 
(1R,2R,3S,4S,5R,6S)-5-((biotin-triazolyl)methyl)-2,3,4-trihydroxy-7-oxabicyclo[4.1.0]heptane (20) 
Azido-epoxide 18 (25 µmol, 5.0 mg) and biotin-alkyne 3622 (25 µmol, 7.0 mg, 1.0 eq.) were dissolved in DMF (0.5 
mL) under argon atmosphere. After addition of copper(II)sulfate pentahydrate (5 µmol, 5 µL 1 M in H2O, 0.2 eq.) 
and sodium ascorbate (10 µmol, 10 µL 1 M in H2O, 0.4 eq.) the reaction mixture was stirred at room temperature 
overnight. The mixture was then concentrated in vacuo and purified by column chromatography (DCM → 30% 
MeOH in DCM) to yield biotin-epoxide 20 as a white solid (8.0 mg, 17 µmol, 68%). 1H NMR (400 MHz, MeOD): δ 
(ppm) 7.93 (s, 1H), 4.75 (d, J = 7.7 Hz, 2H), 4.52 (ddd, J = 8.0, 5.0, 0.9 Hz, 1H), 4.46 (s, 2H), 4.32 (dd, J = 7.9, 4.5 Hz, 
1H), 3.98 (d, J = 8.5 Hz, 1H), 3.63 (ddd, J = 4.1, 2.7, 1.2 Hz, 1H), 3.38-3.36 (m, 1H), 3.25-3.22 (m, 1H), 3.21 (d, J = 3.8 
Hz, 1H), 3.14-3.08 (m, 1H), 2.96 (dd, J = 12.7, 5.0 Hz, 1H), 2.78 (ddt, J = 7.7, 5.4, 2.7 Hz, 1H), 2.73 (d, J = 12.8 Hz, 1H), 
2.27 (t, J = 7.3 Hz, 2H), 1.81-1.55 (m, 4H), 1.50-1.38 (m, 2H). 13C NMR (100 MHz, MeOD): δ (ppm) 174.62, 144.82, 
123.89, 74.73, 68.46, 67.88, 61.95, 60.23, 56.79, 55.59, 53.25, 48.86, 39.87, 39.65, 35.14, 34.22, 28.29, 28.04, 25.30. 
LC/MS analysis: Rt 3.7 min (linear gradient 10 → 50% B in 15 min), m/z 483.3 [M+H]+, 965.0 [2M+H]+, 1447.1 
[3M+H]+. HRMS: calcd. for [C20H31O6N6S]+ 483.20203, found 483.20179; calcd. for [C20H30O6N6SNa]+ 505.18397, found 
505.18357. [α]D20 (c = 0.1, MeOH): +36°. 
8-(Bodipy-triazole)-octanoic acid 38 
8-Azidooctanoic acid 3725 (0.50 mmol, 93 mg) and Bodipy-alkyne 3521 (0.50 mmol, 0.24 g, 1.0 eq.) were dissolved in 
DMF under argon atmosphere. After addition of copper(II)sulfate pentahydrate (100 µmol, 100 µL 1 M in H2O, 0.2 
eq.) and sodium ascorbate (200 µmol, 200 µL 1 M in H2O, 0.4 eq.) the reaction mixture was heated to 80 °C and 
stirred for 4.5 hrs. The mixture was then concentrated in vacuo and purified by column chromatography (DCM → 




(ppm) 7.83 (d, J = 8.8 Hz, 4H), 7.27-7.26 (m, 2H), 7.18 (s, 1H), 6.92 (d, J = 8.8 Hz, 4H), 6.58 (d, J = 3.2 Hz, 2H), 4.30-
4.28 (m, 2H), 3.83 (s, 6H), 2.96-2.95 (m, 2H), 2.79-2.77 (m, 2H), 2.32 (t, J = 7.2 Hz, 2H), 1.90-1.83 (m, 6H), 1.62-1.58 
(m, 2H), 1.32-1.25 (m, 6H). 13C NMR (100 MHz, CDCl3): δ (ppm) 178.12, 160.29, 157.15, 144.67, 135.88, 130.71, 
126.73, 124.89, 119.73, 113.47, 55.00, 53.33, 33.77, 32.72, 30.02, 29.78, 29.05, 28.49, 28.30, 25.95, 24.71, 24.31. 
(3S,4R,5S,6R)-6-(benzyloxymethyl)-3,4,5-tribenzyloxy-cyclohex-1-ene (41) 
A solution of (3S,4S,5S,6R)-6-(hydroxymethyl)-3,4-dibenzyloxy-5-hydroxy-cyclohex-1-ene (27) (3.5 mmol, 1.2 g) in 
DMF under argon atmosphere was cooled to 0 °C before tetrabutylammonium iodide (35 µmol, 13 mg, 1 mol%), 
benzyl bromide (8.4 mmol, 1.0 mL, 2.4 eq.) and sodium hydride (8.4 mmol, 0.33 g (60% in mineral oil), 2.4 eq.) were 
added. The reaction mixture was stirred overnight at room temperature and subsequently quenched with MeOH. 
Next, H2O was added and the resulting mixture was extracted with EtOAc (3x). The combined organic layers were 
washed with H2O (1x) and Brine (1x), dried over MgSO4, filtered and concentrated in vacuo, yielding a mixture of 
products having 3 or 4 benzyl groups. These were separated by column chromatography (pentane → 5% EtOAc in 
pentane → 20% EtOAc in pentane) after which the tribenzylated products were again subjected to the benzylation 
reaction as before. After work-up and column chromatography purification (pentane → 5% EtOAc in pentane) the 
fully benzylated product 41 was obtained (total yield 1.5 g, 3.0 mmol, 85%). 1H NMR (400 MHz, CDCl3): δ (ppm) 
7.39-7.23 (m, 20H), 5.80-5.76 (m, 1H), 5.48 (d, J = 10.4 Hz, 1H), 4.93 (d, J = 11.6 Hz, 1H), 4.78-4.68 (m, 4H), 4.64 (d, J 
= 11.6 Hz, 1H), 4.50-4.43 (m, 3H), 4.20 (dd, J = 1.6, 1.6 Hz, 1H), 3.75 (dd, J = 1.6, 8.0 Hz, 1H), 3.62-3.46 (m, 2H), 2.72-
2.68 (m, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) 139.03, 138.77, 138.70, 138.15, 128.40, 128.32, 128.30, 128.17, 
127.87, 127.81, 127.79, 127.67, 127.49, 127.47, 127.44, 127.38, 126.66, 83.20, 77.66, 75.12, 74.03, 73.28, 72.37, 
72.16, 70.17, 41.92. LC/MS analysis: Rt 10.8 min (linear gradient 10 → 90% B in 15 min), m/z 521.1 [M+H]+, 543.3 
[M+Na]+. HRMS: calcd. for [C35H37O4]+ 521.26864, found 521.26864; calcd. for [C35H36O4Na]+ 543.25058, found 
543.24988. [α]D20 (c = 0.1, CHCl3): +105°. 
(2R,3S,4S,5R)-5-(benzyloxymethyl)-2,3,4-tribenzyloxy-7-oxabicyclo[4.1.0]heptane: β-epoxide (42) 
To a solution of 41 (0.70 mmol, 0.36 g) in DCM under argon atmosphere was added 3-chloroperoxybenzoic acid (1.7 
mmol, 0.30 g, 2.5 eq.). After stirring overnight, the reaction mixture was quenched with saturated aqueous Na2SO3 
and extracted with DCM (2x). The combined organic layers were washed with saturated aqueous NaHCO3 (1x), 
dried over MgSO4, filtered and concentrated in vacuo. The crude products were purified and separated by column 
chromatography (pentane → 10% EtOAc in pentane) to afford α-epoxide isomer of 42 (37 mg, 70 µmol, 10%) and β-
epoxide 42 (0.24 g, 0.43 mmol, 63%). 1H NMR (400 MHz, CDCl3) α-epoxide: δ (ppm) 7.41-7.22 (m, 20H), 4.90-4.79 
(m, 3H), 4.70 (dd, J = 11.8, 17.8 Hz, 2H), 4.53-4.45 (m, 3H), 4.25 (dd, J = 2.4, 8.4 Hz, 1H), 3.93-3.92 (m, 1H), 3.62 (dd, 
J = 8.6, 1.0 Hz, 1H), 3.58 (d, J = 8.0 Hz, 2H), 3.37 (dd, J = 2.4, 4.0 Hz, 1H), 2.96 (dd, J = 1.4, 4.0 Hz, 1H), 2.32-2.28 (m, 
1H). 13C NMR (100 MHz, CDCl3) α-epoxide: δ (ppm) 138.68, 138.60, 138.58, 137.89, 128.40, 128.31, 128.26, 128.21, 
128.10, 127.97, 127.88, 127.85, 127.75, 127.73, 127.67, 127.52, 127.45, 81.10, 76.73, 75.68, 74.23, 73.68, 73.35, 
73.04, 68.53, 55.20, 54.35, 40.89. 1H NMR (400 MHz, CDCl3) β-epoxide 42: δ (ppm) 7.38-7.20 (m, 20H), 4.86 (d, J = 
12.0 Hz, 1H), 4.81-4.66 (m, 4H), 4.56 (d, J = 12.0 Hz, 1H), 4.49-4.42 (m, 2H), 4.14 (d, J = 8.8 Hz, 1H), 3.94 (dd, J = 4.0, 
2.0 Hz, 1H), 3.73-3.62 (m, 2H), 3.45 (dd, J = 2.0, 8.8 Hz, 1H), 3.23 (d, J = 4.0 Hz, 1H), 3.16-3.15 (m, 1H), 2.32-2.30 (m, 
1H). 13C NMR (100 MHz, CDCl3) β-epoxide 42: δ (ppm) 138.80, 138.44, 137.96, 128.36, 128.33, 128.25, 128.05, 
127.81, 127.77, 127.71, 127.68, 127.63, 127.44, 127.42, 127.21, 82.47, 76.11, 74.27, 73.38, 73.15, 72.79, 72.62, 
68.79, 54.37, 52.38, 40.19. LC/MS analysis: α-epoxide: Rt 10.3 min (linear gradient 10 → 90% B in 15 min), m/z 
537.0 [M+H]+, 559.3 [M+Na]+; 42: Rt 10.3 min (linear gradient 10 → 90% B in 15 min), m/z 537.1 [M+H]+, 559.3 
[M+Na]+. HRMS: calcd. for [C35H37O5]+ 537.26355, found for α-epoxide 537.26385, for 42 537.26391; calcd. for 
[C35H36O5Na]+ 559.24550, found for α-epoxide 559.24515, for 42 559.24491. [α]D20 (c = 0.1, CHCl3): α-epoxide +30°, 
42 +66°. 





A solution of β-epoxide 42 (0.48 mmol, 0.26 g) in ACN under argon atmosphere was heated to 80 °C before addition 
of sodium azide (24 mmol, 1.6 g, 50 eq.) and lithium perchlorate (4.8 mmol, 0.51 g, 10 eq.). After stirring under 
reflux overnight, the reaction mixture was allowed to cool to room temperature, quenched with H2O and extracted 
with DCM (3x). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (pentane → 10% EtOAc in pentane) yielded a mixture of two azido alcohols 
43 in a ratio of 1:1.3 (0.20 g, 0.35 mmol, 73%). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.39-7.18 (m, 20H isomer 1 + 20H 
isomer 2), 5.02-4.67 (m, 5H isomer 1 + 5H isomer 2), 4.51-4.40 (m, 3H isomer 1 + 3H isomer 2), 4.30-4.26 (m, 2H 
isomer 1 + 1H isomer 2), 4.11-4.09 (m, 1H isomer 1), 3.91-3.87 (m, 1H isomer 1 + 1H isomer 2), 3.79-3.77 (m, 2H 
isomer 1 + 1H isomer 2), 3.69-3.41 (m, 2H isomer 1 + 5H isomer 2), 2.05-2.02 (m, 1H isomer 1), 1.68-1.62 (m, 1H 
isomer 2). 13C NMR (100 MHz, CDCl3): δ (ppm) 138.14, 138.04, 137.99, 137.85, 137.80, 128.59, 128.45, 128.43, 
128.41, 128.35, 128.23, 128.05, 127.94, 127.90, 127.81, 127.78, 127.75, 127.70, 127.66, 127.59, 127.51, 127.44, 
127.42, 83.58, 81.21, 80.68, 78.25, 76.93, 76.60, 75.86, 75.59, 75.02, 73.54, 73.43, 73.39, 73.32, 73.28, 72.50, 71.55, 
67.71, 64.75, 61.58, 42.31, 38.59. LC/MS analysis: Rt 10.4 min (linear gradient 10 → 90% B in 15 min), m/z 579.9 
[M+H]+; and Rt 10.6 min, m/z 580.0 [M+H]+. HRMS: calcd. for [C35H38N3O5]+ 580.28060, found 580.28078; calcd. for 
[C35H37N3O5Na]+ 602.26254, found 602.26211. [α]D20 (c = 0.1, CHCl3): -2°. 
(1S,2S,3S,4S,5R,6S)-5-(benzyloxymethyl)-2,3,4-tribenzyloxy-7-azabicyclo[4.1.0]heptane (44) 
A mixture of azido alcohols 43 (0.50 mmol, 0.29 g) was dissolved in ACN under argon atmosphere. After addition of 
triphenylphosphine (0.65 mmol, 0.17 g, 1.3 eq.), the reaction mixture was heated to 80 °C and stirred under reflux 
for 2 hrs. The mixture was then allowed to cool to room temperature and concentrated in vacuo. The crude product 
was purified by column chromatography (DCM → 0.8% MeOH in DCM) to give α-aziridine 44 (pure yield 70 mg, 0.13 
mmol, 26%; and an additional 77 mg product containing triphenylphosphine oxide). 1H NMR (400 MHz, CDCl3): δ 
(ppm) 7.47-7.22 (m, 20H), 4.89-4.79 (m, 3H), 4.70 (dd, J = 11.6, 22.8 Hz, 2H), 4.55-4.43 (m, 3H), 4.23 (dd, J = 4.0, 8.4 
Hz, 1H), 3.88-3.87 (m, 1H), 3.61-3.55 (m, 3H), 2.55-2.52 (m, 1H), 2.19-2.15 (m, 1H), 2.02 (d, J = 6.0 Hz, 1H). 13C NMR 
(100 MHz, CDCl3): δ (ppm) 139.09, 138.92, 138.84, 138.06, 132.03, 131.93, 128.47, 128.35, 128.32, 128.25, 128.20, 
128.13, 128.11, 127.85, 127.79, 127.72, 127.65, 127.60, 127.36, 127.31, 127.27, 81.88, 76.87, 76.25, 73.99, 73.10, 
72.91, 72.35, 69.81, 41.89, 34.15, 32.08. LC/MS analysis: Rt 7.7 min (linear gradient 10 → 90% B in 15 min), m/z 
536.1 [M+H]+, 1071.2 [2M+H]+. HRMS: calcd. for [C35H38NO4]+ 536.27954, found 536.27943. [α]D20 (c = 0.1, MeOH): 
+56°. 
(1S,2S,3S,4S,5R,6S)-5-(hydroxymethyl)-2,3,4-trihydroxy-7-azabicyclo[4.1.0]heptane (45) 
Ammonia was condensed at -60 °C (~5 mL) under argon flow using Birch equipment. Lithium (50 mg) was added 
and the solution was stirred for 30 min at -60 °C, before a solution of α-aziridine 44 (0.10 mmol, 36 mg) in THF (5 
mL) was added. The reaction mixture was stirred at -60 °C under argon for 45 min, quenched with MilliQ (2 mL) and 
allowed to warm to room temperature. After all ammonia had evaporated, the mixture was further concentrated in 
vacuo and redissolved in MilliQ. Neutralization with Amberlite-H+ resulted in resin-bound product, which was 
filtered, washed with MilliQ and then eluted using a 1M aqueous NH4OH solution (10x 1 mL). After evaporation in 
vacuo the product was redissolved in MilliQ and Amberlite-NH4+ was added. Product was eluted from the resin by 
filtration and washing with MilliQ until the pH of the eluted solution was neutral (pH 7). The combined eluates were 
concentrated in vacuo to yield the crude deprotected α-aziridine 45, which was used without further purification. 
1H NMR (400 MHz, D2O): δ (ppm) 4.01 (dd, J = 4.2, 9.0 Hz, 1H), 3.78 (s, 1H), 3.68-3.64 (m, 2H), 3.28 (d, J = 8.8 Hz, 





8-Azidooctanoic acid 3725 (0.40 mmol, 78 mg) was preactivated with EEDQ (0.40 mmol, 99 mg, 1.0 eq.) in DMF (0.4 
mL) under argon for 2 hours at room temperature. Deprotected aziridine 45 (65 µmol) was dissolved in DMF (1 mL) 
under argon and cooled to 0 °C, after which 33 µL of the activated ester solution was added (33 µmol, 0.5 eq.) and 
the mixture was stirred at 0 °C for 30 min. Then another 0.5 eq. of the activated ester was added and the reaction 
mixture was stirred at 0 °C for another 60 min. After quenching with MeOH, the mixture was concentrated in 
vacuo, purified by HPLC under neutral conditions using a gradient of 22 → 28% ACN in H2O in 12 min, and 
lyophilized to yield aziridine 15 as a white powder (3.0 mg, 9.0 µmol, 14%). 1H NMR (600 MHz, MeOD): δ (ppm) 4.08 
(dd, J = 4.2, 9.0 Hz, 1H), 3.87-3.86 (m, 1H), 3.82-3.75 (m, 2H), 3.37 (dd, J = 1.8, 8.4 Hz, 1H), 3.30-3.27 (m, 2H), 2.97 
(dd, J = 4.2, 6.0 Hz, 1H), 2.61 (d, J = 6.0 Hz, 1H), 2.56-2.44 (m, 2H), 2.02 (td, J = 7.8, 7.2, 3.6 Hz, 1H), 1.66-1.57 (m, 
4H), 1.39-1.34 (m, 6H). 13C NMR (150 MHz, MeOD): δ (ppm) 188.72, 74.36, 73.13, 69.15, 62.84, 52.44, 44.54, 43.27, 
39.44, 37.12, 30.17, 29.94, 27.68, 27.66, 25.90. LC/MS analysis (ammonium acetate): Rt 7.5 min (linear gradient 0 → 
50% B in 15 min), m/z 343.4 [M+H]+, 360.5 [M+NH4]+. HRMS: calcd. for [C15H27N4O5]+ 343.19760, found 343.19757; 
calcd. for [C15H27N4O5Na]+ 365.17954, found 365.17939. 
(1S,2S,3S,4S,5R,6S)-5-(hydroxymethyl)-2,3,4-trihydroxy-N-(8-(Bodipy-triazole)-octanoyl)-7-
azabicyclo[4.1.0]heptane (16) 
Bodipy acid 38 (0.10 mmol, 67 mg) was preactivated with EEDQ (0.10 mmol, 25 mg, 1.0 eq.) in DMF (1 mL) under 
argon for 2 hours at room temperature. Deprotected aziridine 45 (60 µmol) was dissolved in DMF (0.5 mL) under 
argon and cooled to 0 °C, after which 0.3 mL of the activated ester solution was added (30 µmol, 0.5 eq.) and the 
mixture was stirred at 0 °C for 30 min. Then another 0.5 eq. of the activated ester was added and the reaction 
mixture was stirred at 0 °C for another 60 min. After quenching with MeOH, the mixture was concentrated in 
vacuo, purified by HPLC under neutral conditions using a gradient of 48 → 51% ACN in H2O in 12 min, and 
lyophilized to yield aziridine 16 as a purple powder (7.4 mg, 9.0 µmol, 15%). 1H NMR (400 MHz, MeOD): δ (ppm) 
7.87 (d, J = 8.8 Hz, 4H), 7.72 (s, 1H), 7.46 (d, J = 4.3 Hz, 2H), 7.00 (d, J = 9.2 Hz, 4H), 6.72 (d, J = 4.3 Hz, 2H), 4.36 (t, J = 
7.0 Hz, 2H), 4.10 (dd, J = 8.6, 4.0 Hz, 1H), 3.88 (s, 6H), 3.87-3.80 (m, 1H), 3.79 (dd, J = 7.4, 4.3 Hz, 2H), 3.38 (dd, J = 
8.6, 1.8 Hz, 1H), 3.12-3.06 (m, 2H), 2.96 (dd, J = 6.0, 4.0 Hz, 1H), 2.82-2.78 (m, 2H), 2.62-2.58 (m, 1H), 2.55-2.35 (m, 
2H), 2.03 (td, J = 7.8, 7.3, 3.6 Hz, 1H), 1.94-1.82 (m, 6H), 1.63-1.52 (m, 2H), 1.32-1.21 (m, 6H). LC/MS analysis: Rt 7.4 
min (linear gradient 10 → 90% B in 15 min), m/z 827.07 [M+H]+, 807.47 [M-F]+, 1653.40 [2M+H]+. Of note, under 
these acidic LC/MS conditions the aziridine is partially opened to give a second peak at Rt 7.2 min (linear gradient 10 
→ 90% B in 15 min), m/z 845.07 [(M+H2O)+H]+, 825.40 [(M+H2O)-F]+, 1689.13 [2(M+H2O)+H]+. HRMS: calcd. for 
[C44H54BF2N6O7]+ 827.41096, found 827.41180. 
(1R,2S,3S,4S,5R,6R)-5-(hydroxymethyl)-2,3-dibenzyloxy-4-hydroxy-7-azabicyclo[4.1.0]heptane (39) 
Cyclohexene 27 (0.50 mmol, 0.17 g) was coevaporated with toluene before being dissolved in DCM (10 mL) at 0 °C 
under argon atmosphere. Next, CCl3CCN (0.50 mmol, 51 µL, 1.0 eq.) and DBU (25 µmol, 2.0 µL, 0.05 eq.) were 
added and the reaction mixture was stirred at 0 °C for 1.5 hrs. The mixture was removed from the ice bath before 
H2O (1.5 mL), NaHCO3 (5.0 mmol, 0.40 g, 10 eq.) and I2 (1.5 mmol, 0.38 g, 3.0 eq.) were added. After stirring at room 
temperature overnight, the reaction was quenched with 10% aqueous Na2S2O3 and the aqueous layer was extracted 
with EtOAc (2x). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. The residue 
was redissolved in MeOH, cooled to 0 °C and concentrated HCl (6.3 mmol, 0.6 mL, 13 eq.) was added after which 
the reaction mixture was stirred at room temperature for 3.5 hrs. Next, the mixture was concentrated in vacuo, the 
residue was redissolved in dioxane and again concentrated HCl (16 mmol, 1.5 mL, 32 eq.) was added. The mixture 
was stirred at 60 °C for 1 hr, concentrated in vacuo and coevaporated with toluene (3x). The residue was 
redissolved in MeOH, NaHCO3 (10 mmol, 0.8 g, 20 eq.) was added and the reaction mixture was stirred at room 
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temperature for 4 days. After addition of H2O the aqueous layer was extracted with EtOAc and the organic layer 
was dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by column 
chromatography (DCM →  6% MeOH in DCM) to afford dibenzylated β-aziridine 39 (92 mg, 0.26 mmol, 52%). 1H 
NMR (400 MHz, CDCl3): δ (ppm) 7.46-7.22 (m, 10H), 4.83-4.61 (m, 4H), 4.13-4.04 (m, 2H), 3.99 (dd, J = 10.9, 7.5 Hz, 
1H), 3.90 (dd, J = 10.9, 6.2 Hz, 1H), 3.39 (dd, J = 7.9, 2.3 Hz, 1H), 2.50-2.32 (m, 2H), 2.06-1.96 (m, 1H). 13C NMR (100 
MHz, CDCl3): δ (ppm) 138.31, 138.17, 128.62, 128.58, 128.54, 128.49, 128.46, 128.43, 128.35, 128.29, 128.17, 
128.15, 128.02, 127.96, 127.93, 127.90, 127.87, 127.85, 127.80, 127.78, 127.63, 83.29, 78.57, 73.10, 71.69, 67.42, 
62.40, 39.47, 32.63, 32.53. LC/MS analysis: Rt 5.4 min (linear gradient 10 → 90% B in 15 min), m/z 356.1 [M+H]+, 
711.1 [2M+H]+. 
(1R,2S,3S,4S,5R,6R)-5-(hydroxymethyl)-2,3,4-trihydroxy-7-azabicyclo[4.1.0]heptane (40) 
The β-aziridine 39 (0.10 mmol, 36 mg) was deprotected using the same procedure as described for α-aziridine 45 to 
give β-aziridine 40. 1H NMR (400 MHz, D2O): δ (ppm) 4.10 (d, J = 8.0 Hz, 1H), 3.87-3.78 (m, 3H), 3.43 (d, J = 8.0 Hz, 
1H), 2.44 (bs, 1H), 2.34-2.33 (m, 1H), 2.04 (bs, 1H). 
(1R,2S,3S,4S,5R,6R)-5-(hydroxymethyl)-2,3,4-trihydroxy-N-(8-azidooctanoyl)-7-azabicyclo[4.1.0]heptane (21) 
Deprotected β-aziridine 40 (0.10 mmol) was acylated with azido-spacer 3725 using the same procedure as described 
for α-aziridine 15 to give β-aziridine 21. After HPLC purification and lyophilization, however, NMR analysis revealed 
that no aziridine proton peaks were present, indicating that the product had degraded by opening of the aziridine. 
DFT calculations 
The calculated 1H NMR coupling constants were obtained by first finding the lowest energy conformation of both 
epoxide isomers, for which a library of gas phase conformations was generated using the conformer distribution 
option included in the Spartan 0426 program employing DFT/B3LYP 6-31G(d). All conformers were further optimized 
by Gaussion 0327 at DFT/B3LYP 6-311G(d,p), their zero-point energies were calculated and the energies corrected 
for solvent by another optimization step employing a Polarizable Continuum Model set for water. The energies of 
these conformers, corrected for their zero-point energies, were compared and of the lowest energy conformer an 
NMR calculation was performed using the Gauge-Independent Atomic Orbital (GIAO) method with added spin-spin 
coupling calculation.  
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6 
A potent and selective activity-based probe 
for human retaining α-galactosidases 
 
6.1 Introduction 
Lysosomal degradation of glycosphingolipids is mediated by the consecutive action of 
several glycosidases, each displaying a unique substrate specificity. A deficiency in one of the 
lysosomal glycosidases can cause accumulation of the corresponding substrates in 
lysosomes and consequently lead to a lysosomal storage disorder. Although the primary 
defects underlying such disorders are similar, they generally show a completely different 
disease progress, phenotype and clinical manifestation.1 An attractive approach to study 
glycosidases and their involvement in disease is the use of activity-based probes (ABPs) that 
allow the visualization of active enzymes in their natural environment.2,3 This method is 
especially useful for the class of retaining glycosidases, since these form a covalent enzyme-
substrate intermediate during hydrolysis and are thus amenable to targeting by ABPs that 
react covalently with the catalytic nucleophile in the active site.  
The human enzyme α-galactosidase A (αGal A) is a retaining glycosidase that resides in 
lysosomes and cleaves terminal α-linked galactosyl moieties from polysaccharides, 
glycolipids and glycoproteins.4 It is one of only two human enzymes within the family of 
retaining α-galactosidases. The related lysosomal enzyme α-N-acetylgalactosaminidase, also 




acetylgalactosamine (NAGA) moiety.5 The two proteins share 46% amino acid sequence 
identity and their active site differs only in two amino acid residues, which are responsible 
for the interaction with the substrate’s C2-substituent.6,7 Consequently, αGal B can 
accommodate the larger C2 substituent in NAGA as compared to α-galactose while it also 
tolerates a C2-hydroxyl substituent and is thus capable of hydrolyzing α-galactosides, though 
with lower efficiency than NAGA substrates. By replacing the two unique active site residues 
in either αGal A or αGalB with the corresponding residues from the other enzyme, the 
specificities of the two enzymes can be interchanged.7 The hydrolysis of α-galactosides by 
both enzymes occurs through a double displacement mechanism resulting in cleavage of the 
glycosidic bond and the release of free galactose with overall retention of the α-anomeric 
configuration (Figure 6.1A). Two carboxylic acid residues are required in the active site to 
function as a nucleophile and a general acid/base. In human αGal A, these residues have 
been identified as the aspartic acid residues D170 and D231, respectively.6 Furthermore it 
was found that the enzyme forms a homodimer with each monomer containing at least 
three distinct N-linked glycosylation sites that are essential for the lysosomal transport of 
αGal A mediated by the mannose-6-phosphate receptor.6 
A deficiency in αGal A is at the basis of the lysosomal storage disorder Fabry disease, an 
X-linked recessive disorder characterized by the lysosomal accumulation of 
glycosphingolipids with terminal α-galactosyl moieties.4,8 More than 400 mutations in the 
gene encoding αGal A (GLA) are known that lead to malfunctioning or absence of the 
enzyme. Symptoms of the classic manifestation of Fabry disease include skin lesions, chronic 
pain, corneal opacity, intolerance to heat, inability to sweat and micro-albuminuria. 
Moreover, non-specific complications can develop later in life including progressive kidney 
disease, cardiac symptoms and cerebrovascular disease. The primary storage lipid 
globotriaosylceramide is further metabolized to globotriaosylsphingosine, which is highly  
 
 
Figure 6.1. A) Mechanism of substrate hydrolysis by αGal A. B) Proposed mechanism by which ABPs 1 and 2 bind to 
αGal A. 
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elevated in plasma of Fabry patients and believed to be responsible for many of the 
symptoms.9,10 However, there appears to be no clear correlation between the GLA mutation, 
residual αGal A activity, the amount of lipid storage and the nature or onset of clinical 
symptoms.10 Diagnosis of Fabry disease is presently confirmed by demonstrating reduced 
αGal A activity using fluorogenic substrate assays. Additionally, elevated plasma levels of 
globotriaosylsphingosine can be used to confirm diagnosis of classic Fabry disease.10,11 In 
atypical patients that usually display uncharacteristic symptoms in combination with 
relatively high residual αGal A activity, diagnosis is generally less straightforward than in 
classic patients. The currently applied treatment for Fabry disease is enzyme replacement 
therapy, in which patients receive recombinant human αGal A to restore enzyme function. 
Two recombinant protein products are currently available, Replagal produced by Shire and 
Fabrazyme produced by Genzyme.12,13 These enzymes have an identical amino acid 
sequence but a different glycosylation pattern as a result of the different cell lines they are 
produced in, which causes a different tissue distribution and dose response.14 Unfortunately, 
the effectiveness of enzyme replacement therapy for the treatment of Fabry disease 
appears to be limited.10  
The development of specific ABPs that enable monitoring of endogenous levels of 
catalytically active retaining α-galactosidases will provide useful new research tools for the 
investigation of αGal A. The α-galactopyranose-configured probes synthesized as described 
in Chapter 5 might serve this purpose (1-5; Figure 6.2). These probes were designed to bind 
in the active site of retaining α-galactosidases by mimicking a galactopyranoside substrate 
  
 
Figure 6.2. Structures of novel retaining α-galactosidase ABPs 1-5 and inhibitor 6, known reversible inhibitors of 




and contain an α-configured electrophilic aziridine or epoxide moiety to allow attack by the 
catalytic nucleophile (Figure 6.1B). The ABPs are functionalized with a Bodipy fluorophore (2, 
4), a biotin tag (5) or an azide (1, 3) as a ligation handle for two-step labeling. The azide-
tagged ABPs may also be used as control probes and serve as α-galactosidase inhibitors. In 
addition, the non-tagged epoxide-based inhibitor 6 was synthesized as a galactopyranose-
configured isomer of the known retaining β-glucosidase inhibitor cyclophellitol.15-17 This 
chapter describes the biological evaluation of compounds 1-6 as retaining galactosidase 
inhibitors and the use of fluorescently labeled ABP 2 for the imaging of recombinant αGal A 
as well as endogenous activity of human retaining α-galactosidases in cell extracts. 
6.2 Results and discussion 
The inhibitory potential of compounds 1-6 on recombinant αGal A (Fabrazyme) was first 
assessed by measuring residual enzyme activity using the fluorogenic substrate 4-
methylumbelliferyl α-D-galactoside (4-mu α-gal) after 30 min of preincubation with varying 
concentrations of the probes. The residual activity was plotted against the inhibitor 
concentration (Figure 6.3A) and these curves were used to calculate apparent IC50 values 
(Table 6.1). Aziridines 1 and 2 proved to be very potent inhibitors of αGal A with apparent 
IC50 values of 3.2 and 2.0 nM, respectively. Epoxide 6 inhibited the enzyme with 10,000-fold 
lower potency, and only reached full inhibition after a prolonged incubation time. 
Modification of the hydroxyl group at C6 by substitution with an azide (3) or 
functionalization with a tag (4, 5) proved to be detrimental for inhibitory potency since no  
 
 
Figure 6.3. Inhibition of recombinant αGal A activity by 1, 2 and 6. A) Fabrazyme was treated for 30 min with the 
inhibitors after which residual activity was determined from hydrolysis of 4-mu α-gal. B) Effect of 30 min 
preincubation (+) (dotted lines) as compared to simultaneous addition of 4-mu α-gal and probes (-) (solid lines) on 
inhibition. The displayed inhibitor concentrations in both cases represent those without addition of the fluorogenic 
substrate solution. 
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Table 6.1. Inhibition of recombinant αGal A activity 
Compound Apparent IC50  
(30 min preincubation) 
% inhibition  Apparent IC50 
30 min 6 hrs without preincubation 
Aziridine 1 3.2 nM 100 (10 µM) 100 (10 µM) 44 nM 
Bodipy-aziridine 2 2.0 nM 100 (10 µM) 100 (10 µM) 24 nM 
Epoxide 6 30 µM 85 (100 µM) 100 (100 µM) >100 µM 
Azido-epoxide 3 n.i. 0 (100 µM) n.d. n.d. 
Bodipy-epoxide 4 n.i. 0 (100 µM) n.d n.d 
Biotin-epoxide 5 n.i. 0 (100 µM) n.d n.d 
Inhibition of Fabrazyme as determined from hydrolysis of 4-mu α-gal after preincubation for 30 min or 6 hrs with 
the indicated concentrations of 1-6. Apparent IC50 values were calculated from plots of residual αGal A activity as a 
function of probe concentration with a preincubation time of 30 min (Figure 6.3A) or without preincubation (Figure 
6.3B). n.i.: no inhibition observed up to 100 µM. n.d.: not determined. 
inhibition was observed under these conditions using up to 100 µM of the probes. These 
findings are in contrast to previously reported data on the inhibition of retaining β-
glucosidases using analogous C6-modified epoxide probes.2 In order to confirm the non-
reversible mode of binding by probes 1, 2 and 6, inhibition of αGal A activity after 
preincubation with the probes was compared to that obtained by simultaneous addition of 
the fluorogenic substrate and the ABPs (Figure 6.3B). The evident shifts in the plots of 
residual activity against probe concentration and the associated 10-fold lower IC50 values 
after preincubation as compared to simultaneous addition of inhibitors and fluorogenic 
substrate (Table 6.1) indicate that the binding of the probes is indeed irreversible.  
In a next experiment the selectivity of compounds 1-6 was evaluated by measuring 
inhibition of recombinant galactocerebrosidase, a closely related retaining galactosidase 
that hydrolyzes β-linked instead of α-linked galactosyl moieties. Residual enzyme activity 
was measured using the fluorogenic substrate 4-methyl-umbelliferyl β-D-galactoside (4-mu 
β-gal) after 30 min of preincubation with the probes. The aziridines 1 and 2 were able to 
inhibit this enzyme but with 7,000-30,000 fold lower potency than αGal A (Figure 6.4A and 
Table 6.2). Interestingly, no evidence of irreversible binding could be obtained (Figure 6.4B). 
On the other hand, it was found that the non-tagged epoxide 6 inhibits galactocerebrosidase 
irreversibly and with similar potency to αGal A. The functionalized epoxides 3 and 4, which 
do not inhibit αGal A activity, appeared to be weak inhibitors of galactocerebrosidase. 
Together these data demonstrate that the aziridines 1 and 2 should enable selective 







Figure 6.4. Inhibition of recombinant galactocerebrosidase activity by 1, 2, 4 and 6. A) Recombinant galacto-
cerebrosidase (βGal) was treated for 30 min with the inhibitors after which residual activity was determined from 
hydrolysis of 4-mu β-gal. B) Effect of 30 min preincubation (+) as compared to simultaneous addition of 4-mu β-gal 
and probes (-) on inhibition. The displayed inhibitor concentrations in both cases represent those without addition 
of the fluorogenic substrate solution. 
Having established the inhibitory potential of the probes, aziridine ABPs 1 and 2 were 
next used to visualize recombinant αGal A on gel. Labeling of Fabrazyme with Bodipy-tagged 
ABP 2 for 1 hr resulted in fluorescent labeling of the enzyme in a concentration-dependent 
manner (Figure 6.5A). The smaller lower-running band most likely represents a non-
glycosylated form of αGal A. The reaction appears to occur in a 1:1 ratio, since saturation is 
reached at 10 to 30 nM of probe when 20 nM of αGal A is used. Denaturation of the enzyme 
prior to labeling led to complete disappearance of the signal on gel, confirming that 
catalytically active enzyme is required for binding of the probe. Pretreatment of Fabrazyme 
with azide-tagged aziridine 1 resulted in concentration-dependent disappearance of the 
fluorescent labeling by ABP 2 (Figure 6.5B). In addition, it was shown that the enzyme can be   
 
Table 6.2. Inhibition of recombinant galactocerebrosidase activity 
Compound Apparent IC50 (µM) % inhibition  
30 min 6 hrs 
Aziridine 1 106 42 (100 µM) 56 (100 µM) 
Bodipy-aziridine 2 14 63 (100 µM) 61 (100 µM) 
Epoxide 6 5 97 (100 µM) 98 (100 µM) 
Azido-epoxide 3 n.d. 20 (100 µM) n.d. 
Bodipy-epoxide 4 40 56 (100 µM) 91 (100 µM) 
Biotin-epoxide 5 n.i. 0 (100 µM) n.d 
Inhibition of recombinant galactocerebrosidase as determined from hydrolysis of 4-mu β-gal after preincubation for 
30 min or 6 hrs with probes 1-6. Apparent IC50 values were calculated from plots of residual galactocerebrosidase 
activity as a function of probe concentration with a preincubation time of 30 min (Figure 6.4A). n.i.: no inhibition 
observed up to 100 µM. n.d.: not determined. 




Figure 6.5. Labeling and inhibition of recombinant αGal A. A) Labeling of Fabrazyme (10 ng) with 1 nM - 1 µM of 
Bodipy-aziridine 2 for 1 hr; where indicated the enzyme was denatured prior to labeling. B) Fabrazyme (50 ng) 
labeled with 100 nM 2 after preincubation with 1 nM - 1 µM of aziridine 1 for 1 hr. C) Two-step labeling of 
Fabrazyme using 1 µM aziridine 1 followed by copper(I)-catalyzed click reaction with 0.5 - 50 µM of Bodipy-alkyne 
10 or biotin-alkyne 11; control samples were treated with 0.3 µM 2 instead of click reagents. D) Fabrazyme or 
Replagal labeled with 100 nM 2 after preincubation with inhibitors 7 (10 µM), 8 (100 mM), 6 (100 µM) or probe 1 
(100 nM) for 1 hr. All gels are 10% SDS-PAGE with fluorescent readout or visualization by streptavidin Western 
blotting (C, lower panel). 
visualized after targeting by ABP 1 by performing a copper(I)-catalyzed click reaction with 
Bodipy- and biotin-functionalized alkyne reagents 1018 and 1119 (Figure 6.5C). Replagal, the 
second recombinant enzyme that can be used for enzyme replacement therapy in Fabry 
disease, was also labeled effectively with probe 2 (Figure 6.5D). Labeling of either of the two 
enzymes was completely abolished by preincubation with aziridine probe 1 or epoxide 
inhibitor 6. The labeling was also blocked by the competitive α-galactosidase inhibitor 
deoxygalactonojirimicin (7) but not by the selective αGal B inhibitor N-acetylgalactosamine 
(8) (see Figure 6.2).  
The optimal pH for αGal A activity is around pH 4.6, consistent with the acidic pH of the 
lysosomal environment. By treating recombinant αGal A with ABP 2 in buffers of varying pH, 
it was revealed that the labeling is indeed pH-dependent with an optimum around pH 5 
(Figure 6.6A). However, at high pH values (6 or 7) there was a discrepancy between the 
enzymatic activity as determined by fluorogenic substrate hydrolysis and the intensity of 
fluorescent labeling on gel (Figure 6.6C). This phenomenon is in agreement with previous 
findings on the labeling of retaining β-glucosidases by the corresponding aziridine probe 920 
(Figure 6.2) and may be explained by the fact that the aziridine moiety forms a better 
leaving group than the aglycon of the (fluorogenic) substrate and therefore allows for a 






Figure 6.6. Dependence of probe binding on catalytic activity. A) Fabrazyme labeled with 50 nM 2 for 1 hr in buffers 
of varying pH. B) Labeling of recombinant wild-type αGal A (WT) and D170G or D231G mutants in lysates of 
transfected Cos-7 cells with 100 nM 2; ‘mock’: mock-transfected cells; ‘control’: non-transfected cells. C) 
Quantification of gel bands in A (circles) as compared to Fabrazyme activity on 4-mu α-gal (triangles) at different pH 
values. Gels are 10% SDS-PAGE with fluorescent readout (A,B) followed by anti-αGal A Western blotting (B). 
mechanism-based inhibition of αGal A by ABP 2,mutants of αGal A lacking either the active 
site nucleophile (D170) or the general ac-id/base residue (D231) were generated. Reaction 
of the resulting recombinant enzymes with aziridine 2 demonstrated that absence of either 
of the aspartic acid residues leads to complete disappearance of the fluorescent signal on 
gel (Figure 6.6B). Hence, both residues are essential for labeling of the enzyme by the ABP 
which underscores the proposed binding mechanism as shown in Figure 6.1B.  
Next, attention was focused on the labeling of endogenous α-galactosidases in cell 
extracts. Treatment of wild-type (WT) fibroblast extracts with Bodipy-aziridine 2 gave two 
fluorescently labeled proteins on gel (Figure 6.7A). In contrast, only one fluorescent signal, 
corresponding to the upper band in the WT fibroblasts, was visible in fibroblast extracts 
from αGal A deficient Fabry patients. This indicates that the lower signal, which is 
completely absent in Fabry cells, is αGal A. The identity of this protein can be further 
confirmed by the fact that the labeling in WT extracts was blocked by 
deoxygalactonojirimicin (7) but not by N-acetylgalactosamine (8). Likewise, competition of 
the upper signal by both inhibitors revealed that this protein is αGal B. The non-fluorescent 
aziridine ABP 1 was also able to bind both enzymes. Interestingly, epoxide inhibitor 6 
selectively blocked labeling of αGal A without affecting αGal B. With the aim to determine 
whether Bodipy-aziridine 2 is more selective for αGal A or αGal B, the probe concentration 
and reaction time used for labeling in WT fibroblast lysates were reduced (Figure 6.7B). 
Although it proved impossible to obtain selective labeling of only one of the two enzymes, 
quantification of the fluorescent bands in Figure 6.7B revealed that the ratio of αGal A/αGal 
B labeling is higher after 2 min of labeling (1/0.9) than after 1 hr (1/2.1) which indicates that 
ABP 2 preferentially targets αGal A (Figure 6.7C). 
  




Figure 6.7. Labeling of endogenous α-galactosidases in cell extracts. A) Wild-type (WT) or Fabry (F) fibroblast 
extracts were treated with 100 nM 2 for 1 hr; where indicated extracts were preincubated for 1 hr with inhibitors 7 
(10 µM), 8 (100 mM), 6 (100 µM) or probe 1 (1 µM). B) Labeling of WT fibroblast extracts with 10 or 100 nM 2 for 2 
- 60 min. C) Ratio of αGal A/αGal B labeling as determined from quantification of gel bands in B. Gels are 10% SDS-
PAGE with fluorescent readout followed by coomassie brilliant blue staining. ‘M’: protein marker. 
In a final experiment the simultaneous labeling of retaining α-galactosidases and 
retaining β-glucosidases was examined by using α-galactosidase ABP 2 together with β-
glucosidase ABP 920, which is equipped with a different Bodipy fluorophore than 2 and can 
therefore be visualized using different scanner settings for in-gel fluorescent readout. 
Labeling of recombinant glucocerebrosidase (GBA1), a lysosomal retaining β-glucosidase, 
and αGal A with the two probes at the same time gave selective labeling of the anticipated 
enzymes without any observed cross-reactivity (Figure 6.8). Similarly, simultaneous 
treatment of fibroblast extracts with both ABPs enabled the selective labeling of 





Figure 6.8. Simultaneous labeling of retaining α-galactosidases and β-glucosidases. Recombinant αGal A, 
recombinant GBA1 or WT fibroblast extracts were labeled with 100 nM 2 and 100 nM 9 and resolved by 10% SDS-
PAGE with fluorescent readout in Cy3 (2) and Cy2 (9) channels followed by coomassie brilliant blue staining. ‘M’: 
protein marker.  
6.3 Conclusion 
A very potent aziridine-based fluorescent activity-based probe was identified (2) that 
enables profiling of endogenous αGal A and αGal B activity in cell extracts. The two enzymes 
can be separated on gel and are easily distinguished by competition with known inhibitors, 
which makes aziridine 2 a valuable probe to study the activity of human retaining α-
galactosidases in vitro. Epoxide 6 is an irreversible inhibitor of αGal A that also inhibits 
galactocerebrosidase but not αGal B. Bodipy-aziridine 2 can be used in combination with the 
previously reported retaining β-glucosidase ABP 9 to study both enzyme classes 
simultaneously. A noteworthy difference between the two ABPs is the labeling of mutant 
enzymes lacking the active site nucleophile or general acid/base residue. While it was 
demonstrated that GBA1 labeling by aziridine 9 occurs in the absence of the acid/base 
residue,20 aziridine 2 does not label either of the αGal A mutants and may thus be 
considered to be a ‘true’ activity-based probe that can report accurately on active enzyme 
levels. Bodipy-aziridine 2 may provide a useful new tool for studying human retaining α-
galactosidases and their role in the development of Fabry disease, for evaluating the various 
phenotypic variants of the disease, and for diagnostic purposes and the assessment of the 
effects of therapeutic intervention. In addition, labeling of αGal B activity may turn out to be 
useful to study a related lysosomal storage disorder that is caused by αGal B deficiency, 
Schindler disease.21 
 





Fibroblasts were obtained with consent from control donors and Fabry patients. Cell lines were cultured in 
DMEM/F-12 medium (Invitrogen) supplied with 10% (v/v) FBS in an incubator at 5% CO2 and 37 °C. Recombinant α-
galactosidase A was obtained from Genzyme (Fabrazyme) and Shire (Replagal), recombinant β-glucocerebrosidase 
(GBA1) was obtained from Genzyme (Cerezyme). For all in vitro assays, a 100 ng/µL stock solution of Fabrazyme or 
Replagal was prepared in McIlvaine pH 4.6/H2O 1/1 (v/v), to which 100 ng/µL (0.1%) BSA was added for stabilization 
of the recombinant proteins. Cell lysates were prepared from cell pellets by resuspension in 50 mM potassium 
phosphate buffer (pH 6.0, 0.1% (v/v) Triton X-100) and sonication on ice for 3x 1 s with 1 min interval, after which 
the protein concentration was determined by BCA assay. SDS-PAGE analysis: in-gel fluorescence was measured on a 
Bio-Rad ChemiDoc MP scanner using Cy3 settings (Green Epi illumination, 605/50 Filter) or Cy2 settings (Blue Epi 
illumination, 530/28 Filter). As a loading control gels were stained with Coomassie Brilliant Blue. For Western 
blotting, the proteins were transferred onto a PVDF membrane (Bio-Rad Trans-Blot Turbo Transfer Pack) using a 
Bio-Rad Trans-Blot Turbo Transfer System. Membranes were blocked with 1% BSA in TBS-t(+) (0.1% Tween 20) for 1 
hr at room temperature, hybridized with antibodies, washed with TBS-t(+) and TBS and then visualized using an 
ECL+ Western blotting detection kit (Amersham Biosciences). For detection of biotinylated proteins, membranes 
were hybridized with Streptavidin-HRP for 1 hr at room temperature (1:10,000 in blocking buffer) (Molecular 
Probes, Life Technologies). For detection of αGal A, membranes were hybridized with rabbit anti-GLA antibody at 4 
°C overnight (1:500 in blocking buffer) followed by goat anti-rabbit-HRP antibody for 1 hr at room temperature 
(1:10,000 in blocking buffer) (Santa Cruz Biotechnology). The protein standard is a PageRuler Plus Prestained 
Protein Ladder (Thermo Scientific). 
Fluorogenic substrate assay on recombinant αGal A 
Fabrazyme (1 ng, 20 fmol per experiment) was diluted in McIlvaine buffer pH 4.6/H2O 1/1 (v/v) containing 0.1% BSA 
(10 µL) and exposed to the indicated concentrations of compounds 1-6 (10 μL 2x solution in H2O) for 30 min at 37 
°C, before addition of 100 µL substrate mix (1.5 mg/mL 4-methylumbelliferyl-α-D-galactopyranoside in McIlvaine 
pH 4.6/H2O 1/1 (v/v) + 0.1% BSA). After incubation at 37 °C for 20 min, the reaction was quenched with 2.5 mL 0.3 
M glycine, pH 10.6 and fluorescence was measured with a fluorimeter LS55 (Perkin Elmer) using λex 366 nm and λem 
445 nm. For tests of irreversibility, the substrate mix was added simultaneously with the inhibitors to the enzyme 
(without any preincubation) and incubated for 20 min. All samples were corrected for background fluorescence 
(sample without enzyme) and residual enzyme activity was calculated as compared to a control sample incubated 
without inhibitors. Displayed values represent mean values from duplicate experiments and error bars indicate 
standard deviation (SD). Graphpad Prism 5 software was used to determine apparent IC50 values. 
pH-dependent activity assay. Fabrazyme (1 ng, 20 fmol per experiment) in McIlvaine buffer pH 4.6/H2O 1/1 (v/v) 
containing 0.1% BSA (10 µL) was mixed with 100 µL substrate mix of various pH values (1.5 mg/mL 4-
methylumbelliferyl-α-D-galactopyranoside in McIlvaine pH 3 - pH 8/H2O 1/1 (v/v) + 0.1% BSA). After incubation at 
37 °C for 20 min, the reaction was quenched and fluorescence measured as described above. Displayed values 
represent mean values from 5 experiments and error bars indicate standard deviation (SD). 
Fluorogenic substrate assay on recombinant galactocerebrosidase 
Recombinant galactocerebrosidase was expressed in Cos-7 cells by transfection with cDNA encoding human 
galactocerebrosidase (gift from professor T. M. Cox, Cambridge). The culture medium containing the secreted 




McIlvaine buffer pH 4.3 (10 µL total volume) and exposed to the indicated concentrations of compounds 1-6 (10 μL 
2x solution in H2O) for 30 min at 37 °C, before addition of 100 µL substrate mix (0.23 mg/mL 4-methylumbelliferyl-
β-D-galactopyranoside in McIlvaine pH 4.3/H2O 1/1 (v/v) with 0.2 M NaCl and 0.1% BSA). After incubation at 37 °C 
for 30 min, the reaction was quenched with 2.5 mL 0.3 M glycine, pH 10.6 and fluorescence was measured with a 
fluorimeter LS55 (Perkin Elmer) using λex 366 nm and λem 445 nm. For tests of irreversibility, the substrate mix was 
added simultaneously with the inhibitors to the enzyme (without any preincubation) and incubated for 30 min. All 
samples were corrected for background fluorescence (sample without enzyme) and residual enzyme activity was 
calculated as compared to a control sample incubated in the same manner but without inhibitors. Displayed values 
represent mean values from triplicate experiments and error bars indicate standard deviation (SD). Graphpad Prism 
5 software was used to determine apparent IC50 values. 
In vitro labeling assays using recombinant αGal A 
In a typical experiment, Fabrazyme (10 ng, 0.20 pmol per experiment) was diluted in McIlvaine buffer pH 4.6/H2O 
1/1 (v/v) (9 μL total volume) and exposed to the indicated concentrations of ABP 2 (1 μL 10x solution in DMSO) for 
1 hr at 37 °C. For denaturation of samples, Fabrazyme was heated to 100 °C for 5 min in McIlvaine buffer pH 
4.6/H2O 1/1 (v/v) containing 1% SDS (9 μL total volume) before addition of probe 2. After labeling, the reaction 
mixtures were boiled for 5 min at 100 °C with 4 μL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and 
resolved on 10% SDS-PAGE. In-gel visualization of the fluorescent labeling was performed in the wet gel slabs 
directly using Cy3 settings. 
Competition assays. Fabrazyme or Replagal (10 ng, 0.20 pmol per experiment) were first exposed for 1 hr at 37 °C 
to either 10 µM of 7, 100 mM of 8, 1 µM of 1, or 100 µM of 6 (0.5 μL 20x solution in DMSO), before labeling with 
100 nM 2 (0.5 μL 2 µM in DMSO) as described above. 
pH-dependent labeling assay. Fabrazyme (50 ng, 1.0 pmol) was labeled with 50 nM of ABP 2 (1 μL 0.5 μM, 0.5 pmol, 
0.5 eq.) as described above using McIlvaine buffers of pH 3 - pH 8. Gel bands were quantified using Image Lab 4.1 
(Bio-Rad) software. Displayed values represent mean values from 5 independent experiments. 
Copper(I)-catalyzed click reaction on recombinant αGal A 
Fabrazyme (100 ng, 2.0 pmol per experiment, 1 µL 100 ng/µL) was mixed with  50 mM potassium phosphate buffer 
pH 4.6 (3.5 μL) and 1 µM of ABP 1 (0.5 μL 10 µM in DMSO, 5.0 pmol, 2.5 eq.). The reaction was incubated for 1 hr at 
37 °C, before being diluted with 50 mM NaOAc containing 0.1% SDS (10 µL) for copper(I)-catalyzed click reaction 
using a slightly modified literature procedure.22 After successive addition of 1 mM TBTA (2 µL 10 mM in DMSO), 2.5 
mM DTT (0.5 µL 100 mM in H2O) and 5 mM CuSO4 (1 µL 100 mM in H2O), the reaction mixtures were treated for 1 
hr at 37 °C with 0.5, 5 or 50 µM of either Bodipy-alkyne 1018 or biotin-alkyne 1119 (1 µL 20x solution in DMSO; 
respectively 10, 100 and 1000 pmol; 5, 50 and 500 eq.). As a control, after exposure to ABP 1 the mixtures were 
diluted with 50 mM potassium phosphate buffer pH 4.6 (4 μL) and labeled with 0.3 µM ABP 2 (1 µL 3 µM in DMSO, 
3.0 pmol, 1.5 eq.) for 1 hr at 37 °C instead of click reaction. The reaction mixtures were then boiled for 5 min at 100 
°C with 7 μL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 10% SDS-PAGE. In-gel 
visualization of the fluorescent labeling by ABP 2 and click reaction with 10 was performed in the wet gel slabs 
directly using Cy3 settings. Proteins labeled by click reaction with 11 were detected by streptavidin Western 
blotting. 
Generation of αGal A mutants D170G and D231G 
Molecular cloning and site-directed mutagenesis. Design of cloning primers and primers for mutation introduction 
were based on NCBI Reference sequence for human αGal A NM_000169.2 (GLA). The full-length αGal A wild-type 
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cDNA sequence was cloned from human mRNA (Hek293 cells) in pcDNA-DEST40 using the Gateway cloning system 
(Invitrogen). Full length cDNA was generated using the Pfx50 DNA polymerase (Invitrogen) and cloned in pDONR-
221 with the following primers:  
- forward: 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTACCACCATGCAGCTGAGGAACCCAGA-3'  
- reverse: 5'- GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAAAGTAAGTCTTTTAATGACATC-3'.  
Site-directed mutagenesis was performed using the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies) in order to change the nucleophilic (D170) and acid/base (D231) aspartic acid to glycine residues, 
using the following primers:  
- nucleophile D170G: 5'-GATCTGCTAAAATTTGGTGGTTGTTACTGTGACAG-3'  
- acid/base D231G: 5'- GGCGAAATTTTGCTGGCATTGATGATTCCTGGAAAAG-3'. 
Recombinant protein expression. Cos-7 cells were cultured in HAMF12-DMEM (Invitrogen) supplied with 10% (v/v) 
FCS. Confluent cells were transfected with FuGENE (Roche) and either wild-type αGal A, D170G αGal A mutant, 
D231G αGal A mutant or chitotriosidase as a mock transfection control. The cells were harvested after 72 hours by 
scraping in 25 mM potassium phosphate buffer (pH 6.5, 0.1% (v/v) Triton X-100, protease inhibitor cocktail 
(Roche)). Control cells were not transfected. 
Labeling of αGal A mutants 
Cos-7 lysates (10 μg total protein per experiment) from cells transfected with either WT αGalA, D170G or D231G 
mutants, chitotriosidase or control cells were diluted in McIlvaine buffer pH 4.6 (9 μL total volume) and exposed to 
100 nM of ABP 2 (1 μL 1 µM in DMSO) for 1 hr at 37 °C. The reaction mixtures were then boiled for 5 min at 100 °C 
with 4 μL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 10% SDS-PAGE. In-gel 
visualization of the fluorescent labeling was performed in the wet gel slabs directly using Cy3 settings. Next, αGal A 
levels were detected by performing anti-GLA Western blotting. 
In vitro labeling assay using cell lysates 
In a typical experiment, fibroblast lysates (20 μg total protein per experiment) were diluted in McIlvaine buffer pH 
4.6 (9 μL total volume) and exposed to 100 nM of ABP 2 (1 μL 1 µM in DMSO) for 1 hr at 37 °C. Where indicated, a 
reduced reaction time or probe concentration was used. The reaction mixtures were then boiled for 5 min at 100 °C 
with 4 μL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 10% SDS-PAGE. In-gel 
visualization of the fluorescent labeling was performed in the wet gel slabs directly using Cy3 settings. The gel 
bands in the fluorescence scan were quantified using Image Lab 4.1 (Bio-Rad) software to calculate the ratio of 
labeling between αGal A (lower signal) and αGal B (upper signal).  
Competition assays. Fibroblast lysates (20 μg total protein per experiment) were first exposed for 1 hr at 37 °C to 
either 10 µM of 7, 100 mM of 8, 1 µM of 1, or 100 µM of 6 (0.5 μL 20x solution in DMSO), before labeling with 100 
nM 2 (0.5 μL 2 µM in DMSO) as described above. 
Simultaneous labeling of retaining α-galactosidases and β-glucosidases 
Wild-type fibroblast lysates (20 µg total protein), recombinant αGal A (Fabrazyme, 10 ng, 0.20 pmol), recombinant 
GBA1 (Cerezyme, 12 ng, 0.20 pmol) or a mixture of both recombinant proteins were diluted in McIlvaine buffer pH 
4.6/H2O 1/1 (v/v) (9 μL total volume) and labeled with 100 nM aziridine 2 plus 100 nM aziridine 920 (each 0.5 μL 2 
µM in DMSO, 1 pmol, 5 eq.) for 1 hr at 37 °C. The reaction mixtures were then boiled for 5 min at 100 °C with 4 μL 
4x Laemmli’s sample buffer containing 2-mercaptoethanol and resolved on 10% SDS-PAGE. In-gel visualization of 
the fluorescent labeling was performed in the wet gel slabs directly using Cy3 settings for probe 2 and Cy2 settings 
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Glycosidases are responsible for the degradation of glycosphingolipids in lysosomes. 
When the activity of one of these hydrolases is deficient, accumulation of the corresponding 
substrates in lysosomes can occur which may lead to a lysosomal storage disorder. Despite 
the similarities in the primary cause of such disorders, they are usually very heterogeneous 
in clinical manifestation and course of the disease.1 Two extreme examples are Morquio B 
syndrome and GM1 gangliosidosis, which are both caused by a deficiency in the lysosomal 
enzyme β-galactosidase but represent two completely different disease phenotypes.2 
Activity-based probes (ABPs) have shown promise as valuable research tools for the 
investigation of glycosidases and their involvement in disease.3,4 The class of retaining 
glycosidases is especially susceptible to targeting by ABPs, since their catalytic mechanism 
involves the formation of a covalent enzyme-substrate intermediate which can be exploited 
for the design of novel ABPs.  
At least three different retaining glycosidases that display β-galactosidase activity are 
known in humans. These include two lysosomal enzymes, galactocerebrosidase and β-
galactosidase, and the membrane-bound non-lysosomal enzyme lactase, also known as 




is responsible for cleaving lactose into galactose and glucose. With the exception of the 
majority of Northern Europeans, its activity rapidly declines after weaning which can cause 
lactose-intolerance in adults.5,6 The lysosomal enzymes β-galactosidase and 
galactocerebrosidase both catalyze the hydrolysis of terminal β-linked galactosyl moieties. 
They have different substrate preferences, although there appears to be some overlap.7,8 
The substrates of β-galactosidase include glycosphingolipids (e.g. ganglioside GM1, 
lactosylceramide), glycoproteins and keratan sulfate-derived oligosaccharides.2 
Malfunctioning of β-galactosidase can result in two distinct lysosomal storage disorders, 
GM1 gangliosidosis and Morquio B syndrome. The former is a neurological disease 
characterized by ganglioside GM1 accumulation, whereas the primary storage lipid in 
Morquio B syndrome is keratin sulfate and main symptoms include dwarfism and skeletal 
abnormalities. These differences are likely caused by different effects of the various 
mutations in the gene encoding β-galactosidase on folding of the enzyme, substrate binding 
or binding of activator proteins that are necessary for GM1 ganglioside catabolism.2,9  
Galactocerebrosidase is involved in the degradation of galactolipids such as 
galactosylceramide, galactosylsphingosine and monogalactosyldiglyceride.10,11 It is an 80-kDa 
protein containing at least four N-linked glycosylation sites which are responsible for 
lysosomal trafficking via the mannose-6-phosphate receptor.12 After entering the lysosomes, 
the enzyme is cleaved into 30- and 50-kDa subunits.13 However, based on the crystal 
structure of the protein it is assumed that this cleavage does not result in dissociation of the 
subunits and has no effect on enzymatic activity.12 Substrate hydrolysis by 
galactocerebrosidase occurs through a double displacement mechanism, similar to the 
mechanism described for retaining α-galactosidases in Chapter 6, with overall retention of 
the β-anomeric configuration (Figure 7.1A). The two carboxylic acid residues in the active 
site that function as a nucleophile and a general acid/base have been identified as the 
glutamic acid residues E258 and E182, respectively.12,14  
A deficiency in galactocerebrosidase is at the basis of the autosomal recessive lysosomal 
storage disorder Krabbe disease, also named globoid cell leukodystrophy. More than 70 
mutations in the gene encoding galactocerebrosidase have been implicated in the 
development of this disease.12 The main pathological consequences are found in the 
peripheral and central nervous system, however the mechanism behind this 
neurodegenerative disorder has not yet been fully elucidated.14 Reduced activity of 
galactocerebrosidase results in a reduced catabolism of galactosphingolipids including 
galactosylceramide. This forms the main lipid component of myelin, the protective sheath 
around neuron axons that is essential for correct functioning of the nervous system. The




Figure 7.1. A) Mechanism of substrate hydrolysis by galactocerebrosidase. B) Proposed mechanism of 
galactocerebrosidase binding by inhibitor 5. 
accumulation of the toxic metabolite galactosylsphingosine eventually leads to the 
apoptosis of myelin-forming cells and consequently results in demyelination and 
neurodegeneration.15,16 Infantile Krabbe disease is usually diagnosed before 1 year of age 
and lethal before the age of 2. Early symptoms include limb stiffness, developmental delay, 
and severe irritability. When diagnosed in adolescents or adults other symptoms may be 
observed such as seizures, feeding difficulties, slowing of mental and motor development, 
muscle weakness, spasticity, deafness, and blindness. The onset and severity of symptoms 
as well as the course of the disease in adult Krabbe patients is very variable, even in patients 
carrying the same mutation.11,17 Diagnosis can be confirmed by measuring the residual 
galactocerebrosidase activity in leukocytes or cultured skin fibroblasts, which is usually 0-5% 
of normal levels. However, the amount of residual activity is not directly correlated to the 
clinical symptoms or course of the disease. Carriers may have as little as 10-20% of normal 
galactocerebrosidase activity without being affected. The only available treatment for 
Krabbe disease involves symptomatic treatment and physical therapy. Clinical trials with 
hematopoietic stem cell transplantation, which aims to restore galactocerebrosidase activity 
in the central nervous system and thereby prevent further demyelination, have shown that 
this therapy can slow the course of juvenile Krabbe disease when diagnosed at an early 
stage.18,19  
Further investigations of galactocerebrosidase and its involvement in Krabbe disease 
would benefit from the availability of ABPs that specifically target this enzyme. In addition, a 
broad-spectrum ABP targeting all human retaining β-galactosidases may provide a valuable 
research tool to study these enzymes and the selectivity of new β-galactosidase inhibitors. 
Numerous fluorescent β-galactosidase probes have been reported in literature. However, 
most of these are reversible and can therefore not be used in, for example, gel-based 




fluorogenic tag attached to the aglycon position that is released after cleavage by the 
enzyme20-26 and fluorescently tagged competitive inhibitors.27,28 A few ABPs that enable non-
reversible mechanism-based labeling of retaining β-galactosidases have been reported 
(Figure 7.2A). Suicide substrates functionalized with a latent quinone methide precursor as 
the aglycon to which a fluorescent or fluorogenic tag is attached (1-3) were shown to act as 
covalent β-galactosidase probes.29-32 Hydrolysis by the enzyme results in the release of a 
quinone methide which can then react covalently with a nearby nucleophilic amino acid 
residue. Of note, this type of probe also labels inverting galactosidases. Suicide substrates 
have found limited use for the specific labeling of glycosidases in cell extracts because the 
released quinone methide can diffuse out of the active site, making the labeling efficiency 
highly dependent on the presence and nature of nearby nucleophilic amino acid residues 
and also allowing the labeling of other proteins. Nonetheless, these probes were found to be 
useful for histological studies and fluorescence-activated cell sorting experiments, enabling 
the in situ fluorescent labeling of various cell types overexpressing bacterial or plant 
enzymes with β-galactosidase activity.31,32 The second type of galactosidase ABPs is based on 
2-fluorogalactoside inhibitors in which the hydroxyl group at C6 is substituted with an azide, 
which enables two-step labeling via Staudinger-Bertozzi ligation (4).33 Although this ABP is 
not strictly irreversible, the covalent enzyme-probe intermediate is sufficiently stable to 
enable visualization of labeled proteins on gel. ABP 4 was used to label Escherichia coli β-
galactosidase (LacZ) in cell extracts. To date, none of these probes has been used for the 
labeling of human retaining β-galactosidases.  
 
 
Figure 7.2. A) Structures of known β-galactosidase ABPs 1-4. B) Structures of novel retaining β-galactosidase 
inhibitor 5 and ABPs 6-8. 
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This chapter describes the evaluation of β-galactopyranose-configured epoxides 5-8 as 
inhibitors and ABPs for human galactocerebrosidase (Figure 7.2B). These probes, 
synthesized as described in Chapter 5, were designed such that they mimic the substrate’s 
terminal galactosyl moiety and bind covalently to their target enzyme via a nucleophilic 
attack of the catalytic residue in the active site on the β-configured electrophilic epoxide 
moiety (Figure 7.1B). The non-tagged inhibitor 5 was synthesized as a galactose-configured 
isomer of the known retaining β-glucosidase inhibitor cyclophellitol.34-36 In ABP 6 the primary 
hydroxyl group is substituted with an azide that can be used for two-step labeling via ‘click’ 
reaction or Staudinger-Bertozzi ligation. In addition, this probe may serve as a control probe 
and an inhibitor. ABPs 7 and 8 were obtained by functionalization of probe 6 with a Bodipy 
fluorophore and a biotin tag, respectively.  
7.2 Results and discussion 
The ability of compounds 5-8 to inhibit recombinant galactocerebrosidase was evaluated 
by measuring residual enzyme activity using the fluorogenic substrate 4-methylumbelliferyl 
β-D-galactoside (4-mu β-gal) after 30 min of preincubation with varying concentrations of 
the probes. The recombinant enzyme used for these assays was obtained by overexpression 
of human galactocerebrosidase in Cos-7 cells, resulting in excretion of the enzyme into the 
culture medium which was used without further purification.37 Therefore the exact amount 
of enzyme is not known. Plots of residual activity against inhibitor concentration reveal a 
clear dose-dependent inhibition of galactocerebrosidase by all probes (Figure 7.3A). The 
apparent IC50 values calculated from these curves are shown in Table 7.1. The non-tagged 
epoxide 5 proved to be a very potent inhibitor of galactocerebrosidase with an apparent IC50 
value of 38 nM. Substitution of the hydroxyl group at the C6 position with an azide (6), 
however, resulted in a dramatic loss of potency with an almost 2000-fold increase of the 
apparent IC50 value (70 µM). Probe 6 was found to reach full inhibition after a prolonged 
incubation time. Interestingly, the inhibitory potency was partially restored by incorporation 
of a Bodipy dye (7), but not a biotin tag (8), at the same position. Hence, it appears that the 
hydrophobic fluorophore leads to enhanced binding of the probe to its target enzyme and 
might be better tolerated in the active site of the enzyme than a small polar azide moiety.  A 
similar result has been found previously for the inhibition of retaining β-glucosidases by 
analogous C6-modified probes, although the beneficial effect of the Bodipy dye was much 
larger in that case.4 On the contrary, the findings described in Chapter 6 suggest that neither 





Figure 7.3. Inhibition of recombinant galactocerebrosidase activity. A) Recombinant galactocerebrosidase (βGal) 
was treated for 30 min with inhibitors 5-8 after which residual activity was determined from hydrolysis of 4-mu β-
gal. B) Effect of 30 min preincubation (+) as compared to simultaneous addition of 4-mu β-gal and probes (-) on 
inhibition. The displayed inhibitor concentrations in both cases represent those without addition of the fluorogenic 
substrate solution.  
retaining α-galactosidases, indicating that this phenomenon is dependent on the specific 
active site features and substrate tolerance of each individual glycosidase. The non-
reversibility of galactocerebrosidase inhibition by epoxides 5-8 was demonstrated by testing 
the effect of preincubation on the amount of inhibition. Residual enzyme activity was 
measured as a function of probe concentration when the substrate and inhibitors were 
added simultaneously to the enzyme, and the obtained values were compared to those after 
preincubation of the enzyme with the inhibitors (Figure 7.3B). The evident shifts of the 
resulting curves confirm that preincubation leads to a higher percentage of inhibition and 
thereby indicate that the binding is irreversible. In order to assess the selectivity of inhibitors 
5-8 for retaining β-galactosidases over the related class of retaining α-galactosidases, 
inhibition of recombinant α-galactosidase A (Fabrazyme) was determined by using a similar 
assay with the fluorogenic substrate 4-methylumbelliferyl α-D-galactoside. No inhibition was 
observed after 30 min of preincubation with up to 100 µM of the probes. 
Table 7.1. Inhibition of recombinant galactocerebrosidase activity 
Compound Apparent IC50 (µM) % inhibition  
30 min 6 hrs 
Epoxide 5 0.038 98 (1 µM) 100 (1 µM) 
Azido-epoxide 6 70 62 (100 µM) 96 (100 µM) 
Bodipy-epoxide 7 2.8 97 (100 µM) 100 (100 µM) 
Biotin-epoxide 8 30 81 (100 µM) 97 (100 µM) 
Inhibition of recombinant galactocerebrosidase as determined from hydrolysis of 4-mu β-gal after preincubation for 
30 min or 6 hrs with probes 5-8. Apparent IC50 values were calculated from plots of residual galactocerebrosidase 
activity as a function of probe concentration with a preincubation time of 30 min (Figure 7.3A).  
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Having shown that compounds 5-8 are able to irreversibly inhibit galactocerebrosidase, 
fluorescently labeled ABP 7 was used to visualize the recombinant enzyme on gel. As before, 
the non-purified enzyme in cell culture medium was used. Exposure to Bodipy-epoxide 7 for 
1 hr resulted in concentration-dependent fluorescent labeling of a band around 80 kDa, 
corresponding to the molecular weight of galactocerebrosidase (Figure 7.4A). The labeling 
was completely abolished by denaturation of the enzyme prior to addition of the ABP, 
confirming the specific binding of the probe to catalytically active enzyme. In addition, a 
second fluorescently labeled band of approximately 60 kDa was visible at higher probe 
concentrations. This protein most likely represents serum albumin, a component of the cell 
culture medium. Unwanted labeling of albumin is a known problem with the use of Bodipy-
functionalized probes and is caused by non-specific interactions of the hydrophobic dye with 
the protein. Evidence for the non-specific nature of these interactions is provided by the fact 
that denaturation of the protein by boiling in assay buffer prior to labeling with ABP 7 
resulted in an even stronger fluorescent signal, which could only be eliminated by addition 
of the surfactant SDS. Moreover, pretreatment of samples with non-tagged inhibitor 5 led to 
complete disappearance of the fluorescent labeling of galactocerebrosidase by Bodipy-
tagged epoxide 7, while the labeling of albumin was unaffected (Figure 7.4B). Preincubation   
  
 
Figure 7.4. Labeling and inhibition of recombinant galactocerebrosidase. A) Labeling with 0.01 - 10 µM of Bodipy-
epoxide 7 for 1 hr; where indicated enzyme was denatured prior to labeling by boiling at 100 °C for 3 min in assay 
buffer (+) or in buffer with 1% SDS (+SDS). B) Labeling with 0.2 µM 7 after preincubation with inhibitors 5 (0.2 µM), 
6 (10 µM) or 8 (10 µM) for 1 hr. C) Labeling with 0.1 - 10 µM of biotin-epoxide 8 for 1 hr; where indicated enzyme 
was denatured prior to labeling by boiling at 100 °C for 3 min. All gels are 10% SDS-PAGE with fluorescent readout 




with azide- and biotin-tagged probes 6 and 8 resulted in partial blocking of the fluorescent 
labeling of galactocerebrosidase. Biotinylated ABP 8 also enables the visualization of 
galactocerebrosidase activity by streptavidin Western blotting (Figure 7.4C). In agreement 
with the higher IC50 value of this probe as compared to its fluorescently labeled analogue 7, 
a relatively large amount of probe is required to (fully) label the enzyme. At the highest 
concentration tested (10 µM) a single biotin-labeled band was clearly visible that 
corresponds to catalytically active galactocerebrosidase. 
Since galactocerebrosidase is a lysosomal enzyme, its activity is highest in a slightly acidic 
environment with an optimum around pH 4.3. The pH-dependence of galactocerebrosidase 
labeling by Bodipy-functionalized ABP 7 was examined by treating the recombinant enzyme 
with the probe in buffers of varying pH. As can be seen in Figure 7.5A, the intensity of 
fluorescent labeling of galactocerebrosidase is indeed highest at pH 4-5 while it is almost 
completely abolished at pH 3 and lower or pH 7 and higher. Quantification of the fluorescent 
gel bands revealed that the amount of labeling by ABP 7 overlaps perfectly with the 
enzymatic activity as determined by fluorogenic substrate hydrolysis (Figure 7.5B). These 
results indicate that binding of the probe occurs in an activity-based manner and support 
the proposed binding mechanism depicted in Figure 7.1B. However, the exact site of binding 
has yet to be confirmed.  
In a final experiment the selective labeling of retaining β-galactosidases and retaining β-
glucosidases by differently configured epoxide-based ABPs was tested. For this purpose, β-
galactosidase ABP 7 and the previously reported β-glucosidase ABP 93  (Figure 7.6) were 
used to label either recombinant galactocerebrosidase or recombinant glucocerebrosidase,  
 
 
Figure 7.5. pH-dependence of galactocerebrosidase labeling. A) Recombinant galactocerebrosidase labeled with 0.5 
µM 7 for 1 hr in buffers of varying pH; 10% SDS-PAGE with fluorescent readout followed by coomassie brilliant blue 
staining. B) Quantification of gel bands in A (circles) as compared to galactocerebrosidase activity on 4-mu β-gal 
(triangles) at different pH values. ‘M’: protein marker. 




Figure 7.6. Selective labeling of retaining β-galactosidases and retaining β-glucosidases with differently configured 
epoxide ABPs. Recombinant galactocerebrosidase (‘galactocer.’) and glucocerebrosidase (‘glucocer.’) were labeled 
with 1 µM of ABP 7 or ABP 9 for 1 hr and labeled proteins were resolved by 7.5% SDS-PAGE with fluorescent 
readout in Cy2 (9) and Cy3 (7) channels. ‘M’: protein marker. 
a lysosomal retaining β-glucosidase. The two ABPs are functionalized with different Bodipy 
fluorophores and can therefore be visualized using different scanner settings for in-gel 
fluorescent readout. While galactocerebrosidase was labeled exclusively by probe 7, 
glucocerebrosidase was labeled by ABP 9 but not by its stereoisomer 7. The absence of 
cross-reactivity demonstrates the selective targeting of each of these enzymes by the 
appropriately configured ABPs. 
7.3 Conclusion 
The β-galactopyranose-configured epoxide-based probes 5-8 were demonstrated to 
inhibit recombinant human galactocerebrosidase covalently and irreversibly. Of these 
probes, non-tagged epoxide inhibitor 5 is the most potent inhibitor. Substitution of the 
hydroxyl group at C6 with an azide (6) results in a dramatic loss of potency, whereas 
installment of a Bodipy tag at the same position (7) partially restores the inhibitory potency. 
Inhibition of other human retaining β-galactosidases, e.g. lysosomal β-galactosidase, by 
epoxides 5-8 remains to be determined but is not unlikely in view of their identical catalytic 
mechanism. Bodipy-functionalized ABP 7 and biotinylated ABP 8 enable the visualization of 
catalytically active galactocerebrosidase on gel. The epoxide probes label the enzyme in an 
activity-based manner and do not target the related glycosidase α-galactosidase A. Further 
experiments will have to reveal whether they can be used to label endogenously expressed 
β-galactosidases in cell extracts and living cells. In view of the positive results obtained with 
the α-galactopyranose- and β-glucopyranose-configured aziridine ABPs described in Chapter 
6 and in literature,38 efforts should also be made to expand the set of available β-
galactosidase ABPs with aziridine-based probes. Finally, it should be noted that Bodipy-




reported glucopyranose-configured stereoisomer 9 and yet the two probes enable selective 
targeting of galactocerebrosidase and glucocerebrosidase, respectively. These results 
demonstrate great potential for targeting different classes of retaining glycosidases by 
appropriate alterations in the probe configuration.  
Experimental procedures 
General 
Recombinant galactocerebrosidase was expressed in Cos-7 cells by transfection with cDNA encoding human 
galactocerebrosidase.37 The culture medium containing the secreted recombinant protein was used directly for 
fluorogenic substrate assays and labeling assays. Recombinant α-galactosidase A (Fabrazyme) and recombinant β-
glucocerebrosidase (Cerezyme) were obtained from Genzyme. SDS-PAGE analysis: in-gel fluorescence was 
measured on a Bio-Rad ChemiDoc MP scanner using Cy3 settings (Green Epi illumination, 605/50 Filter) or Cy2 
settings (Blue Epi illumination, 530/28 Filter). As a loading control gels were stained with Coomassie Brilliant Blue. 
For Western blotting, the proteins were transferred onto a PVDF membrane (Bio-Rad Trans-Blot Turbo Transfer 
Pack) using a Bio-Rad Trans-Blot Turbo Transfer System. Membranes were blocked with 1% BSA in TBS-t(+) (0.1% 
Tween 20) for 1 hr at room temperature, hybridized with Streptavidin-HRP for 1 hr at room temperature (1:10,000 
in blocking buffer) (Molecular Probes, Life Technologies), washed with TBS-t(+) and TBS and then visualized using an 
ECL+ Western blotting detection kit (Amersham Biosciences). Protein standards are PageRuler Plus Prestained 
Protein Ladder (Thermo Scientific) and biotinylated protein marker (Bio-Rad). 
Fluorogenic substrate assay on recombinant galactocerebrosidase 
Culture medium containing recombinant galactocerebrosidase was diluted 2/1 (v/v) with McIlvaine buffer pH 4.3 
(10 µL total volume) and exposed to the indicated concentrations of compounds 5-8 (10 μL 2x solution in H2O) for 
30 min at 37 °C, before addition of 100 µL substrate mix (0.23 mg/mL 4-methylumbelliferyl-β-D-galactopyranoside 
in McIlvaine pH 4.3/H2O 1/1 (v/v) with 0.2 M NaCl and 0.1% BSA). After incubation at 37 °C for 30 min, the reaction 
was quenched with 2.5 mL 0.3 M glycine, pH 10.6 and fluorescence was measured with a fluorimeter LS55 (Perkin 
Elmer) using λex 366 nm and λem 445 nm. For tests of irreversibility, the substrate mix was added simultaneously 
with the inhibitors to the enzyme (without any preincubation) and incubated for 30 min. All samples were 
corrected for background fluorescence (sample without enzyme) and residual enzyme activity was calculated as 
compared to a control sample incubated in the same manner but without inhibitors. Displayed values represent 
mean values from triplicate experiments and error bars indicate standard deviation (SD). Graphpad Prism 5 
software was used to determine apparent IC50 values.  
pH-dependent activity assay. Culture medium containing recombinant galactocerebrosidase was diluted 2/1 (v/v) 
with McIlvaine buffer pH 4.3 (10 µL total volume) and mixed with 100 µL substrate mix of various pH values (0.23 
mg/mL 4-methylumbelliferyl-β-D-galactopyranoside in McIlvaine pH 3 - pH 8/H2O 1/1 (v/v) with 0.2 M NaCl and 
0.1% BSA). After incubation at 37 °C for 30 min, the reaction was quenched and fluorescence measured as 
described above. Displayed values represent mean values from 6 experiments and error bars indicate standard 
deviation (SD). 
Fluorogenic substrate assay on recombinant αGal A 
Fabrazyme was diluted to a concentration of 0.1 ng/µL in McIlvaine pH 4.6/H2O 1/1 (v/v) containing 0.1% BSA for 
stabilization of the recombinant protein. A solution of Fabrazyme (1 ng, 20 fmol per experiment, 10 µL 0.1 ng/µL) 
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was exposed to the indicated concentrations of compounds 5-8 (10 μL 2x solution in H2O) for 30 min at 37 °C, 
before addition of 100 µL substrate mix (1.5 mg/mL 4-methylumbelliferyl-α-D-galactopyranoside in McIlvaine pH 
4.6/H2O 1/1 (v/v) + 0.1% BSA). After incubation at 37 °C for 20 min, the reaction was quenched with 2.5 mL 0.3 M 
glycine, pH 10.6 and fluorescence was measured with a fluorimeter LS55 (Perkin Elmer) using λex 366 nm and λem 
445 nm. All samples were corrected for background fluorescence (sample without enzyme) and residual enzyme 
activity was calculated as compared to a control sample incubated in the same manner but without inhibitors.  
In vitro labeling assays using recombinant galactocerebrosidase 
In a typical experiment, culture medium containing recombinant galactocerebrosidase (5 µL) was diluted with 
McIlvaine buffer pH 4.3/H2O 2/1 (v/v) (14 µL) and exposed to the indicated concentrations of ABPs 7 or 8 (1 μL 20x 
solution in DMSO) for 1 hr at 37 °C. For denaturation of samples, the enzyme was heated to 100 °C for 3 min in 
buffer with or without 1% SDS (9 μL total volume) before addition of the probes. After labeling, the reaction 
mixtures were boiled for 5 min at 100 °C with 7 μL 4x Laemmli’s sample buffer containing 2-mercaptoethanol and ½ 
of each sample was resolved on 10% SDS-PAGE. In-gel visualization of the fluorescent labeling by probe 7 was 
performed in the wet gel slabs directly using Cy3 settings. In case of probe 8, biotinylated proteins were detected 
by performing streptavidin Western blotting. 
Competition assays. Culture medium containing recombinant galactocerebrosidase (5 µL) in McIlvaine buffer pH 
4.3/H2O 2/1 (v/v) (14 µL) was first exposed for 1 hr at 37 °C to either 0.2 µM of 5, 10 µM of 6 or 10 µM of 8 (1 μL 
20x solution in DMSO), before labeling with 0.2 µM 7 (1 μL 4 µM in DMSO) as described above. 
pH-dependent labeling assay. Culture medium containing recombinant galactocerebrosidase (5 µL) was diluted with 
McIlvaine buffers of pH 3 - pH 8/H2O 2/1 (v/v) (14 µL) and labeled with 0.5 µM of ABP 7 (1 μL 10 μM in DMSO) for 1 
hr at 37 °C. Gel bands were quantified using Image Lab 4.1 (Bio-Rad) software. Displayed values represent mean 
values from 4 independent experiments. 
In vitro labeling assays using recombinant galactocerebrosidase and glucocerebrosidase 
Recombinant glucocerebrosidase (Cerezyme) in McIlvaine buffer pH 5.2/H2O 1/1 (v/v) (9 µL 0.22 µM, 2.0 pmol, 0.12 
µg per experiment) or culture medium containing recombinant galactocerebrosidase (2.5 µL) in McIlvaine buffer pH 
4.3/H2O 2/1 (v/v) (6.5 µL) were exposed to either 1 µM of epoxide 7 or 1 µM of epoxide 94 (1 μL 10 µM in DMSO) 
for 1 hr at 37 °C. The reaction mixtures were then boiled for 5 min at 100 °C with 4 μL 4x Laemmli’s sample buffer 
containing 2-mercaptoethanol and resolved on 7.5% SDS-PAGE. In-gel visualization of the fluorescent labeling was 
performed in the wet gel slabs directly using Cy3 settings for probe 7 and Cy2 settings for probe 9. 
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Summary and future prospects 
 
The research described in this thesis involves the development of novel chemical tools 
and methods for the activity-based profiling of proteases and glycosidases. Activity-based 
protein profiling (ABPP) is a field of research that aims to obtain information on the activity 
of a protein or protein family within the context of a biological system. In order to enable 
the monitoring of enzymatic activity rather than protein expression levels, ABPP strategies 
make use of active-site directed chemical probes, termed activity-based probes (ABPs), that 
bind in a mechanism-based and irreversible manner to a specific target enzyme or multiple 
members of an enzyme family. An essential element of an ABP is a means to visualize, 
isolate, quantify and/or identify the labeled proteins. Depending on the nature of the 
detectable agent, ABPP experiments can involve either direct or two-step labeling strategies. 
Direct ABPs are functionalized with a reporter entity such as a fluorescent tag and/or an 
affinity tag. Alternatively, in two-step ABPs the reporter group is replaced by a small reactive 
moiety, referred to as ‘ligation handle’, that provides the option to introduce a tag after 
binding of the probe to a target enzyme. The attachment of a reporter group in two-step 
labeling strategies is realized by making use of bioorthogonal ligation reactions, which 
proceed with high selectivity and efficiency and are non-perturbing to the biological system 
at hand. In Chapter 1 the principles of ABPP and ABP design are discussed. Chapter 2 
presents an overview of the various bioorthogonal ligation reactions that have been 




The development of a two-step ABPP strategy based on the Diels-Alder cycloaddition is 
described in Chapter 3. Previously reported two-step ABPP methods all rely on the use of an 
alkyne or azide as a ligation handle for labeling of enzymatic activity via Staudinger-Bertozzi 
ligation or azide-alkyne cycloaddition (‘click’ reaction), which may either be catalyzed by 
copper(I) or driven by ring-strain. In contrast, the Diels-Alder approach makes use of ABPs 
that are functionalized with a conjugated diene to enable reaction with a tagged maleimide 
reagent as a dienophile. The Diels-Alder strategy was applied to label the activity of 
endogenously expressed proteasome β-subunits and cysteine proteases of the cathepsin 
family in cell extracts. Moreover, it was demonstrated that this ligation reaction can be 
performed in tandem with the Staudinger-Bertozzi ligation for the labeling of two different 
enzymatic activities in the same sample. Although the Diels-Alder method forms a useful 
complement to Staudinger-Bertozzi and click ligation strategies, its broad utility is limited by 
the need to mask cysteine residues prior to the addition of the dienophile, which precludes 
in situ and in vivo applications. In addition, a considerable amount of background labeling 
was observed that might hamper the detection of proteins with low endogenous activity.  
To avoid non-specific reaction of the dienophile with cysteine residues, Chapter 4 details 
the development of a two-step ABPP strategy that is based on the inverse-electron-demand 
Diels-Alder reaction. By using tetrazine as a diene and norbornene as a dienophile, the 
selectivity and speed of the ligation reaction is drastically improved. A proteasome ABP 
functionalized with norbornene as a ligation handle enabled the efficient and selective 
labeling of endogenous proteasome activity in cell extracts and in cultured cells by reaction 
with fluorescently labeled or biotin-tagged tetrazine reagents. Furthermore, a triple ligation 
strategy was developed that combines the tetrazine ligation, Staudinger-Bertozzi ligation 
and copper(I)-catalyzed click reaction for the simultaneous labeling of three different 
enzymatic activities with different tags in the same sample. Despite the fact that tetrazines 
are not directly compatible with copper-catalyzed click chemistry, a simple washing step 
between these two ligation reactions allows their consecutive use in the same experiment.  
The triple labeling procedure developed in Chapter 4 should not only be useful for ABPP 
applications but also for the simultaneous monitoring of other biomolecules, for instance 
modified cell surface glycans or post-translationally modified proteins, in complex biological 
samples. Furthermore, the fact that tetrazine and Staudinger-Bertozzi ligations can both be 
performed inside living cells1,2 and in living animals3,4 provides the possibility to develop 
tandem labeling procedures in situ and in vivo. In situ labeling via copper(I)-catalyzed click 
chemistry can be achieved without affecting cell viability by making use of specific ligands 
that accelerate the cycloaddition and sequester the copper-induced toxicity.5,6  
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Several reports have already described the metabolic incorporation of two differently 
tagged unnatural sugars for the simultaneous imaging of the corresponding glycan 
structures on live cell surfaces by strain-promoted click reaction and tetrazine ligation,7-9 for 
example by making use of azide-modified N-acetylglucosamine derivative 110 and 
cyclopropene-functionalized mannosamine 27 (Figure 8.1A). The parallel labeling of 
additional cell surface glycans could be achieved by using alkyne-functionalized sugars, such 
as N-acetylneuraminic acid derivative 3.11 Alternatively, unnatural sugars that are tagged 
with a 3,3-disubstituted cyclopropene moiety, for instance N-acetylgalactosamine derivative 
4, may be used for bioorthogonal reaction with nitrile imines, which can be generated from 
tetrazoles in situ by exposure to UV light. In contrast to 1,3-disubstituted cyclopropenes, the 
3,3-disubstituted cyclopropene moiety was demonstrated to show virtually no reactivity 
towards tetrazines, which enables the concurrent use of both ligation handles in a tandem 
labeling procedure.12 Together, the ligation handles in compounds 1-4 should enable the 
parallel labeling of up to four different cell surface glycans or, for example, enzymatic 
activities (Figure 8.1B). Such a tandem ligation strategy would entail a number of steps 
starting with the inverse-electron-demand Diels-Alder reaction of the 1,3-disubstituted 
cyclopropene with a tetrazine and the (simultaneous) elaboration of the azide ligation 
handle via Staudinger-Bertozzi ligation with a phosphine, or alternatively via strain-  
  
 
Figure 8.1. A) Peracetylated N-azidoacetyl glucosamine (1), cyclopropene-functionalized mannosamine derivative 
(2), alkyne-equipped neuraminic acid analogue (3) and N-acetyl galactosamine derivative with a 3,3-disubstituted 
cyclopropene (4) for bioorthogonal labeling of cell surface glycans. B) Tandem bioorthogonal labeling strategy 




promoted click reaction with a cyclooctyne. Subsequently, light-induced 1,3-dipolar 
cycloaddition of the 3,3-disubstituted cyclopropene with a nitrile imine can be performed, 
followed by copper(I)-catalyzed click reaction of the terminal alkyne with an azide. 
The analysis of labeled proteins by mass spectrometry is an important method to identify 
target proteins and/or active-site peptides and to determine the exact site and mechanism 
of ABP binding. For this purpose, proteins are usually labeled with a biotin-tagged ABP and 
subsequently enriched by affinity-purification using streptavidin beads. Since the release of 
captured proteins from the beads requires harsh conditions and may result in contamination 
of the purified sample with endogenously biotinylated proteins, these methods benefit 
greatly from the use of cleavable linker systems. These may be incorporated in a direct ABP 
or in a bioorthogonal ligation reagent and enable the mild and chemoselective release of 
target proteins.  
With the aim to make the developed tetrazine-based ABPP method suitable for such 
selective enrichment experiments, a tetrazine reagent was designed in which a hydrazine-
cleavable linker separates the biotin tag from the tetrazine moiety (11, Figure 8.2).13 A short 
polyethylene glycol (PEG) spacer was included to enhance water-solubility of the probe. The 
synthesis of biotin-cleavable linker-tetrazine 11 commenced with reduction of the azide in 
PEG spacer 1414 to an amine followed by reaction with the acid chloride generated from 6-
heptynoic acid to give 15 (Scheme 8.1). After Boc-deprotection and reaction with biotin-OSu, 
the resulting alkyne-modified compound (16) was subjected to copper(I)-catalyzed click 
reaction with azide-functionalized levulinoyl derivative 1813 to give biotinylated cleavable 
linker 17. The second building block was synthesized from tetrazine 12 (see Chapter 4), 
which was extended with an aminohexanoic acid spacer (13) to minimize potential steric  
  
 
Figure 8.2. Biotinylated hydrazine-cleavable tetrazine reagent 11. 
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Scheme 8.1 Synthesis of biotin-cleavable linker-tetrazine 11 
 
Reagents and conditions: a) i) TFA/DCM 1/1 (v/v), rt, 15 min, ii) Boc-Ahx-OSu, DiPEA, DCE/DMF, rt, overnight, 88%; 
b) i) PPh3, THF/H2O, rt, overnight, ii) [6-heptynoic acid preactivated with (COCl)2, DMF, toluene, rt, 3 hrs], DiPEA, 
DCE, rt, overnight, 54%; c) i) TFA/DCM 1/1 (v/v), rt, 20 min, ii) biotin-OSu, DiPEA, DCE/DMF, rt, overnight, 87%; d) 
18, CuSO4, sodium ascorbate, tBuOH/toluene/H2O/DMF 1/1/1/1 (v/v/v/v), 80 °C, overnight, 60%; e) i) TFA/DCM 1/1 
(v/v), rt, 30 min, ii) [13 deprotected with TFA/DCM 1/1 (v/v), rt, 20 min], HCTU, DiPEA, DCM/DMF, rt, overnight, 
70%. 
hindrance of the linker system during the ligation reaction. Removal of the tBu and Boc 
protecting groups in 17 and 13, respectively, enabled HCTU-mediated coupling to afford the 
biotinylated hydrazine-cleavable tetrazine reagent 11.  
Two-step labeling experiments with norbornene-functionalized proteasome ABP 19 (see 
Chapter 4) and tetrazine reagent 11 demonstrated the selective labeling of the catalytically 
active proteasome β-subunits (β1, β2, β5) in cell extracts (Figure 8.3). Subsequent treatment 
with an excess of hydrazine resulted in disappearance of the specifically labeled protein 
bands on Western blot, indicating that the biotin tag was separated from the probe and thus 
that cleavage of the levulinoyl linker had occurred. Furthermore, preliminary enrichment 
experiments have revealed that the catalytically active proteasome β-subunits labeled by 
ABP 19 and biotin-cleavable linker-tetrazine 11 could be isolated from cell extracts using 






Figure 8.3. Labeling of proteasome activity in HEK cell extracts by 1 μM of ABP 19 for 1 hr followed by 5 - 100 µM of 
tetrazine 11 for 1 hr. Right panel: after the ligation reaction, samples were treated with 10, 50 or 100 mM hydrazine 
(‘hydr.’) overnight to cleave the levulinoyl linker. Proteins were resolved by 12.5% SDS-PAGE and detected by 
streptavidin Western blotting. ‘ep’: 100 μM epoxomicin added to compete for proteasome labeling by 19. 
The second part of this thesis describes the synthesis and biological evaluation of novel 
glycosidase ABPs. Glycosidases are hydrolytic enzymes responsible for the hydrolysis of 
glycosidic bonds in (oligo)saccharides and glycoconjugates such as glycosphingolipids in 
lysosomes. A deficiency in one of the lysosomal glycosidases can cause accumulation of the 
corresponding substrates in lysosomes, which may consequently lead to a lysosomal storage 
disorder. Despite the similarities in their primary defects, these disorders generally show a 
completely different disease progress, phenotype and clinical manifestation.15 ABPP forms 
an attractive approach to study glycosidases and their involvement in disease.16,17 At present 
a limited number of glycosidase ABPs has been developed, which is likely due to the tight 
substrate preference and the lack of covalent interactions with the substrate in the catalytic 
mechanism of many of these enzymes. Most of the retaining type of glycosidases, however 
form a covalent enzyme-substrate intermediate and are therefore amenable to targeting by 
ABPs that react covalently with the catalytic nucleophile in the active site.  
Chapter 5 describes the design and synthesis of two series of irreversible inhibitors and 
ABPs for retaining α- and β-galactosidases. These probes are equipped with an electrophilic 
epoxide or aziridine moiety as the warhead in either an α- or a β-configuration to allow 
attack by the respective active site nucleophiles. The α- and β-galactopyranose-configured 
epoxide-based compounds include a non-tagged inhibitor as well as three ABPs in which the 
hydroxyl group at C6 (carbohydrate numbering) is substituted with an azide, a Bodipy 
fluorophore or a biotin tag. In addition, two aziridine-based α-galactosidase ABPs were 
synthesized in which an azide or Bodipy tag is installed via acylation of the aziridine nitrogen. 
Unfortunately, efforts to isolate the β-galactopyranose-configured isomers of these aziridine 
probes have so far proven unsuccessful, since even the use of a completely acid-free 
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procedure for HPLC purification and ensuing lyophilization resulted in opening of the 
acylated aziridine.  
The inhibitory potency of the α-configured probes as well as their application for the 
labeling of human retaining α-galactosidases is described in Chapter 6. The aziridine-based 
ABPs proved to be very potent inhibitors of the human enzyme α-galactosidase A (αGal A), 
the deficiency of which is at the basis of the lysosomal storage disorder Fabry disease. The 
non-tagged epoxide inhibitor displayed a more than 10,000 fold lower potency towards αGal 
A than the aziridine probes, whereas none of the C6-modified epoxide ABPs showed any 
inhibition at all, revealing that the primary hydroxyl group is essential for binding of the 
probes to their target enzyme. Interestingly, the non-tagged epoxide proved to be an 
equally potent inhibitor of galactocerebrosidase, a human retaining β-galactosidase, while 
the aziridine ABPs did not inhibit this enzyme. The exact binding mechanism of the α-
galactosidase probes to αGal A has yet to be confirmed by mass spectrometry analysis of the 
labeled active site peptides and/or crystallization of the recombinant enzyme with the 
probes covalently bound in the active site. The Bodipy-tagged aziridine ABP was 
demonstrated to enable the fluorescent labeling of endogenous αGal A activity in wild-type 
fibroblast cell extracts. Besides αGal A, the probe also labeled N-acetyl-galactosaminidase 
(αGal B), a related human enzyme displaying retaining α-galactosidase activity. In addition, 
the fluorescently labeled ABP was used to directly compare α-galactosidase activity in 
extracts from wild-type cells with those obtained from classic Fabry patients, which lack 
αGal A activity and accordingly showed only labeling of αGal B. An interesting application of 
the ABP would be to profile retaining α-galactosidase activity in samples from Fabry patients 
that have different mutations in αGal A and/or different phenotypic variants of the disease.  
Preliminary in situ labeling experiments with the Bodipy-tagged aziridine ABP in 
fibroblast cell cultures revealed that no specific fluorescent signals could be detected on gel, 
despite the fact that inhibition of αGal A activity could clearly be demonstrated in extracts of 
probe-treated cells by measuring residual enzyme activity with the fluorogenic substrate 4-
methylumbelliferyl α-D-galactoside (Figure 8.4). A possible explanation for the lack of 
fluorescent labeling is that the levels of enzymatic activity might be very low and thereby 
make it difficult to detect the labeled proteins, and/or that the ester bond formed between 
the enzyme and the probe is labile under the conditions used for SDS-PAGE analysis. The in 
situ inhibition of αGal A and αGal B activity by either tagged or non-tagged aziridine probes 
(20 and 21), regardless of their ability to enable visualization on gel, can be used to provide 
insight into the nature and extent of glyco(sphingo)lipid accumulation that results from 





Figure 8.4. Inhibition of αGal A activity in wild-type fibroblast cells by treatment with 0.01 nM - 10 µM of ABPs 20 
and 21 for 2 hrs. After cell lysis residual activity was determined from hydrolysis of 4-methylumbelliferyl α-D-
galactoside. 
In order to enable the visualization of enzymatic activity in situ and in vivo, it might be 
useful to improve the intensity and/or signal-to-background ratio of the fluorescent labeling. 
More sensitive detection of the labeled proteins could for example be realized by using an 
aziridine that is functionalized with a different (near-infrared) fluorophore such as Cy5 (22, 
Figure 8.5). Alternatively, the background labeling may be strongly reduced by performing 
two-step labeling with a cyclopropene-modified ABP (25) in combination with a quenched 
tetrazine reagent which only becomes fluorescent after reaction with the dienophile (e.g. 
2620). Biotin-tagged aziridines (23 and 24) would also form a useful complement to the set of 
available α-galactosidase ABPs by providing the option to enrich the labeled proteins in 
order to facilitate subsequent detection on Western blot and/or identification by mass 
spectrometry. Efforts have been undertaken to synthesize biotin-aziridine 24, however the 
  
 
Figure 8.5. Putative aziridine-based retaining α-galactosidase ABPs functionalized with a Cy5 fluorophore (22), a 
biotin tag (23 and 24) or a cyclopropene ligation handle (25), and quenched Bodipy-tagged tetrazine 26. 
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isolation of this compound proved difficult due to solubility issues and opening of the 
aziridine. It appears that these problems are at least partly due to the low solubility of the 
biotin spacer, and therefore the introduction of a PEG-spacer such as in probe 23 might offer 
a more practical alternative. 
Chapter 7 describes the evaluation of the β-galactopyranose-configured epoxide probes 
for their ability to inhibit and label recombinant galactocerebrosidase, a human retaining β-
galactosidase. The non-tagged epoxide proved to be the most potent inhibitor of this 
enzyme. While the inhibitory potency was almost 2,000-fold decreased for the ABP with an 
azide at C6, the installment of a Bodipy tag at the same position partially restored the 
inhibitory potency. A similar trend has been reported for the inhibition of retaining β-
glucosidases by C6-modified β-glucopyranose-configured epoxide probes, although the 
beneficial effect of the Bodipy dye was much larger in that case.16 In contrast, neither of the 
C6-functionalized α-galactopyranose-configured epoxide isomers (Chapter 6) appeared to 
inhibit retaining α-galactosidases, indicating that the substrate tolerance and restrictions in 
the active site of each individual glycosidase play an important role for the successful 
targeting with epoxide-based ABPs. The Bodipy- and biotin-functionalized β-galactosidase 
ABPs were shown to enable the visualization of catalytically active recombinant 
galactocerebrosidase on gel. It remains to be determined whether these probes also target 
other human retaining β-galactosidases, for instance lysosomal β-galactosidase, and 
whether they can be used to label endogenously expressed β-galactosidases in cell extracts 
and living cells. In addition, the exact binding mechanism of the ABPs to the active site of 
their target enzyme(s) has yet to be confirmed. Notably, the epoxide probes selectively 
labeled galactocerebrosidase without affecting the related enzymes α-galactosidase A and 
glucocerebrosidase. The fact that this latter enzyme can be targeted selectively by ABPs that 
differ only in the configuration of a single hydroxyl substituent from the β-galactosidase 
probes described here16 demonstrates the potential to target different classes of retaining 
(exo)glycosidases by using similar ABPs that are modified in such a way that they mimic the 
natural substrate of the target enzyme.  
Considering the results obtained with the α-galactopyranose- and β-glucopyranose-
configured aziridine-based ABPs (see above), the synthesis of aziridine-based probes for β-
galactosidases will likely provide ABPs with higher reactivity and/or altered selectivity than 
the epoxide-based probes. The availability of broad-spectrum as well as specific 
fluorescently labeled β-galactosidase ABPs would be useful to analyze differences in 
substrate preference of the different retaining β-galactosidases and to monitor enzymatic 




deficiency. A deficiency in galactocerebrosidase is at the basis of Krabbe disease while a 
deficiency in lysosomal β-galactosidase can lead to either Morquio B syndrome or GM1 
gangliosidosis. The potential overlap in substrate preferences and the interplay between 
these enzymes have not yet been fully elucidated, and in this respect a set of β-
galactosidase probes with different selectivity profiles might provide useful research tools. 
In addition, the (non-tagged) epoxide inhibitor may also be a valuable tool to study the 
accumulation of glyco(sphingo)lipids that occurs after inhibition of retaining β-galactosidase 
activity.  
The instability of acylated aziridines is a recurring problem during the synthesis of 
aziridine-based ABPs and is mainly due to the electron-withdrawing nature of the carbonyl 
group, which activates the aziridine towards nucleophilic ring-opening. At the same time this 
property is probably also responsible for the superior reactivity of aziridine probes as 
compared to their epoxide analogues (Chapter 6).16,21 An optimal balance between synthetic 
access and reactivity of an aziridine-based ABP may be realized by changing the nature of 
the functional group added to the aziridine nitrogen, for example by alkylation or 
sulfonylation as in probes 27 and 28 (Figure 8.6). Moreover, since the high reactivity of 
acylated aziridine probes was demonstrated to be accompanied by a loss in selectivity,21 the 
synthesis of other substituted aziridines with varying reactivity may provide the option to 
tune their selectivity and thereby develop both highly specific and broad-spectrum ABPs. A 
non-substituted aziridine has a ring strain similar to an epoxide but is in principle less 
electrophilic due to its lower electronegativity,22 so that the intrinsic reactivity of a non-
activated aziridine (27) is likely lower than that of an epoxide. However, the aziridine-based 
ABPs have the advantage that the hydroxyl substituents are not used for the attachment of 
a tag and are therefore all available for making interactions with the active site of their 
target enzymes, potentially resulting in more tight binding and an increase in potency. In 
addition, it seems likely that the aziridine nitrogen will be protonated by the general 
acid/base residue in the active site, thereby strongly activating the aziridine towards 
nucleophilic ring-opening. Alkylated β-aziridine 27 can be derived from α-epoxide 29 (see 
Chapter 5) by opening of the epoxide with azido-PEG-amine 30, mesylation of the resulting 
hydroxyl group and subsequent treatment with base to achieve aziridine formation.23 A 
fluorophore or an affinity tag can then be introduced by copper(I)-catalyzed click reaction of 
the azide in 27 with an alkyne-functionalized tag. Sulfonylated aziridine 28 may be 
synthesized from deprotected aziridine 31 in a manner similar to the acylated aziridines 
described in Chapter 5 by selective reaction of the aziridine nitrogen with an activated ester 
of sulfonic acid 32 (e.g. an N-hydroxybenzotriazole ester).24     




Figure 8.6. Alkylated (27) and sulfonylated (28) β-galactopyranose-configured aziridines. 
Recently, a new method has been reported for the direct and mild conversion of olefins 
to N-H aziridines via a rhodium-catalyzed reaction with O-(2,4-dinitrophenyl) hydroxylamine 
(DPH) in trifluoroethanol.25 This reaction can be performed in the presence of various 
functional groups, including unprotected alcohols, and may offer a useful alternative 
strategy to synthesize aziridine-based glycosidase ABPs. For example, galactopyranose- and 
glucopyranose-configured aziridines 34-35 and 37-38 can be obtained in a single step from 
the appropriately substituted cyclohexene precursors (33 and 36, respectively) (Scheme 
8.2). This method would eliminate the need to first synthesize an epoxide or to form the 
aziridine with the aid of the primary hydroxyl group, procedures that were applied in 
Chapter 5. Although in general both diastereomeric aziridine products are formed, it seems 
likely that directing effects by the unprotected hydroxyl groups will affect the 
stereochemical outcome of the reaction. Hence, protection of one or more hydroxyl groups 
may be necessary to achieve formation of the desired α- and/or β-configured aziridines. 
 
Scheme 8.2 Proposed new strategy for aziridine formation during the synthesis of glycosidase ABPs 
 




The synthetic strategy towards the galactosidase probes that was developed in this 
thesis can also be applied to the synthesis of a number of differently configured probes. For 
example, α-N-acetylgalactopyranose-configured probes (39 and 40, Figure 8.7) may enable 
the selective targeting of α-N-acetylgalactosaminidase (αGal B), the deficiency of which is at 
the basis of the lysosomal storage disorder Schindler disease. Although this enzyme was 
targeted by the aziridine-based α-galactosidase probes described in Chapter 6, the labeling 
was not selective. In fact, it was demonstrated that these probes label αGal A more 
efficiently than αGal B. Since this latter enzyme binds α-linked N-acetylgalactosamine 
substrates with much higher efficiency than α-galactosides, it is likely that substitution of the 
hydroxyl group at C2 (carbohydrate numbering) in the ABPs with an acetylated amine will 
increase their selectivity for αGal B and might even completely abolish the labeling of αGal 
A. A proposed strategy towards the synthesis of these probes is depicted in Scheme 8.3 and 
involves the same synthetic route as was used for the galactosidase probes but starts from a 
differently configured and orthogonally protected aldehyde (43). This compound may be 
obtained by procedures similar to those described in literature,26 using D-ribose as the 
starting material to achieve the required stereochemistry.27 Aldol condensation with 
oxazolidinone 44, removal of the Evans template and ring-closing metathesis as described in 
Chapter 5 will lead to compound 45. Next, several protective group manipulations are 
necessary to selectively unmask the hydroxyl group at C2 (46), which can then be activated 
with triflic anhydride and substituted with TMS azide to yield compound 47. Reduction of 
the azide to an amine and subsequent acetylation may provide compound 48, from which 
the epoxide- and aziridine-based probes 39 and 40 can be synthesized.  
Other compounds that can be synthesized via a similar synthetic strategy are α-L-
fucopyranose-configured probes (41, Figure 8.7), which might enable the labeling of human 
retaining α-L-fucosidases. Epoxide-based inhibitors are also an option (42), but since the 
natural substrates of these enzymes lack a substituent at C6 the attachment of a tag at this 
position will likely not be tolerated, so that the tag would need to be introduced at a less 
straightforward position. The synthesis of probes 41 and 42 requires the use of the 
enantiomers of the starting materials that were used in Chapter 5, i.e. oxazolidinone 50 
  
 
Figure 8.7. Putative inhibitors and ABPs to target α-N-acetylgalactosaminidase (39, 40) and α-L-fucosidase (41, 42). 
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Scheme 8.3 Proposed route of synthesis towards building blocks 48 and 54 
 
Reagents and conditions: a) i) ZnBr2, DCM, ii) BzCl, pyridine, iii) BCl3, DCM; b) i) Tf2O, DMAP, pyridine, DCM, ii) 
TMSN3, TBAF, THF; c) i) Ph3P, H2O, THF, ii) Ac2O, pyridine; d) i) Ph3CCl, Et3N, DMAP, DMF, ii) BnBr, NaH, TBAI, DMF, 
iii) BF3.OEt2, MeOH/toluene; e) pTsCl, pyridine; f) LiAlH4, THF. 
derived from D-valine instead of L-valine and aldehyde 49, which can be obtained from L-
xylose instead of D-xylose (Scheme 8.3). Aldol condensation, removal of the Evans template 
and ring-closing metathesis should lead to compound 51, after which several protective 
group manipulations may afford tribenzylated compound 52. The free hydroxyl group can 
then be selectively activated by tosylation (53) and subsequently substituted with a hydride 
donor to provide 54, which serves as a basis for the synthesis of the α-L-fucopyranose-
configured inhibitors (41, 42). 
The absence of covalent interactions with a substrate in the catalytic mechanism of an 
enzyme of interest hampers the development of ‘classic’ ABPs that act via direct alkylation 
of the catalytically active amino acid residue. A possible solution is the use of suicide 
substrates, which are cleaved by the enzyme in the same manner as a natural substrate and 
consequently release a highly reactive species that can react with a nearby nucleophilic 
amino acid residue. This type of ABPs has for instance been applied to the activity-based 
profiling of a number of inverting glycosidases.28-31 Another possibility to label enzymes that 
do not form a covalent enzyme-substrate intermediate is the use of affinity-based probes 
(AfBPs), which also carry a (latent) reactive group but do not require activation by the 
catalytic machinery of the enzyme. Instead, these probes bind with high affinity to a specific 
site on the enzyme of interest and achieve labeling by non-specific covalent reaction of an 
amino acid residue with an electrophile or a photoreactive group in the AfBP.
32,33 Frequently 
used photoaffinity labels include aryl azides, benzophenones and diazirines, which are all 




wavelength and can subsequently crosslink to proximal amino acid residues. A limitation of 
the use of photoaffinity probes is the propensity of the activated molecules to react with 
water, so that the success of labeling strongly depends on the speed of crosslinking as well 
as on the ability of the probes to tightly bind their target enzymes. Since these probes do 
not bind in a mechanism-based manner, they are strictly no ‘true’ ABPs. Nonetheless, AfBPs 
can be valuable tools to examine the structural integrity of a target enzyme, for example if 
binding only occurs to an intact active site. Moreover, these probes can be useful to image 
the cellular localization and/or degradation of proteins and to identify the targets of drugs 
and inhibitors.33  
A class of enzymes that does not employ a catalytic nucleophile in the active site is that 
of the α-ketoglutarate dependent oxygenases, also named 2-oxoglutarate (2-OG) 
oxygenases.34-35 These enzymes catalyze the oxidation of C-H bonds in proteins, nucleotides, 
lipids and small molecules. This process results in hydroxylation of the substrates and can 
also lead to lysine demethylation. More than 60 different 2-OG oxygenases are known in 
humans and these are involved in a wide variety of cellular processes, including for example 
gene control, fatty acid metabolism and the response to hypoxia. The catalytic mechanism 
of 2-OG oxygenases involves an Fe(II) cofactor that is bound in the active site and in turn 
coordinates to the cosubstrate 2-OG (Figure 8.8A).35 Binding of a substrate and O2 results in 
oxidative decarboxylation of 2-OG with concomitant formation of CO2 and oxidation of the 
substrate. Since the cofactor and cosubstrate binding sites are highly conserved, these sites  
 
 
Figure 8.8. A) Catalytic mechanism of 2-OG oxygenases. B, C) Known 2-OG oxygenase inhibitors (55-57) and probes 
(58-59). D) Putative two-step photoaffinity probes for 2-OG oxygenases (60, 61). 
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form attractive targets for the development of broad-spectrum inhibitors or AfBPs. A 
number of reversible 2-OG oxygenase inhibitors has been reported in literature, including 
metal ions, substrate derivatives and analogues of 2-OG such as compounds 55-57 (Figure 
8.8B), which act via coordination to Fe(II) and competition with binding of 2-OG in the active 
site.36-40 The only probe that has been described so far for the labeling of this class of 
enzymes in complex biological samples is the hydroxyquinoline-based probe 58, which is 
derivatized with a biotin tag and an aryl azide as a photoaffinity label (Figure 8.8C).41 In the 
same study, the oxalylglycine derivative 59 proved to be only a very weak inhibitor of a small 
set of 2-OG oxygenases. Hence it appears that in this case the attachment of the relatively 
large photoreactive group and the biotin tag is not tolerated by the majority of 2-OG 
oxygenases, indicating that the modifications made to the 2-OG core should be sterically 
limited. The development of a two-step labeling probe may provide a means to enhance 
affinity by minimizing the steric bulk that is added to the probe scaffold and may also 
increase cell permeability. Therefore, two photoreactive 2-OG oxygenase probes were 
designed that are based on the structure of 2-OG integrated into a norbornene moiety for 
two-step labeling via tetrazine ligation (60 and 61, Figure 8.8D). A diazirine photoaffinity tag 
is included for crosslinking of the probe to target proteins and is added either directly onto 
the norbornene core (60) or via a short spacer (61). 
Several strategies have been explored to synthesize AfBPs 60 and 61. It was reasoned 
that 60 can be derived from compound 62 (Figure 8.9) by conversion of the ketone into a 
diazirine moiety via a previously reported procedure42 followed by deprotection and 
oxidation of the hydroxyl groups. Compound 61 can be obtained from 63 by 
functionalization of the hydroxyl group with a diazirine-containing spacer. These key building 
blocks may in turn be derived from for instance compound 64, with the hydroxyl groups 
orthogonally protected to enable separate oxidation steps, or from compound 65 in which 
an α-keto acid or ester would need to be installed prior to introduction of the diazirine 
moiety. Initial efforts to synthesize compounds 62 and 63 started with the Et2AlCl-catalyzed 
Diels-Alder reaction of silylated diene 67 and dienophile 66 (Scheme 8.4A), which gave a 
mixture of various diastereomers assumed to be the regio-isomers with the silyl group away   
  
 




from the other substituents (68a and 68b plus the corresponding endo/exo isomers). Next, 
cyclization of 68b with bromine was attempted in order to enable silver nitrate-induced 
desilylation of 69 and intramolecular rearrangement as described in literature (see below).43 
However, the acetonide was not stable towards treatment with bromine. Other conditions 
for bromocyclization of 68b, including hydrolysis of the ester with aqueous NaOH followed 
by reaction with N-bromosuccinimide, also failed to give the expected product (69).  
 
Scheme 8.4 Synthetic routes towards building blocks 62 and 63 
 
Reagents and conditions: a) Et2AlCl, toluene, -78 °C  rt, overnight, 68 86%, 72 quant.; b) Br2, pyridine, DCM, 0 °C 
 rt, 6 hrs; c) Br2, DCM, 0 °C  rt, 4.5 hrs, 83%; d) AgNO3, MeOH, 70 °C, 3.5 hrs, 68%; e) Me3SnOH, toluene, 100 °C, 
5 hrs, 83%; f) TBDMS-Cl, imidazole, DMF, rt, overnight, 76 28% or TrCl, DMAP, pyridine, 60 °C, 6 hrs, 77 <30%; g) 
Ac2O, DMAP, pyridine, 40 °C, 1.5 hrs, 65%; h) i) LDA, diethyl oxalate, THF/TMEDA, rt, overnight, ii) HCl, 100 °C, 5 hrs; 
j) i) (COCl)2, DMF, DCM, 0 °C  rt, 5 hrs, ii) CuCN, ACN, 90 °C, overnight; k) toluene, rt, 1 hr, 80%; l) KBr, NaOAc, 
AcOOH, AcOH, rt, 1.5 hrs or Hg(OTFA)2, AcOK, AcOH, AcOOH, 0 °C  rt, 4.5 hrs. 
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Taking into account the difficulties that were associated with the use of 66 as a starting 
material, resulting in the formation of complicated mixtures of Diels-Alder products 
including undesired compound 68a, a second strategy was designed starting from diethyl 
fumarate (71) (Scheme 8.4B). Diels-Alder reaction with silylated diene 67 gave Diels-Alder 
adduct 72 (plus its enantiomer) in quantitative yield. Treatment with bromine afforded 
compound 73, which was then reacted with silver nitrate in methanol to induce desilylation 
with concomitant opening of the lactone and intramolecular rearrangement,43 giving 
compound 74. Attempts to increase the yield of this reaction by using a longer reaction time 
resulted in transesterification of the ethyl ester to a methyl ester. Selective hydrolysis of the 
methyl ester in 74 with Me3SnOH gave 75, after which efforts were undertaken to protect 
the hydroxyl group by silylation or tritylation. Both procedures, however, proceeded slowly 
and gave low yields of products 76 and 77, respectively. Moreover, the main product 
isolated after reaction with TBDMS-Cl appeared to be disilylated (at the hydroxyl group and 
the carboxylic acid). Acetylation of 75, on the other hand, successfully afforded compound 
78, which corresponds to one of the potential building blocks shown in Figure 8.9 (65). The 
introduction of an α-keto acid was then attempted by Claisen condensation with diethyl 
oxalate followed by decarboxylation under acidic conditions (79). An alternative procedure 
involved the formation of an acid chloride and reaction with copper cyanide to give acyl 
cyanide 80, which can be hydrolyzed to an α-keto acid. Unfortunately, neither of these 
procedures proved to yield the desired products.  
Therefore, a third route of synthesis was designed in which an α-keto ester is already 
present in the starting material (81) (Scheme 8.4C). Since this procedure does not involve 
the bromocyclization and rearrangement steps as in routes A and B, a cyclopentadienyl-
silane reagent was synthesized in which one of the methyl substituents is replaced with a 
phenyl substituent (82) so that the silyl group can be oxidized to a hydroxyl group. Diels-
Alder reaction of 81 and 82 gave a mixture of products (presumably 83a and 83b and their 
enantiomers), which were subjected to several Fleming oxidation procedures. However, 
compounds 84a and 84b could not be isolated. The use of differently substituted silane 
reagents and/or the use of different oxidation conditions may provide a means to obtain the 
hydroxylated products 84a and 84b (which correspond to building block 63, Figure 8.9). 
Alternatively, synthetic route B also holds potential to synthesize the target compounds via 
selective reduction of the ethyl ester in 78 to an aldehyde, e.g. with DIBAL-H (which will 
likely also require the use of another hydroxyl protecting group). Stille reaction or Grignard 





Another promising option to synthesize putative AfBPs for 2-OG oxygenases is by making 
use of 5-methoxymethyl-cyclopenta-1,3-diene (85)44 as a starting material (Scheme 8.5). This 
compound contains a methoxymethyl substituent that acts as a latent attachment site for 
the photoreactive group, since it can be mildly converted into a hydroxyl group during a 
later stage of synthesis. As depicted in Scheme 8.5, the use of cyclopentadiene 85 would 
lead to probes 88a and 88b, the latter of which is structurally similar to compound 61 
(Figure 8.8D) except for the placement of the diazirine-containing linker: in probes 88a and 
88b an extra carbon atom is added between the norbornene core and the alkoxy 
substituent. The proposed synthetic strategy commences with Diels-Alder reaction of 
cyclopentadiene 85 with compound 81 to provide adducts 86a and 86b, with the 
hydroxymethyl group away from the (α-keto) ester substituents.45 In order to prevent 
isomerization of 85 to 1-methoxymethyl-1,3-cyclopentadiene, Et2AlCl can be used as a 
catalyst to accelerate the Diels-Alder reaction and to allow the reaction to proceed at low 
temperatures (see also Schemes 8.4A and 8.4B). Subsequently, demethylation of the 
hydroxymethyl group may be achieved by reaction with BBr3 in DCM and the methyl esters 
can be hydrolyzed under acidic conditions, procedures that have both been reported to 
proceed well in the presence of an α-keto moiety.46-47 The resulting compounds 87a and 87b 
contain the 2-OG motif as well as a primary hydroxyl group for further functionalization with 
a photoaffinity label. 
 
 
Scheme 8.5 Proposed strategy to synthesize AfBPs 88a and 88b 
 
Reagents and conditions: a) Et2AlCl, toluene, -78 °C  0 °C; b) i) BBr3, DCM, ii) HCl/H2O. 




The work described in this thesis provides novel approaches for the two-step profiling of 
enzymatic activity and for the simultaneous bioorthogonal labeling of multiple cellular 
targets, and presents novel probes for the activity-based profiling of two specific classes of 
enzymes, the retaining α- and β-galactosidases. Two-step labeling strategies are 
fundamental for enzymes that do not tolerate the attachment of a bulky reporter group 
onto an inhibitor scaffold. In addition, the application of ABPs for the imaging of enzymatic 
activity in vivo poses additional demands on the cell-permeability of the probes and may 
therefore necessitate the use of two-step ABPP strategies. At the same time there is an 
increasing interest in the use of tandem bioorthogonal ligation strategies that allow the 
monitoring of multiple targets simultaneously. Tandem labeling strategies such as those 
described in this thesis may provide valuable approaches to study multiple components 
involved in a particular biological processes or disease state at the same time. 
Originally, the development of ABPs was mainly directed towards a few classes of 
hydrolytic enzymes with well-defined catalytic mechanisms, including serine hydrolases and 
cysteine/threonine proteases.48 Nowadays, specific ABPs have also been developed for a 
variety of other enzyme classes including protein tyrosine phosphatases,49-51 
monooxygenases,52 monoamine oxidases,53 and carbohydrate processing enzymes.54 For 
those enzymes that do not make use of an active site nucleophile in their catalytic 
mechanism or that are not susceptible to targeting by ABPs for another reason, the use of 
AfBPs can provide a valuable alternative. Such probes have for instance proven successful for 
the labeling of metalloproteases, phosphatases, histone deacetylases, 2OG oxygenases and 
kinases.32 Although AfBPs do not label their target proteins in an activity-based manner, the 
careful design of a probe such that binding is dependent on the integrity of the active site 
may provide a means to monitor the functional state of an enzyme. As the field of ABPP is 
gradually moving towards the targeting of enzyme classes with different and sometimes 
poorly understood catalytic mechanisms, tight substrate specificity and/or low expression 
levels, continuing efforts are being made to generate novel strategies for the activity-based 
profiling of such difficult to target enzymes. This thesis presents a number of strategies that 
open up new opportunities for future research directions, both for the activity-based 
profiling of new enzyme classes as well as for the bioorthogonal labeling of enzymatic 








All reagents were commercial grade and were used as received unless stated otherwise. MeOH was obtained from 
Biosolve. Toluene, EtOAc and PetEt (Riedel-de Haën) used for column chromatography were of technical grade and 
distilled before use. DCE, DCM, DMF, and THF (Biosolve) were of analytical grade and when used under anhydrous 
conditions stored over flame-dried 4 Å molecular sieves. Reactions were monitored by TLC-analysis using DC-
alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254/366 nm), spraying with a solution of 20% 
H2SO4 in EtOH or a solution of (NH4)6Mo7O24∙4H2O (25 g/L) and (NH4)4Ce(SO4)4∙2H2O (10 g/L) in 10% aqueous sulfuric 
acid followed by charring at ~150 °C or by spraying with an aqueous solution of KMnO4 (7%) and K2CO3 (2%). 
Column chromatography was performed on silica gel (Screening Devices BV, 0.040 - 0.063 mm, 60 Å). LC/MS 
analysis was performed on an LCQ Adventage Max (Thermo Finnigan) ion-trap spectrometer (ESI+) coupled to a 
Surveyor HPLC system (Thermo Finnigan) equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 5μm particle size, 
Phenomenex). The applied buffers were A: H2O, B: ACN and C: 1 % aqueous TFA. Reported gradients represent the 
percentage of buffer B in buffer A with 10% buffer C. HRMS analysis was performed on an LTQ Orbitrap (Thermo 
Finnigan) mass spectrometer equipped with an electronspray ion source in positive mode (source voltage 3.5 kV, 
sheath gas flow 10 mL min−1, capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z 
= 150 - 2000) and dioctylphtalate (m/z = 391.28428) as a "lock mass". The high resolution mass spectrometer was 
calibrated prior to measurements with a calibration mixture (Thermo Finnigan). 1H- and 13C-APT-NMR spectra were 
recorded on a Brüker AV-400 (400/100MHz) instrument. Chemical shifts are given in ppm (δ) relative to the solvent 
peak or to tetramethylsilane as internal standard. Coupling constants (J) are given in Hz. All presented 13C-APT 
spectra are proton decoupled. Peak assignments are based on 2D 1H-COSY and 13C-HSQC NMR experiments.  
N-(Boc-6-aminohexanoyl)-4-(6-(2-pyrimidinyl)-1,2,4,5-tetrazin-3-yl)benzylamine (13) 
Boc-protected tetrazine 12 (0.50 mmol, 0.18 g) was treated with TFA/DCM (1/1, v/v) for 15 min and then 
concentrated in vacuo in the presence of toluene. The residue was dissolved in DCE/DMF under argon atmosphere 
and DiPEA (1.0 mmol, 0.17 mL, 2.0 eq.) and Boc-6-Ahx-OSu (0.50 mmol, 0.16 g, 1.0 eq.) were added. The reaction 
mixture was stirred at room temperature overnight before being concentrated in vacuo. The crude product was 
purified by column chromatography (DCM → 2% MeOH in DCM), followed by recrystallization from DCM/n-hexane 
to yield Boc-Ahx-tetrazine 13 as purple crystals (0.21 g, 0.44 mmol, 88%).1H NMR (400 MHz, CDCl3): δ (ppm) 9.15 (d, 
J = 4.9 Hz, 2H), 8.70 (dd, J = 8.3, 1.3 Hz, 2H), 7.61 (t, J = 4.9 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), 6.19 (d, J = 7.4 Hz, 1H), 
4.61-4.59 (m, 3H), 3.15-3.11 (m, 2H), 2.31 (t, J = 7.5 Hz, 2H), 1.79-1.71 (m, 2H), 1.55-1.48 (m, 2H), 1.44 (s, 9H), 1.43-
1.35 (m, 2H). 13C NMR: (100 MHz, CDCl3): δ (ppm) 172.95, 164.28, 163.08, 159.57, 158.41, 156.04, 144.43, 130.38, 
129.15, 128.57, 122.50, 79.11, 43.23, 40.30, 36.49, 29.80, 28.43, 26.40, 25.25. LC/MS analysis: Rt 6.9 min (linear 
gradient 10 → 90% B in 15 min), m/z 479.0 [M+H]+, 379.2 [M-Boc+H]+, 957.2 [2M+H]+. HRMS: calcd. for 
[C24H31N8O3]+ 479.25136, found 479.25184; calcd. for [C24H30N8O3Na]+ 501.23331, found 501.23367. 
N-Boc-2-(2-(2-amino-N-(1-heptyn-7-oyl)ethoxy)ethoxy)ethylamine (15) 
Boc-protected compound 1414 (1.9 mmol, 0.53 g) was dissolved in THF and triphenylphosphine (2.3 mmol, 0.60 g, 
1.2 eq.) was added. The reaction mixture was stirred overnight at room temperature, before a few drops of H2O 
were added. After stirring for an additional 2 hrs, toluene was added and the mixture was extracted with H2O. The 
aqueous layer was washed with toluene and the combined organic layers were again extracted with H2O until no 
more product was detected in the organic phase. The combined aqueous layers were concentrated in vacuo to give 
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the monoprotected PEG-diamine. A solution of 6-heptynoic acid (1.9 mmol, 0.24 mL, 1.0 eq.) in toluene was put 
under argon atmosphere, after which oxalyl chloride (2.9 mmol, 0.25 mL, 1.5 eq.) and one drop of DMF were 
added. After stirring for 3 hours at room temperature, the mixture was concentrated in vacuo and coevaporated 
with toluene (3x). The acyl chloride was then redissolved in DCE under argon atmosphere, neutralized with DiPEA 
(2.9 mmol, 0.50 mL, 1.5 eq.) and added to the crude PEG-amine. The mixture was stirred overnight at room 
temperature, quenched with MeOH and concentrated in vacuo. Purification by column chromatography (30% 
EtOAc in PetEt  EtOAc) yielded alkyne-functionalized PEG spacer 15, contaminated with some triphenylphosphine 
oxide (0.37 g, ~1.0 mmol, 54% over two steps). This product was used without further purification for the next step. 
LC/MS analysis: Rt 6.7 min (linear gradient 10 → 90% B in 15 min), m/z 356.9 [M+H]+, 257.2 [M-Boc+H]+, 379.1 
[M+Na]+. HRMS: calcd. for [C18H33N2O5]+ 357.23840, found357.23855; calcd. for [C18H32N2O5Na]+ 379.22034, found 
379.22042. 
N-biotin-2-(2-(2-amino-N-(1-heptyn-7-oyl)ethoxy)ethoxy)ethylamine (16) 
Boc-protected compound 15 (0.60 mmol, 0.21 g) was treated with TFA/DCM (1/1, v/v) for 20 min and then 
concentrated in vacuo in the presence of toluene. The residue was dissolved in DCE/DMF (1/1, v/v) under argon 
atmosphere and DiPEA (1.2 mmol, 0.21 mL, 2.0 eq.) and biotin-OSu (0.60 mmol, 0.20 g, 1.0 eq.) were added. The 
reaction mixture was stirred at room temperature overnight before being concentrated in vacuo. The crude 
product was purified by column chromatography (DCM → 10% MeOH in DCM). To remove final impurities, the 
product was redissolved in DCM and washed with H2O (2x), after which the combined aqueous layers were 
extracted with DCM/MeOH (9/1, v/v) until no more product was detected in the aqueous phase. The combined 
organic layers were dried over MgSO4, filtered and evaporated in vacuo to give alkyne-functionalized and biotin-
tagged PEG spacer 16 (0.25 g, 0.52 mmol, 87%). 1H NMR (400 MHz, MeOD): δ (ppm) 4.52 (ddd, J = 7.9, 5.0, 1.0 Hz, 
1H), 4.33 (dd, J = 7.9, 4.5 Hz, 1H), 3.65 (s, 4H), 3.57 (dt, J = 5.6, 1.1 Hz, 4H), 3.39 (t, J = 5.5 Hz, 4H), 3.23 (ddd, J = 8.8, 
5.9, 4.5 Hz, 1H), 2.95 (dd, J = 12.8, 5.0 Hz, 1H), 2.73 (d, J = 12.7 Hz, 1H), 2.27-2.18 (m, 6H), 1.84-1.37 (m, 11H). 13C 
NMR (100 MHz, MeOD): δ (ppm) 174.75, 174.61, 164.70, 83.28, 69.90, 69.22, 68.40, 61.97, 60.23, 55.60, 39.65, 
38.89, 35.34, 35.07, 28.37, 28.10, 27.80, 25.44, 24.70, 17.40. LC/MS analysis: Rt 5.0 min (linear gradient 10 → 90% B 
in 15 min), m/z 483.3 [M+H]+, 965.1 [2M+H]+. HRMS: calcd. for [C23H39N4O5S]+ 483.26357, found 483.26329; calcd. 
for [C23H38N4O5SNa]+ 505.24551, found 505.24477. 
Biotinylated levulinoyl linker 17 
Azide-modified levulinoyl derivative 1813 (0.50 mmol, 0.24 g) and biotin-tagged alkyne 16 (0.50 mmol, 0.24 g, 1.0 
eq.) were dissolved in tBuOH/toluene/H2O (2/2/1, v/v/v) (10 mL). Copper(II)sulphate pentahydrate (50 µmol, 1 mL 
50 mM in H2O, 0.1 eq.) and sodium ascorbate (75 µmol, 1 mL 75 mM in H2O, 0.15 eq.) were added, followed by a 
few drops of DMF until the mixture became clear. The reaction mixture was heated to 80 °C and stirred overnight, 
before being concentrated in vacuo. The product was purified by column chromatography (DCM/acetone/MeOH, 
8/2/0 (v/v/v)  6.5/2/1.5 (v/v/v)), redissolved in DCM and washed with H2O, upon which the biotinylated levulinoyl 
linker 17 precipitated from the organic phase as white crystals (0.29 g, 0.30 mmol, 60%). 1H NMR (400 MHz,CDCl3): 
δ (ppm) 7.34 (s, 1H), 6.96 (s, 2H), 6.89 (bs, 1H), 6.71 (bs, 1H), 6.63 (bs, 1H), 5.86 (bs, 1H), 4.49 (d, J = 7.0 Hz, 1H), 
4.33-4.31 (m, 3H), 3.64-3.53 (m, 8H), 3.44-3.42 (m, 4H), 3.14-3.13 (m, 1H), 2.97-2.62 (m, 12H), 2.55-2.50 (m, 4H), 
2.24-2.15 (m, 6H), 1.81-1.60 (m, 8H), 1.43 (s, 11H), 1.17 (d, J = 6.9 Hz, 12H). 13C NMR (100 MHz,CDCl3): δ (ppm) 
207.22, 173.46, 173.28, 172.34, 171.69, 164.18, 143.74, 140.12, 138.76, 123.81, 121.11, 80.31, 70.07, 70.01, 69.94, 
69.85, 63.85, 61.80, 60.27, 55.63, 48.98, 40.45, 39.16, 39.11, 38.81, 37.06, 37.00, 36.06, 35.91, 31.00, 29.68, 28.81, 
28.20, 28.08, 27.72, 27.43, 25.57, 25.22, 25.12, 24.24. LC/MS analysis: Rt 8.8 min (linear gradient 10 → 90% B in 15 
min), m/z 956.5 [M+H]+. HRMS: calcd. for [C49H78N7O10S]+ 956.55254, found 956.55331; calcd. for [C49H77N7O10SNa]+ 





tBu-protected compound 17 (50 µmol, 48 mg) was treated with TFA/DCM (1/1, v/v) for 30 min and then 
concentrated in vacuo in the presence of toluene. Boc-protected tetrazine 13 (0.10 mmol, 48 mg, 2.0 eq.) was also 
treated with TFA/DCM (1/1, v/v) for 20 min and then concentrated in vacuo in the presence of toluene. The residue 
was dissolved in DCE/DMF under argon atmosphere, added to the deprotected levulinoyl acid and the mixture was 
neutralized with DiPEA (0.2 mmol,33 µL, 4.0 eq.). After addition of HCTU (0.15 mmol, 62 mg, 3.0 eq.), the reaction 
mixture was stirred at room temperature overnight. The mixture was then washed with H2O, the aqueous layers 
was extracted with DCM (2x) and the combined organic layers were dried over MgSO4, filtered and concentrated in 
vacuo. Purification by column chromatography (DCM → 10% MeOH in DCM) followed by recrystallization from 
DCM/PetEt yielded biotin-levulinoyl-tetrazine 11 as a purple powder (44 mg,35 µmol, 70%).1H NMR (400 MHz, 
CDCl3): δ (ppm) 9.12 (d, J = 4.9 Hz, 2H), 8.64 (d, J = 8.0 Hz, 2H), 7.60 (t, J = 4.9 Hz, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.32 (s, 
1H), 7.04-6.92 (m, 4H), 6.89 (t, J = 5.6 Hz, 1H), 6.45 (s, 1H), 6.20 (t, J = 5.8 Hz, 1H), 5.77 (s, 1H), 4.55 (d, J = 5.9 Hz, 
2H), 4.46 (dd, J = 7.9, 4.8 Hz, 1H), 4.32-4.26 (m, 3H), 3.57-3.52 (m, 8H), 3.41-3.40 (m, 4H), 3.20 (q, J = 6.7 Hz, 2H), 
3.11 (d, J = 4.7 Hz, 1H), 2.98-2.56 (m, 12H), 2.52-2.44 (m, 4H), 2.28 (t, J = 7.5 Hz, 2H), 2.21-2.13 (m, 6H), 1.70-1.65 
(m, 10H), 1.52-1.28 (m, 6H), 1.14 (d, J = 6.9 Hz, 12H). 13C NMR (100 MHz,CDCl3): δ (ppm) 207.35, 173.52, 173.39, 
173.35, 172.43, 171.84, 164.29, 164.01, 163.02, 159.47, 158.40, 147.81, 144.82, 143.77, 140.23, 139.06, 130.15, 
129.01, 128.49, 123.80, 122.57, 121.23, 70.06, 70.01, 69.91, 69.84, 61.75, 60.20, 55.58, 48.92, 43.09, 40.45, 39.17, 
39.15, 39.10, 38.77, 38.47, 36.92, 36.20, 35.98, 35.84, 31.75, 29.68, 29.14, 28.74, 28.14, 28.03, 27.77, 27.42, 26.39, 
25.55, 25.11, 25.09, 24.22. LC/MS analysis: Rt 6.9 min (linear gradient 10 → 90% B in 15 min), m/z 1260.8 [M+H]+, 
631.1 [M+H]2+. HRMS: calcd. for [C64H90N15O10S]+ 1260.67103, found 1260.67164; calcd. for [C64H89N15O10SNa]+ 
1282.65298, found 1282.65323. 
Ethyl 3-(2,2-dimethyl-1,3-dioxolan-4-yl)-7-(trimethylsilyl)bicyclo[2.2.1]hept-5-ene-2-carboxylate (68) 
Compound 66 (5.0 mmol, 0.98 mL) was dissolved in toluene and cooled to -78 °C under argon atmosphere, before 
Et2AlCl (5.0 mmol, 2.8 mL 1.8 M in toluene, 1.0 eq.) was added. After stirring for 15 min at -78 °C, cyclopenta-2,4-
dien-1-yltrimethylsilane (67) (10 mmol, 1.7 mL, 2.0 eq.) was added dropwise and the reaction mixture was stirred 
overnight while allowing the temperature to slowly rise to room temperature. The reaction was then quenched 
with saturated aqueous NaHCO3, the aqueous layer was extracted with Et2O (2x) and the combined organic layers 
were dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (PetEt  1.5% 
acetone in PetEt) gave Diels-Alder adduct 68 in two separate fractions with mixtures of 3 and 2 diastereomers, 
respectively (1st fraction: 1.4 g, 4.1 mmol, 81%; 2nd fraction: 78 mg, 0.23 mmol, 5%). 1H NMR (400 MHz, CDCl3) 
fraction 1 (3 diastereomers): δ (ppm) 6.25-6.16 (m, 1Ha+1Hb), 6.16-6.08 (m, 2Hc), 5.93 (dd, J = 5.6, 2.7 Hz, 1Ha), 
5.91-5.87 (m, 1Hb), 4.20-3.87 (m, 4Ha+4Hb+3Hc), 3.79-3.60 (m, 1Ha+1Hb+1Hc), 3.47 (dtd, J = 10.6, 5.6, 2.5 Hz, 1Hc), 
3.24 (bs, 1Hb), 3.22-3.17 (m, 1Ha), 3.18-3.10 (m, 1Hc), 3.08 (bs, 1Hc), 3.06-2.99 (m, 1Ha), 2.88 (q, J = 3.3, 2.5 Hz, 
1Hb), 2.56 (d, J = 3.0 Hz, 1Hb), 2.45-2.35 (m, 1Ha+1Hc), 2.02 (ddd, J = 7.1, 4.5, 2.1 Hz, 1Hb), 1.97-1.88 (m, 1Ha), 1.68 
(dd, J = 5.0, 2.0 Hz, 1Hc), 1.44 (s, 3Ha+3Hb+3Hc), 1.40 (s, 3Ha+3Hb+3Hc), 1.36 (m, 1Ha+1Hb+1Hc), 1.35-1.19 (m, 
3Ha+3Hb+3Hc), -0.02--0.16 (m, 9Ha+9Hb+ 9Hc). 1H NMR (400 MHz, CDCl3) fraction 2 (2 diastereomers): δ (ppm) 
6.20 (ddd, J = 8.1, 5.5, 3.2 Hz, 1Ha+1Hb), 5.97-5.92 (m, 1Ha), 5.90 (dd, J = 5.6, 2.8 Hz, 1Hb), 4.14-4.04 (m, 3Ha+3Hb), 
4.04-3.93 (m, 1Ha+1Hb), 3.80-3.68 (m, 1Ha+1Hb), 3.28-3.23 (m, 1Hb), 3.21 (tdq, J = 2.7, 1.8, 1.0 Hz, 1Ha), 3.02 (t, J = 
2.1 Hz, 1Ha), 2.89 (t, J = 4.0 Hz, 1Hb), 2.60-2.55 (m, 1Hb), 2.41 (dd, J = 4.7, 3.5 Hz, 1Ha), 2.03 (dd, J = 7.9, 4.4 Hz, 
1Hb), 1.91 (dd, J = 8.9, 4.8 Hz, 1Ha), 1.44 (s, 3Ha+3Hb), 1.39 (bs, 3Ha+4Hb), 1.36-1.33 (m, 1Ha), 1.24 (t, J = 7.1 Hz, 
3Ha+3Hb), -0.04--0.09 (m, 9Ha+9Hb). 13C NMR (100 MHz,CDCl3) fraction 1: δ (ppm) 175.40, 175.06, 173.58, 137.92, 
137.64, 136.01, 135.35, 133.44, 133.41, 109.05, 108.94, 108.81, 79.64, 79.44, 79.21, 69.03, 68.70, 68.63, 60.55, 
60.35, 60.14, 50.72, 50.46, 49.82, 49.73, 49.20, 48.99, 48.95, 48.72, 48.66, 48.60, 48.45, 48.22, 48.09, 47.53, 47.50, 
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47.19, 26.96, 26.79, 26.72, 25.94, 25.88, 25.72, 14.27, 14.23, 14.20, -0.18, -0.23. 13C NMR (100 MHz,CDCl3) fraction 
2: δ (ppm) 173.96, 173.63, 144.61, 137.94, 133.45, 122.42, 109.09, 108.97, 79.66, 79.46, 69.04, 68.64, 60.39, 60.17, 
49.84, 49.23, 49.01, 48.73, 48.67, 48.62, 48.47, 48.12, 47.55, 47.52, 26.80, 26.73, 25.95, 25.73, 14.28, 14.24, -0.18, -
0.23. LC/MS analysis: fraction 1: Rt 7.7, 7.8 and 8.3 min (linear gradient 10 → 90% B in 15 min), m/z 338.9 [M+H]+, 
299.0 [M-acetonide+H]+; fraction 2: Rt 7.8 and 8.0 min (linear gradient 10 → 90% B in 15 min), m/z 338.8 [M+H]+, 
299.0 [M-acetonide+H]+. 
(1R,2S,3S,4S,7R)-diethyl 7-(trimethylsilyl)bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate and (1R,2R,3R,4S,7R)-diethyl 
7-(trimethylsilyl)bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate (72) 
Diethyl fumarate (71) (10 mmol, 1.7 mL) was dissolved in toluene (10 mL) and cooled to -78 °C under argon 
atmosphere, before Et2AlCl (10 mmol, 5.6 mL 1.8 M in toluene, 1.0 eq.) was added. After stirring for 15 min at -78 
°C, cyclopenta-2,4-dien-1-yltrimethylsilane (67) (20 mmol, 3.3 mL, 2.0 eq.) was added dropwise and the reaction 
mixture was stirred overnight while allowing the temperature to slowly rise to room temperature. The reaction was 
then quenched with saturated aqueous NaHCO3, the aqueous layer was extracted with Et2O (3x) and the combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography 
(PetEt  2% EtOAc in PetEt) gave Diels-Alder adduct 72 (3.1 g, 10 mmol, quant.). 1H NMR (400 MHz, CDCl3): δ (ppm) 
6.16 (dd, J = 5.7, 3.1 Hz, 1H), 5.94 (dd, J = 5.6, 2.8 Hz, 1H), 4.23-4.09 (m, 2H), 4.09-4.03 (m, 2H), 3.34 (t, J = 3.9 Hz, 
1H), 3.31-3.26 (m, 1H), 3.13 (d, J = 3.1 Hz, 1H), 2.71-2.66 (m, 1H), 1.32-1.14 (m, 7H), -0.07--0.17 (m, 9H). 13C NMR 
(100 MHz,CDCl3): δ (ppm) 174.32, 172.93, 136.95, 134.32, 60.54, 60.26, 50.61, 49.95, 49.17, 48.89, 48.45, 14.10, -
0.50. 
(1S,2S,3S,7S,8S,9S)-ethyl 2-bromo-5-oxo-8-(trimethylsilyl)-4-oxatricyclo[4.2.1.03,7]nonane-9-carboxylate and 
(1R,2R,3R,7R,8R,9R)-ethyl 2-bromo-5-oxo-8-(trimethylsilyl)-4-oxatricyclo[4.2.1.03,7]nonane-9-carboxylate (73) 
Compound 72 (25 mmol, 7.8 g) was dissolved in DCM under argon atmosphere and cooled to 0 °C. Bromine (50 
mmol, 2.6 mL, 2.0 eq.) was added and the reaction mixture was stirred at 0 °C for 40 min and then at room 
temperature for 4 hrs, before being quenched with saturated aqueous NaHCO3. The aqueous layer was extracted 
with DCM (3x) and the combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
Purification by column chromatography (PetEt  8% EtOAc in PetEt) gave bromo-functionalized compound 73 (7.5 
g, 21 mmol, 83%). 1H NMR (400 MHz, CDCl3): δ (ppm) 4.92 (d, J = 4.7 Hz, 1H), 4.26-4.11 (m, 2H), 3.78 (d, J = 2.1 Hz, 
1H), 3.27 (t, J = 4.6 Hz, 1H), 3.11-3.01 (m, 2H), 2.79 (d, J = 2.1 Hz, 1H), 1.35-1.30 (m, 1H), 1.26 (t, J = 7.2 Hz, 3H), 0.19 
(s, 9H). 13C NMR (100 MHz,CDCl3): δ (ppm) 177.34, 170.38, 88.02, 61.86, 53.12, 52.50, 52.32, 49.04, 42.45, 36.98, 
14.17, 0.32. 
(1R,2S,3S,4S,7R)-2-ethyl 3-methyl 7-(hydroxy)bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate and (1R,2R,3R,4S,7S)-2-
methyl 3-ethyl 7-(hydroxy)bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate (74) 
To a solution of bromo-functionalized compound 73 (1.0 mmol, 0.36 g) in MeOH (10 mL) under argon atmosphere 
was added AgNO3 (5.0 mmol, 0.84 g, 5.0 eq.) and the reaction mixture was stirred at 70 °C for 3.5 hrs. The mixture 
was then filtered, concentrated in vacuo and redissolved in EtOAc. After addition of H2O, the layers were separated 
and the aqueous layer was extracted with EtOAc (3x). The combined organic layers were dried over MgSO4, filtered 
and concentrated in vacuo. The crude product was purified by column chromatography (10% EtOAc in PetEt  50% 
EtOAc in PetEt) to yield alcohol 74 (0.16 g, 0.68 mmol, 68%). 1H NMR (400 MHz, CDCl3): δ (ppm) 6.23 (dt, J = 4.5, 2.3 
Hz, 1H), 5.95 (dd, J = 6.3, 3.2 Hz, 1H), 4.15 (qd, J = 7.1, 2.4 Hz, 2H), 4.03 (bs, 1H), 3.81-3.72 (m, 4H), 3.58 (t, J = 4.5 
Hz, 1H), 3.13 (td, J = 3.4, 1.6 Hz, 1H), 3.11-3.03 (m, 1H), 2.82 (d, J = 5.0 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (100 
MHz,CDCl3): δ (ppm) 175.87, 173.81, 135.63, 132.73, 83.80, 60.82, 52.27, 50.38, 49.79, 45.89, 45.51, 14.08. LC/MS 




(1R,2S,3S,4S,7R)-2-ethyl 7-(hydroxy)bicyclo[2.2.1]hept-5-ene-2-carboxylate-3-carboxylic acid and (1R,2R,3R,4S, 
7S)-3-ethyl 7-(hydroxy)bicyclo[2.2.1]hept-5-ene-3-carboxylate-2-carboxylic acid (75) 
Diester 74 (1.2 mmol, 0.29 g) and Me3SnOH (1.4 mmol, 0.46 g, 1.2 eq.) were dissolved in toluene and stirred at 100 
°C for 5 hrs. The mixture was then cooled to room temperature, washed with 1 M HCl and the aqueous layer was 
extracted with EtOAc (6x). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by column chromatography (PetEt  50% EtOAc in PetEt) to yield monoester 75 
(0.23 g, 1.0 mmol, 83%). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.44 (bs, 1H), 6.21-6.10 (m, 1H), 5.94-5.86 (m, 1H), 4.09 
(q, J = 7.2 Hz, 2H), 3.74 (t, J = 1.9 Hz, 1H), 3.59 (t, J = 4.3 Hz, 1H), 3.10 (dd, J = 3.7, 1.8 Hz, 1H), 3.03 (td, J = 3.6, 1.8 
Hz, 1H), 2.78 (d, J = 4.7 Hz, 1H), 1.21 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz,CDCl3): δ (ppm) 179.30, 174.00, 135.63, 
132.97, 83.61, 60.96, 50.06, 50.00, 45.98, 45.47, 14.20. 
(1R,2S,3S,4S,7R)-2-ethyl 7-((tert-butyl-dimethyl-silyl)hydroxy)bicyclo[2.2.1]hept-5-ene-2-carboxylate-3-carbo-
xylic acid and (1R,2R,3R,4S,7S)-3-ethyl 7-((tert-butyl-dimethyl-silyl)hydroxy)bicyclo[2.2.1]hept-5-ene-3-
carboxylate-2-carboxylic acid (76) 
Compound 75 (0.53 mmol, 0.12 g) was dissolved in DMF under argon atmosphere, after which imidazole (0.80 
mmol, 54 mg, 1.5 eq.) and TBDMS-Cl (0.66 mmol, 99 mg, 1.3 eq.) were added. The reaction mixture was stirred at 
room temperature overnight, diluted with H2O and extracted with EtOAc (3x). The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. Purification by column chromatography (PetEt  2% EtOAc 
in PetEt  50% EtOAc in PetEt) gave monosilylated compound 76 (50 mg, 0.15 mmol, 28%) as well as disilylated 
byproduct (0.10 g, 0.22 mmol, 42%). 1H NMR (400 MHz, CDCl3) 76: δ (ppm) 6.18 (ddd, J = 6.3, 3.6, 1.1 Hz, 1H), 5.92 
(ddd, J = 6.3, 3.2, 1.0 Hz, 1H), 4.18-4.03 (m, 2H), 3.73-3.64 (m, 2H), 3.12 (dd, J = 3.6, 1.8 Hz, 1H), 2.93 (td, J = 3.5, 1.6 
Hz, 1H), 2.80 (d, J = 4.4 Hz, 1H), 1.24 (t, J = 7.1 Hz, 3H), 0.83 (s, 9H), 0.04 (s, 3H), 0.01 (s, 3H). 13C NMR (100 MHz, 
CDCl3) 76: δ (ppm) 179.54, 174.04, 135.29, 132.87, 84.30, 60.62, 50.72, 50.55, 46.31, 44.89, 25.50, 14.26, -5.11, -
5.30. 1H NMR (400 MHz, CDCl3) disilylated product: δ (ppm) 6.23-6.15 (m, 1H), 5.88-5.83 (m, 1H), 4.09 (dd, J = 7.1, 
2.7 Hz, 2H), 3.67-3.57 (m, 2H), 3.03 (dd, J = 3.7, 1.8 Hz, 1H), 2.88 (dt, J = 3.8, 1.8 Hz, 1H), 2.73 (d, J = 5.1 Hz, 1H), 1.21 
(t, J = 7.1 Hz, 3H), 0.89 (s, 9H), 0.84 (s, 9H), 0.24 (s, 3H), 0.23 (s, 3H), 0.03 (s, 3H), 0.01 (s, 3H). 13C NMR (100 MHz, 
CDCl3) disilylated product: δ (ppm) 174.33, 172.90, 135.85, 132.21, 84.52, 60.42, 50.99, 50.11, 48.10, 44.72, 25.80, 
25.44, 18.08, 17.53, 14.26, -4.69, -4.80, -5.00, -5.02. LC/MS analysis: 76: Rt 10 min (linear gradient 10 → 90% B in 15 
min), m/z 340.9 [M+H]+; disilylated product: Rt 14 min (linear gradient 10 → 90% B in 15 min), m/z 455.0 [M+H]+. 
(1R,2S,3S,4S,7R)-2-ethyl 7-((trityl)hydroxy)bicyclo[2.2.1]hept-5-ene-2-carboxylate-3-carboxylic acid and (1R,2R, 
3R,4S,7S)-3-ethyl 7-((trityl)hydroxy)bicyclo[2.2.1]hept-5-ene-3-carboxylate-2-carboxylic acid (77) 
Compound 75 (0.44 mmol, 0.10 g) was dissolved in pyridine under argon atmosphere, after which TrCl (0.88 mmol, 
0.24 g, 2.0 eq.) and DMAP (88 µmol, 11 mg, 0.2 eq.) were added. The reaction mixture was stirred at 60 °C for 6 hrs, 
allowed to cool temperature and quenched with MeOH. Next, H2O was added and the mixture was extracted with 
EtOAc (5x). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. After 
purification by column chromatography (PetEt/EtOAc 1/0  6/4) a mixture of product 77 and starting material 75 
(ratio 3:7) was obtained that was not further purified. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.45-7.39 (m, 6H 77), 
7.32-7.20 (m, 9H 77), 6.21 (dd, J = 6.2, 3.5 Hz, 1H 75), 6.05 (dd, J = 6.2, 3.6 Hz, 1H 77), 5.95 (dd, J = 6.1, 3.2 Hz, 1H 
75), 5.73 (dt, J = 6.2, 3.0 Hz, 1H 77), 4.18-4.09 (m, 2H 75 + 2H 77), 3.83-3.72 (m, 1H 75 + 1H 77), 3.71-3.66 (m, 1H 
77), 3.65-3.61 (m, 1H 75), 3.57-3.52 (m, 1H 77), 3.15-3.05 (m, 2H 75), 2.84 (d, J = 4.8 Hz, 1H 75), 2.77 (d, J = 4.9 Hz, 
1H 77), 2.69 (d, J = 3.5 Hz, 1H 77), 1.30-1.21 (m, 3H 75 + 3H 77). 
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(1R,2S,3S,4S,7R)-2-ethyl 7-((acetyl)hydroxy)bicyclo[2.2.1]hept-5-ene-2-carboxylate-3-carboxylic acid and (1R,2R, 
3R,4S,7S)-3-ethyl 7-((acetyl)hydroxy)bicyclo[2.2.1]hept-5-ene-3-carboxylate-2-carboxylic acid (78) 
Compound 75 (0.20 mmol, 45 mg) was dissolved in pyridine under argon atmosphere, after which Ac2O (0.40 mmol, 
40 µL, 2.0 eq.) and DMAP (20 µmol, 2.4 mg, 0.1 eq.) were added. The reaction mixture was stirred at 40 °C for 1.5 
hrs and then allowed to cool temperature. Next, H2O was added and the mixture was extracted with DCM (3x). The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. Purification by column 
chromatography (PetEt  25% EtOAc in PetEt) gave acetylated product 78 (35 mg, 0.13 mmol, 65%).1H NMR (400 
MHz, CDCl3): δ (ppm) 6.28 (ddd, J = 6.2, 3.6, 1.1 Hz, 1H), 6.02 (ddd, J = 6.2, 3.3, 0.9 Hz, 1H), 4.54 (t, J = 2.0 Hz, 1H), 
4.16 (q, J = 7.2 Hz, 2H), 3.63 (t, J = 4.3 Hz, 1H), 3.40 (dt, J = 4.5, 1.5 Hz, 1H), 3.27 (dq, J = 4.5, 1.6 Hz, 1H), 2.94 (d, J = 
4.6 Hz, 1H), 1.96 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ (ppm) 178.53, 172.89, 169.91, 135.21, 
132.76, 83.20, 60.99, 47.63, 47.45, 46.01, 45.03, 20.70, 14.19. 
Cyclopenta-2,4-dien-1-yl-dimethylphenylsilane (82) 
Freshly distilled cyclopentadiene (20 mmol, 1.7 mL) was dissolved in THF under argon atmosphere and cooled to -
78 °C, before n-BuLi (20 mmol, 13 mL 1.6 M in hexanes, 1.0 eq.) was added. The reaction mixture was stirred at -78 
°C for 20 min, then at 0 °C for 40 min and then cooled back to -78 °C. Me2PhSiCl (20 mmol, 3.5 mL, 1.0 eq.) was 
added and the reaction mixture was stirred overnight while the temperature was allowed to rise to room 
temperature. After concentrating the solvents in vacuo, H2O was added and the mixture was extracted with Et2O 
(5x). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. Half of the crude 
product (82) was then purified by column chromatography (pentane) and used directly for the next step (0.2 g, 1.0 
mmol, 10%). 
Dimethyl 7-(dimethylphenylsilyl)bicyclo[2.2.1]hept-5-ene-3-(2-oxoacetylate)-2-carboxylate and dimethyl 7-
(dimethylphenylsilyl)bicyclo[2.2.1]hept-5-ene-2-(2-oxoacetylate)-3-carboxylate (83) 
Diester 8155 (0.5 mmol, 86 mg) and silane 82 (1.0 mmol, 0.2 g, 2.0 eq.) were dissolved in toluene and stirred at 
room temperature for 1 hr, before being concentrated in vacuo. Purification by column chromatography (pentane 
 10% EtOAc in pentane) gave Diels-Alder adduct 83 (0.15 g, 0.40 mmol, 80%) as a mixture of 2 isomers (ratio 3:2). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.60-7.23 (m, 5Ha + 5Hb), 6.32-6.24 (m, 1Hb), 6.18 (t, J = 4.2 Hz, 1Ha), 6.11-6.03 
(m, 1Hb), 5.93-5.79 (m, 1Ha), 4.05 (t, J = 4.2 Hz, 1Ha), 3.96-3.80 (m, 3Ha + 3Hb), 3.73 (s, 3Ha), 3.66 (s, 3Hb), 3.58-
3.45 (m, 1Ha + 2Hb), 3.44-3.30 (m, 1Hb), 3.32-3.22 (m, 1Ha + 1Hb), 2.83 (d, J = 4.5 Hz, 1Ha), 1.77-1.67 (m, 1Ha), 
1.44-1.34 (m, 1Hb), 0.32-0.19 (m, 6Ha + 6Hb). 13C NMR (100 MHz, CDCl3): δ (ppm) 193.48, 192.40, 174.43, 173.07, 
161.67, 160.58, 138.85, 138.70, 137.60, 136.85, 135.53, 133.98, 133.63, 133.62, 128.93, 127.77, 55.44, 53.66, 
53.12, 53.01, 52.19, 51.89, 51.02, 50.63, 49.55, 49.46, 48.87, 48.25, 47.75, 47.12, -1.36, -1.47. 
B. Biochemistry 
General 
HEK-293T cells were cultured in DMEM supplemented with 10% (v/v) FCS, 10 units/mL penicillin and 10 μg/mL 
streptomycin in a 5% CO2 humidified incubator at 37 °C. Cells were harvested, washed with PBS (2x) and lysed in 
digitonin lysis buffer (50 mM Tris pH 7.5, 250 mM sucrose, 5 mM MgCl2, 1 mM DTT, 2 mM ATP, 0.025% digitonin) 
for 30 min on ice. After centrifugation of the cells at 16,100 g for 20 min at 4 °C, the supernatants were collected 
and the protein concentration was determined by Bradford assay. Fibroblasts were obtained with consent from 
control donors and cultured in DMEM/F-12 medium (Invitrogen) supplied with 10% (v/v) FBS in an incubator at 5% 
CO2 and 37 °C. Precipitation of proteins was done using a chloroform/methanol (c/m) precipitation protocol.56 




Trans-Blot cell system. Membranes were blocked with 1% BSA in TBS-t(+) (0.1% Tween 20) overnight at room 
temperature, hybridized with Streptavidin-HRP for 1 hr at room temperature (1:10,000 in blocking buffer) 
(Molecular Probes, Life Technologies), washed with TBS-t(+) and TBS and then visualized using an ECL+ Western 
blotting detection kit (Amersham Biosciences).  
In vitro two-step labeling with biotin-cleavable linker-tetrazine 11  
HEK cell lysates (20 μg total protein per experiment) in digitonin lysis buffer (9 μL) were exposed to 1 μM of ABP 19 
(1 μL 10 μM in DMSO) for 1 hr at 37 °C in the presence or absence of 100 μM epoxomicin (1 μL 1 mM in DMSO). 
Next, the indicated concentrations of tetrazine 11(1.1 μL 10x solution in DMSO) were added and the mixtures were 
again incubated for 1 hr at 37 °C. After quenching by c/m precipitation, proteins were taken up in 15 μL Laemmli’s 
sample buffer containing 2-mercaptoethanol, boiled for 5 min at 100 °C and resolved on 12.5% SDS-PAGE. 
Biotinylated proteins were detected by streptavidin Western blotting.  
Hydrazine cleavage. After boiling in sample buffer, the samples were treated with 10, 50 or 100 mM hydrazine (5 µL 
4x solution in H2O) and incubated at room temperature overnight. The samples were then again boiled for 5 min at 
100 °C and resolved on 12.5% SDS-PAGE. Biotinylated proteins were detected by streptavidin Western blotting.  
In situ inhibition of α-galactosidase A activity 
Cultured WT fibroblasts were grown to confluency in 12-wells plates and incubated with 0.01 nM - 10 µM aziridine 
20 or 21 in medium for 2 hrs at 37 °C. The cells were washed with PBS and lysed by scraping in 25 mM potassium 
phosphate buffer (pH 6.5, 0.1% (v/v) Triton X-100) with protease inhibitor cocktail (Roche). The protein 
concentration was determined by BCA assay. The lysates (25 µL) were then mixed with 100 µL substrate mix (1.5 
mg/mL 4-methylumbelliferyl-α-D-galactopyranoside in McIlvaine pH 4.6 + 0.1% BSA). After incubation for 1 hr at 37 
°C, the reaction was quenched with 2.5 mL 0.3 M glycine, pH 10.6 and fluorescence was measured with a 
fluorimeter LS55 (Perkin Elmer) using λex 366 nm and λem 445 nm. All samples were corrected for background 
fluorescence (sample without enzyme) and residual enzyme activity was calculated as compared to control samples 
from cells incubated without inhibitors. Displayed values represent mean values from duplicate experiments and 
error bars indicate standard deviation (SD). 
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Chemisch biologisch onderzoek richt zich op het toepassen van chemische benaderingen 
voor het bestuderen en controleren van biologische processen. Principes en kennis uit de 
organische chemie worden gebruikt om bepaalde biomoleculen te manipuleren in een 
biologisch systeem. Op die manier kan inzicht worden verkregen in de processen waarbij de 
betreffende moleculen betrokken zijn. Dit proefschrift beschrijft de ontwikkeling van nieuwe 
chemische verbindingen en methodes voor ´activity-based protein profiling´ (ABPP), een 
vakgebied binnen de chemische biologie met als doel de activiteit van enzymen zichtbaar te 
maken en te kwantificeren in de context van een complex biologisch systeem. Om dit doel te 
bereiken wordt er gebruik gemaakt van verbindingen die covalent en irreversibel binden aan 
het actieve centrum van een specifiek enzym of een klasse van enzymen, op een dusdanige 
manier dat alleen de actieve enzympopulatie wordt gelabeld. Deze zogenoemde ´activity-
based probes´ (ABPs) worden onderverdeeld in twee typen afhankelijk van de identiteit van 
de detecteerbare groep waarmee ze zijn uitgerust. Directe ABPs bevatten een label, zoals 
een fluorescent label of biotine, waarmee de target enzymen direct gevisualiseerd, 
geïsoleerd, gekwantificeerd en/of geïdentificeerd kunnen worden. Tweestaps ABPs zijn 
uitgerust met een kleine reactieve groep die kan worden gebruikt om het label in een later 
stadium te introduceren, nadat de ABP aan zijn target enzym is gebonden. Om de labeling te 
realiseren wordt er gebruik gemaakt van bioorthogonale ligatiereacties. Bioorthogonale 
chemie kenmerkt zich door een hoge mate van selectiviteit, een hoge efficiëntie en vooral 
ook door de afwezigheid van enige interacties met het biologische systeem waarin de 
reactie wordt uitgevoerd. Hoofdstuk 1 beschrijft de principes van ABPP en het ontwerp van 
ABPs.  
In Hoofdstuk 2 wordt een overzicht gegeven van de verscheidene bioorthogonale 
ligatiereacties die tot nu toe in de literatuur zijn beschreven, met de nadruk op het gebruik 
van deze methodes voor de tweestaps labeling van enzymactiviteit. Voorafgaand aan het 
werk beschreven in dit proefschrift berustten alle gerapporteerde tweestaps ABPP 




van enzymactiviteit werd gerealiseerd via Staudinger-Bertozzi ligatie, de reactie tussen een 
azide en een phosphine, of via azide-alkyn cycloadditie (‘click’ reactie), die ofwel 
gekatalyseerd wordt door koper(I) of wordt gedreven door de ring-spanning in een 
cyclooctyn.  
In Hoofdstuk 3 wordt een nieuwe tweestaps ABPP methode beschreven die is gebaseerd 
op de Diels-Alder cycloadditie. De Diels-Alder strategie maakt gebruik van ABPs die zijn 
uitgerust met een geconjugeerd dieen en een maleimide reagens als de dienofiel waaraan 
een fluorescent Bodipy label is gekoppeld. Deze strategie werd succesvol toegepast voor de 
labeling van de endogene activiteit van het 20S proteasoom en van cathepsines, een klasse 
van cysteine proteases, in celextracten. Daarnaast werd aangetoond dat de ontwikkelde 
ligatiemethode gecombineerd kan worden met de Staudinger-Bertozzi ligatie voor de 
labeling van twee verschillende enzymactiviteiten in hetzelfde experiment. De Diels-Alder 
ABPP strategie vormt een bruikbaar alternatief voor bestaande methodes die gebaseerd zijn 
op Staudinger-Bertozzi ligatie en click chemie. Desondanks wordt de bredere 
toepasbaarheid ervan gelimiteerd door de noodzaak om cysteine residuen te beschermen 
vóór toevoeging van de dienofiel, waardoor in situ en in vivo toepassingen niet mogelijk zijn. 
Een ander nadeel van deze methode is de aanzienlijke hoeveelheid achtergrond labeling, 
waardoor de detectie van eiwitten met lage endogene activiteit wordt bemoeilijkt. 
Hoofdstuk 4 beschrijft de ontwikkeling van een alternatieve ABPP strategie die is 
gebaseerd op de ‘inverse-electron-demand’ Diels-Alder reactie. Het gebruik van tetrazine als 
een dieen en norborneen als een dienofiel, welke beide niet met cysteine residuen 
reageren, resulteert in een ligatiereactie met sterk verbeterde selectiviteit en verhoogde 
snelheid. Een norborneen-gemodificeerde proteasoom ABP werd gebruikt om endogene 
proteasoom activiteit efficiënt en selectief te labelen in celextracten en in levende cellen via 
reactie met Bodipy- en biotine-gelabelde tetrazines. Bovendien werd er een drievoudige 
bioorthogonale ligatiestrategie ontwikkeld waarbij de tetrazine ligatie werd gecombineerd 
met de Staudinger-Bertozzi ligatie en de koper(I)-gekatalyseerde click reactie voor de 
simultane labeling van drie verschillende enzymactiviteiten met verschillende labels in een 
enkel experiment. Ondanks het feit dat tetrazines niet stabiel zijn onder de condities voor 
koper(I)-gekatalyseerde click chemie, maakt een simpele wasstap tussen de twee 
ligatiereacties het mogelijk beide ligaties opeenvolgend uit te voeren in hetzelfde 
experiment. Dit onderzoek creëert de mogelijkheid drie verschillende biomoleculen 




Het tweede deel van dit proefschrift beschrijft de synthese en biologische evaluatie van 
nieuwe glycosidase ABPs. Glycosidases zijn enzymen die verantwoordelijk zijn voor de 
hydrolyse van glycosidische bindingen in (oligo)sacchariden en glycoconjugaten en zijn 
cruciaal voor de afbraak van glyco(sphingo)lipiden in lysosomen. Een deficiëntie in één van 
de lysosomale glycosidases kan ophoping van de corresponderende substraten in lysosomen 
veroorzaken, wat op zijn beurt kan leiden tot een lysosomale stapelingsziekte. Ondanks de 
vergelijkbare defecten die ten grondslag liggen aan de verschillende lysosomale 
stapelingsziekten, zijn deze opvallend heterogeen wat betreft loop van de ziekte, 
phenotypes en klinische manifestatie. ABPP kan een nuttige techniek zijn om de 
verschillende glycosidases en hun rol in de verscheidene ziektes te bestuderen. Tot op 
heden is er slechts een beperkt aantal glycosidase ABPs ontwikkeld, waarschijnlijk vanwege 
de nauwe substraatspecificiteit en de afwezigheid van covalente interacties met het 
substraat in het katalytische mechanisme van vele van deze enzymen. Niettemin vormen de 
meeste glycosidases met een ‘retaining’ mechanisme wel een covalent enzym-substraat 
intermediair en zijn daarom geschikte kandidaten voor ABPP studies, waarbij ABPs 
ontworpen kunnen worden die covalent reageren met het katalytisch actieve nucleofiel van 
één (of meerdere) van deze enzymen. 
Hoofdstuk 5 beschrijft het ontwerp en de synthese van irreversibele remmers en ABPs 
voor twee klassen van glycosidases, de retaining α- en β-galactosidases. De galactopyranose-
geconfigureerde probes bevatten een electrofiele epoxide of aziridine groep die op een 
dusdanige manier is gepositioneerd (in een α- of β-configuratie) dat deze aangevallen kan 
worden door de katalytisch actieve nucleofiel van respectievelijk α- en β-galactosidases. 
Voor beide enzymen werden vier epoxide probes gesynthetiseerd, waaronder één niet-
gelabelde remmer en drie ABPs waarin de hydroxyl group op C6 (koolhydraat nummering) is 
gesubstitueerd met een Bodipy label, biotine of een azide voor tweestaps labeling. 
Daarnaast werden er twee α-galactosidase aziridine probes gesynthetiseerd waarin een 
azide of Bodipy label werd geïntroduceerd via acylering van de aziridine amine. Pogingen om 
ook β-galactosidase aziridine probes te isoleren waren tot dusver niet succesvol, aangezien 
zelfs het gebruik van volledig zuurvrije procedures voor zuivering en vriesdrogen van deze 
verbindingen resulteerde in opening van de geacyleerde aziridine. 
In Hoofdstuk 6 wordt de remming en labeling van humane retaining α-galactosidases 
door de α-galactopyranose-geconfigureerde probes beschreven. De aziridine ABPs bleken 
zeer potente remmers te zijn van α-galactosidase A (αGal A), het humane lysosomale enzym 
dat deficiënt is in patiënten met de ziekte van Fabry, een lysosomale stapelingsziekte. 




galactosidase, galactocerebrosidase, en een retaining β-glucosidase, glucocerebrosidase. De 
niet-gelabelde epoxide remmer was een factor 10.000 minder potent op αGal A dan de 
aziridine probes. Daarentegen vertoonde geen van de C6-gelabelde epoxide ABPs enige 
remming van dit enzym, wat aantoont dat de primaire hydroxyl groep op C6 essentieel is 
voor binding van de probes. De fluorescent gelabelde aziridine kan gebruikt worden om de 
endogene activiteit van αGal A te labelen in celextracten van wild-type fibroblasten. Naast 
αGal A labelt de ABP ook de activiteit van N-acetyl-galactosaminidase (αGal B), het tweede 
humane enzym in de familie van retaining α-galactosidases. In fibroblast celextracten die 
afkomstig zijn van klassieke Fabry patiënten is overeenkomstig het gebrek aan αGal A 
activiteit uitsluitend labeling van αGal B zichtbaar. Een mogelijk zeer waardevolle toepassing 
van de Bodipy-gelabelde probe is het labelen en vergelijken van de retaining α-galactosidase 
activiteit in celextracten van Fabry patiënten met verschillende mutaties in αGal A en/of 
phenotypische varianten van de ziekte. 
In Hoofdstuk 7 worden de β-galactopyranose-geconfigureerde epoxide probes 
geëvalueerd met betrekking tot remming en labeling van het humane enzym 
galactocerebrosidase. Deficiëntie van deze lysosomale β-galactosidase leidt eveneens tot 
een lysosomale stapelingsziekte, de ziekte van Krabbe. De meest potente remmer van 
galactocerebrosidase was de niet-gelabelde epoxide, terwijl substitutie van de hydroxyl 
groep op C6 met een azide resulteerde in een factor 2.000 lagere potentie. Daarentegen 
bleek de introductie van een Bodipy label, en in mindere mate biotine, op dezelfde positie 
de potentie weer gedeeltelijk te herstellen. Zowel de Bodipy- als de biotine-gelabelde 
probes werden toegepast om katalytisch actief galactocerebrosidase te visualiseren op gel. 
Verder werd aangetoond dat de probes selectief zijn voor dit enzym ten opzichte van 
retaining α-galactosidases en β-glucosidases. Eerdere publicaties hebben laten zien dat deze 
laatste klasse van enzymen selectief kan worden gelabeld met ABPs die slechts verschillen 
van de β-galactosidase probes in de configuratie van een enkele hydroxyl substituent. Het 
onderzoek beschreven in hoofdstukken 6 en 7 laat zien dat het mogelijk moet zijn 
verschillende klassen van retaining glycosidases te labelen door ABPs te ontwikkelen die 
dusdanig gemodificeerd zijn dat de configuratie overeenkomt met het natuurlijke substraat 
van de target enzymen. Bovendien vormen de beschreven α- en β-galactosidase remmers en 
ABPs nuttige middelen voor het bestuderen van de betreffende enzymen en hun 






In Hoofdstuk 8 wordt een overzicht gegeven van het onderzoek dat in dit proefschrift is 
beschreven. Daarnaast worden verdere toepassingen van de ontwikkelde probes en 
methodes besproken en worden voorstellen gedaan voor nieuwe glycosidase ABPs die 
andere eigenschappen hebben (stabiliteit, reactiviteit) en/of gericht zijn tegen andere 
enzymklassen. Ook worden twee lopende projecten geïntroduceerd, waarvan de eerste 
betrekking heeft op tweestaps labeling van enzymactiviteit met behulp van de tetrazine 
ligatie. Een biotine-gelabeld tetrazine reagens waarin een splitsbare linker is opgenomen 
kan gebruikt worden om gelabelde eiwitten te isoleren met behulp van geïmmobiliseerd 
streptavidine en vervolgens selectief af te splitsen onder milde condities om zo een zuiver 
preparaat te verkrijgen. Het tweede project beschrijft het ontwerp en de (gedeeltelijke) 
synthese van probes voor 2-oxoglutaraat-afhankelijke oxygenases. Omdat deze klasse van 
enzymen geen covalent enzym-substraat intermediair vormt, is er gekozen voor het gebruik 
van ‘affiniteit-gebaseerde probes’ in plaats van ABPs. De probes zijn gebaseerd op de 
structuur van 2-oxoglutaraat en bevatten een norborneen groep voor labeling via tetrazine 
ligatie en een ‘fotoreactieve’ groep, waarmee door middel van fotochemie irreversibele 
binding aan target enzymen gerealiseerd kan worden.  
De focus binnen het vakgebied van ABPP verschuift in steeds hogere mate richting het 
labelen van enzymklassen met andere en soms slechts deels opgehelderde katalytische 
mechanismes, nauwe substraatspecificiteit en/of lage expressie niveaus. Daarom worden 
voortdurend inspanningen gewijd aan het ontwikkelen van nieuwe benaderingen die het 
mogelijk maken de activiteit van deze enzymen zichtbaar te maken en/of te kwantificeren. 
Het onderzoek beschreven in dit proefschrift biedt een aantal nieuwe strategieën die aanzet 
geven tot verdere onderzoekslijnen, zowel voor het labelen van de activiteit van nieuwe 
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